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Abstract 
 
Cough is a disabling symptom in patients with Idiopathic pulmonary fibrosis (IPF). 
Reflux disease is frequently associated with IPF and implicated in pathogenesis of 
both IPF and cough.  
Therefore, acid suppression by omeprazole should ameliorate cough and improve 
quality of life in IPF patients, which is the hypothesis underlying the planned PPIPF 
study. My thesis is based on the baseline assessments of cough and reflux in IPF 
patients recruited for the study. 
45 patients with mean age of 71.2 years; 35 (77.8%) male were recruited. 24-hour 
cough recording at baseline showed significantly raised cough frequency (mean 
11.99/hour) with impaired quality of life (mean LCQ-total score 15.22).  
Reflux related health questionnaires [RSI (mean score 15.6,) and GIQLI (mean score 
105.56,)] suggested impaired quality of life, possibly due to reflux disease in our 
study cohort [but not DeMRQ (mean score 1.16)]. Consent for GI studies and 
bronchoscopy was low. GI studies demonstrated oesophageal dysmotility in 4 (44%) 
and acid reflux in 6 (67%) out of the 9 IPF patients, who completed the assessment.  
BAL samples showed leucocytosis in all 8 participants with bacterial growth on 
cultures in 2 participants.  
 
Additionally, I undertook a case-series study to assess the outcome of pulsed 
cyclophosphamide and methyl-prednisolone therapy in patients with progressive 
interstitial lung disease (ILD) in our institute.  
Medical records of 53 patients with mean age of 60 years; 29 (55%) male were 
reviewed. The median number of cyclophosphamide pulses received was 6. The 
average rate of change of lung function was significantly less after cyclophosphamide 
therapy both for FVC (p=0.0004) and TLco (p=0.00015). In our single centre, 
retrospective study pulsed cyclophosphamide and methyl-prednisolone was associated 
with stabilisation of lung function in a mixed cohort of patients with progressive ILD. 
Adverse events were common but transient and managed with dose reduction and/or 
delayed schedule. 
							
iv	
Acknowledgements 
 
I would like to acknowledge and thank everybody for his or her continued help and 
support. Without them the conduction of the study projects and my thesis would not 
have been possible. 
 
I am indebted to my supervisors Professor John Simpson, Dr Ian Forrest, Dr Chris 
Ward, Institute of Cellular Medicine (ICM), Newcastle University for their advice, 
support and feedback with all my study projects. They designed the PPIPF study, 
obtained research funding and helped me with interpretation of results and reviewed 
my manuscripts. British Lung Foundation (BLF) funded the PPIPF study. Dr Ian 
Forrest performed bronchoscopy during the early phase of the study (to teach specific 
principles of research bronchoscopy). In addition, Prof Simpson, Dr Forrest helped 
me with designing the Cyclophosphamide study, interpreting and presenting results at 
academic meetings. My sincere thanks to Dr Wendy Funston, Clinical Research 
Fellow for help with continued recruitment and conduction of the PPIPF study 
(following my return to compulsory clinical training). 	
I am grateful to Vicky Ryan (senior trial statistician) and Helen Mossop (trial 
statistician) from Biostatistics Research Group, Institute of Health and Society, 
Newcastle University. Their help with setting up of online randomisation website, 
data management (via secure websites) for the PPIPF study have been invaluable for 
conduction of the study. They also helped in generating mandatory trial progress 
reports for the trial regulatory committees. My thesis is based on the baseline “raw” 
data they kindly provided (reproduced from the secure website where I have 
previously uploaded the data collected during study visits). 
 
Further, I express my gratitude to Dr Bridget Griffiths, Consultant Rheumatologist in 
Freeman Hospital for her input in planning and carrying out the Cyclophosphamide 
project. I would also like to thank Ms Karen Walker, Rheumatology specialist nurse 
							
v	
for help with the list of names and prescription of the patients who received 
Cyclophosphamide therapy.  
 
I am grateful to Dr Sylvia Worthy and Dr Anna Beattie (Consultant Thoracic 
Radiologist, Royal Victoria Infirmary) for their review of the chest CT scans of 
patients for both PPIPF and Cyclophosphamide studies. 
 
I am grateful to Dr Peter Avery, Senior Lecturer, Institute of Mathematics and 
Statistics at Newcastle University for his help and support with the interpretation of 
results of the cyclophosphamide study. Without his advice poster publication of the 
cyclophosphamide study would not have been possible.		
Chest OPD team in RVI: My sincere thanks to the Chest Clinic nursing staff and the 
receptionists for their help and support especially for their work in locating and 
collecting notes, arranging appointments for the research study. I have spent huge 
time in the clinic for screening, calling potential patients and actually conducting the 
study. Additionally, thanks to the lung function physiologists for their help in 
performing the lung function tests on the study patients. 	
Endoscopy Unit in RVI: I would like to thank Mr Rhys Jones (Surgical Registrar and 
Upper GI clinical research fellow), Rachel Colver (Specialist upper GI nurse) and 
Gillian (Health Care Assistant) for their support with the GI physiology study. I learnt 
to perform and report the test from Mr Rhys Jones. With help from Rachel and Gillian 
I have performed the GI physiology tests. Their continued support (specially with the 
mandatory administrative paperwork) with the GI procedures is much appreciated. 
Additionally I would like to thank the nurses in the bronchoscopy unit for their 
assistance with the research bronchoscopy procedures.  	
Sir William Leech Research Center in Freeman Hospital: I am grateful to Dr Gail 
Johnson and Kasim Jiwa, clinical scientists in the Sir William Leech Research Center 
							
vi	
for their training in processing of BAL fluid samples. I can independently perform 
total and differential counts on BAL samples. I am thankful for Kasim’s continued 
support with storage of the BAL samples. 	
NCTU:  The NCTU monitored the trial. I would like to thank Ms Jessica Qian (Trial 
Manager), Dr Jennifer Wilkinson (Senior Trial Manager) for their continuous advice 
and guidance on conduction of the study. I am grateful to Mr Mark Palmer and Dr 
Leslie Hall who took over from Jessica (on maternity leave from March 2015) and 
Jennifer (seconded to other study projects) respectively for their support and 
assistance with my trial study. Additionally for the painstaking work with the trial 
master file and the investigator site file, I would like to thank Rebecca Forbes, Trial 
Manager (she took over from Mark) and Jared Thornton, Senior Trial Manager, (who 
took over from Leslie).  They also organised the compulsory trial meetings for which 
I am obliged.  	
Secretaries: My sincere thanks to Ms Linda Ward (secretary to Prof Simpson), Ms 
Joanna McNichol, Ms Wendy Fairbairn (secretary to Dr Forrest and secretary for the 
ILD services) for their assistance with patient appointments, clinical notes and 
clinic/research letters. 
I would also like to thank Ms Carole Fairless, secretary to Dr Griffiths for her help 
with regular collection of notes for the Cyclophosphamide audit.		
 
							
vii	
							
viii	
Abbreviations 
 
ACEi – Angiotensin converting enzyme inhibitors 
AEC – Alveolar epithelial cell 
ALP – Alkaline phosphatase  
ALT – Alanine transaminase 
ANA – Antinuclear antibody 
ATS – American Thoracic Society 
BAL – Bronchoalveolar lavage 
BDNF – Brain derived neurotropic factor 
BLF – British Lung Foundation 
BMI – Body mass index 
COPD – Chronic obstructive pulmonary disease 
CRF – Case report forms 
CTA – Clinical Trials Authorisation 
CTD – Connective tissue disease 
CTD-ILD – Connective tissue disease related-interstitial lung disease 
CTIMP – Clinical Trial of an Investigational Medicinal Product 
CTU – Clinical Trials Unit 
DeMRQ – DeMeester Reflux associated Questionnaire 
DMSC – Data and Safety Monitoring Committee 
dsDNA – Double-stranded DeoxyriboNucleic acid antibody 
ECG – Electrocardiogram 
EMT – Epithelial-mesenchymal transition 
FXa – Activated factor X 
FEV1 – Forced expiratory volume in 1 second 
FVC – Forced vital capacity 
GGT – Gamma-glutamyl transferase 
GI – Gastro-intestinal 
GIQLI – Gastro-Intestinal Quality of Life index Questionnaire 
GORD – Gastro-oesophageal reflux disease 
							
ix	
GP – General practitioners 
HRCT – High resolution computer tomography 
IIP – Idiopathic interstitial pneumonia 
ILD – Interstitial lung disease 
ILD-MDT – Interstitial lung disease multidisciplinary team 
IPF – Idiopathic Pulmonary Fibrosis 
IV – Intravenous 
Kco – Transfer factor coefficient of lung for carbon monoxide gas 
LCQ – Leicester cough questionnaire 
LOS – Lower oesophageal sphincter 
MHRA – Medicine and Healthcare products Regulatory Agency 
MID – Minimal important difference 
NCTU – Newcastle Clinical Trials Unit 
NGF – Nerve growth factor 
NSIP – Non specific interstitial pneumonia 
NUTH – The Newcastle upon Tyne Hospitals Foundation Trust 
PAI – Plaminogen activator inhibitor 
PARs – Proteinse-activated receptors 
PDGF – platelet-derived growth factor 
PIC – Participant Identification Center 
PIS – Participant Information Sheet 
PPI – Proton pump inhibitor 
RCT – Randomised controlled trial 
REC – Research Ethics Committee 
RSI – Reflux Symptom Index Questionnaire 
RVI – Royal Victoria Infirmary, Newcastle 
SAP – Symptom-associated probability 
SmPC – Summary of product characteristics  
TERC – Telomerase RNA 
TERT – Telomerase reverse transcriptase 
TF – Tissue factor 
							
x	
TGF-β – Transforming growth factor-β 
TLco – Transfer factor of lung for carbon monoxide gas 
TLOSRs – Transient lower oesophageal sphincter relaxations 
TMG – Trial Management Group 
TNF-α – Tumour necrosis factor-α 
TSG – Trial Steering Group 
UIP – Usual interstitial pneumonia 
VC – Vital capacity 
ZES – Zollinger-Ellison syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
							
xi	
Table of Contents 
LIST OF TABLES	............................................................................................................................	1	
LIST OF FIGURES	..........................................................................................................................	2	
CHAPTER 1. BACKGROUND TO THE THESIS	...................................................................	3	
CHAPTER 2. INTRODUCTION: IDIOPATHIC PULMONARY FIBROSIS (IPF)	........	5	
2.1 IPF: BACKGROUND AND PATHOGENESIS	.....................................................................................	5	
2.1.1 Pathogenesis of IPF	..........................................................................................................................	5	
2.2 IPF AND COUGH	...................................................................................................................................	12	
2.3 IPF AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	..........................................	14	
2.3.1 Gastro-oesophageal reflux disease	...........................................................................................	14	
2.3.2 IPF and gastro-oesophageal reflux disease	..........................................................................	17	
2.3.3 Reflux, Aspiration and IPF	..........................................................................................................	19	
CHAPTER 3. METHODS: PPIPF STUDY	.............................................................................	21	
3.1 PPIPF STUDY HYPOTHESIS	.............................................................................................................	21	
3.2 USEFULNESS OF THE PPIPF STUDY	.............................................................................................	21	
3.3 STUDY DRUG: OMEPRAZOLE - DRUG CLASS AND LICENSED INDICATION	....................	22	
3.3.1 Dose and duration	...........................................................................................................................	23	
3.3.2 Clinical pharmacology	..................................................................................................................	23	
3.3.3 Adverse effects	...................................................................................................................................	24	
3.3.4 Administration schedule	................................................................................................................	24	
3.3.5 Manufacture and supply	................................................................................................................	24	
3.4 PPIPF STUDY DESIGN	........................................................................................................................	25	
3.4.1 Patient population/Recruitment	.................................................................................................	25	
3.4.2 Sample size	.........................................................................................................................................	25	
3.4.3 Inclusion criteria	..............................................................................................................................	26	
3.4.4 Exclusion criteria	.............................................................................................................................	27	
3.4.5 Intervention	........................................................................................................................................	28	
3.4.6 Primary outcomes	............................................................................................................................	28	
Primary efficacy outcome	........................................................................................................................	28	
Primary feasibility outcomes	..................................................................................................................	28	
3.4.7 Secondary outcomes	.......................................................................................................................	28	
3.5 PPIPF STUDY PROCEDURES	............................................................................................................	29	
3.5.1 Screening	.............................................................................................................................................	29	
3.5.2 Consent	................................................................................................................................................	29	
3.5.3 Randomisation	..................................................................................................................................	30	
3.5.4 Drug termination criteria	.............................................................................................................	30	
3.5.5 Process of unblinding	.....................................................................................................................	31	
3.6 PPIPF STUDY ASSESSMENTS	...........................................................................................................	31	
3.6.1 Demographics	...................................................................................................................................	31	
3.6.2 Questionnaires	..................................................................................................................................	31	
3.6.3 Lung function tests	...........................................................................................................................	34	
3.6.4 Six minute walk test (6MWT)	.......................................................................................................	34	
3.6.5 Twenty-four hour cough recording	...........................................................................................	35	
3.6.6 Gastro-intestinal physiology study	............................................................................................	38	
High Resolution Manometry – oesophagus (HRM)	.......................................................................	39	
Twenty-hour hour pH-impedance study	.............................................................................................	41	
							
xii	
3.6.7 Bronchoscopy and BAL assessment	..........................................................................................	45	
Bronchoscopy	...............................................................................................................................................	45	
BAL assessment	............................................................................................................................................	46	
3.6.8 Patient visits for study assessments	..........................................................................................	47	
3.7 PPIPF STUDY PHARMACOVIGILANCE/SAFETY MONITORING	...........................................	49	
3.7.1 Data Monitoring and Safety Committee (DMSC)/ Trial Steering Group (TSG) 
appointment	...................................................................................................................................................	49	
3.7.2 Patient diary card	............................................................................................................................	50	
3.7.3 Data collection	..................................................................................................................................	50	
3.7.4 Regulations, Ethics, Governance	...............................................................................................	51	
CHAPTER 4. RESULTS	..............................................................................................................	52	
4.1 SCREENING AND RECRUITMENT	...................................................................................................	52	
4.2 PATIENT CHARACTERISTICS AT BASELINE OR RANDOMISATION	....................................	56	
4.3 SUBJECTIVE ASSESSMENT OF COUGH AND GASTRO-OESOPHAGEAL REFLUX DISEASE 
IN PATIENTS WITH IPF	.............................................................................................................................	61	
4.4 OBJECTIVE ASSESSMENT OF COUGH IN PATIENTS WITH IPF	...........................................	64	
4.4.1 Relation between subjective and objective assessment of cough	..................................	67	
4.5 OBJECTIVE ASSESSMENT OF GASTRO-OESOPHAGEAL REFLUX DISEASE IN PATIENTS 
WITH IPF	........................................................................................................................................................	68	
4.6 RELATION BETWEEN COUGH AND REFLUX DISEASE IN PATIENTS WITH IPF	.............	72	
4.7 BRONCHOSCOPE AND BAL SAMPLES	..........................................................................................	78	
CHAPTER 5. DISCUSSION	........................................................................................................	82	
5.1 DIFFICULTIES/CHALLENGES ENCOUNTERED IN THE PPIPF STUDY	..............................	85	
5.2 ACTION/MEASURES PUT IN PLACE	...............................................................................................	86	
5.3 CHALLENGES IN RECRUITMENT TO THE STUDY	.....................................................................	87	
5.3.1 IPF patients prescribed PPI therapy	.......................................................................................	87	
5.3.2 IPF severity and comorbidities	..................................................................................................	88	
5.3.3 Study procedure-related	................................................................................................................	89	
5.3.4 Mandatory compliance with regulatory framework around clinical trials with an 
IMP	...................................................................................................................................................................	90	
5.4 STRENGTHS AND WEAKNESSES OF THE STUDY	.......................................................................	96	
5.4.1 Strengths	..............................................................................................................................................	96	
5.4.2 Weaknesses	.........................................................................................................................................	96	
CHAPTER 6. EFFICACY OF PULSED CYCLOPHOSPHAMIDE AND 
METHYLPREDNISOLONE THERAPY IN PATIENTS WITH PROGRESSIVE 
INTERSTITIAL LUNG DISEASE (ILD) – A RETROSPECTIVE STUDY	...................	99	
6.1 BACKGROUND	.......................................................................................................................................	99	
6.2 TREATMENT PROTOCOL	.................................................................................................................	100	
6.3 STUDY AIMS	.........................................................................................................................................	101	
CHAPTER 7. METHODS AND DATA COLLECTION	...................................................	102	
7.1 PATIENT IDENTIFICATION	.............................................................................................................	102	
7.2 DATA COLLECTION	...........................................................................................................................	102	
7.3 PRE-DETERMINED STUDY PARAMETERS AND OUTCOME DEFINITIONS FOR DATA 
ANALYSIS	......................................................................................................................................................	102	
CHAPTER 8. RESULTS	...........................................................................................................	104	
8.1 PATIENT DEMOGRAPHICS	..............................................................................................................	104	
8.2 DIAGNOSIS OF ILD AT INITIATION OF THERAPY	..................................................................	105	
							
xiii	
8.3 DOSAGE OF CYCLOPHOSPHAMIDE AND METHYLPREDNISOLONE DELIVERED AND 
FOLLOW ON IMMUNOSUPPRESSION	..................................................................................................	105	
8.4 ASSESSMENT OF CHANGE IN LUNG FUNCTION POST-THERAPY	......................................	106	
8.5 ASSESSMENT OF ANY SIGNIFICANT CHANGE IN PRE-THERAPY MAINTENANCE 
PREDNISOLONE DOSE	..............................................................................................................................	111	
8.6 ASSESSMENT OF ANY CHANGE IN WEIGHT POST-THERAPY	.............................................	111	
8.7 ASSESSMENT OF ANY SIGNIFICANT CHANGE IN OXYGEN PRESCRIPTION POST-
THERAPY	......................................................................................................................................................	112	
8.8 ADVERSE EVENTS DURING THERAPY	........................................................................................	112	
8.9 REVIEW OF PRE-THERAPY CHEST CT SCAN FEATURES	....................................................	114	
CHAPTER 9. DISCUSSION	.....................................................................................................	115	
REFERENCES	............................................................................................................................	117	
APPENDIX 1: PPIPF STUDY: QUESTIONNAIRES	........................................................	132	
APPENDIX 2: PPIPF STUDY: PROTOCOL	......................................................................	144	
APPENDIX 3: PPIPF STUDY: CONSENT FORMS	.........................................................	177	
APPENDIX 4: PPIPF STUDY: PIS	........................................................................................	180	
APPENDIX 5: PPIPF STUDY: PATIENT DIARY CARD	...............................................	197	
APPENDIX 6: BTS POSTER PRESENTATION: CYCLOPHOSPHAMIDE STUDY
	.........................................................................................................................................................	203	
									 	
List of tables 	
1. Table 1 – Proposed data/results to be recorded from the 24-hour pH-
impedance study for the research study……………………………………...44 
2. Table 2 – PPIPF study visits…………………………………………………48 
3. Table 3 – Why identified IPF patients were excluded from the study based on 
inclusion/exclusion criteria, clinical grounds and/or other reasons………….55 
4. Table 4 – Baseline patients’ demographics………………………………….57  
5.  Table 5 – List of co-existing medical illness among the participants recruited 
for the study………………………………………………………………….59 
6. Table 6 – List of concomitant medications at screening among the participants 
recruited for the study……………………………………………………….60 
7. Table 7 – Impact of cough on quality of life at baseline as assessed by 
LCQ………………………………………………………………………….61 
8. Table 8 – Impact of reflux on quality of life at baseline as assessed by RSI, 
GIQLI and DeMRQ…………………………………………………………62 
9. Table 9 – Example of 24-hour cough count data at baseline………………..65 
10. Table 10 – Baseline cough frequency (cough/hour) of participants………...66 
11. Table 11 – HRM-oesophagus study at baseline…………………………….69 
12. Table 12 – Baseline data of the 24-hour pH-impedance studies……………70 
13. Table 13 – Baseline GI physiology studies with cough count (cough/hour) and 
reported quality of life scores………………………………………………..72 
14. Table 14  – Results of bronchoscopy and BAL sample analysis…………….79 
15. Table 15 – Dates of submission of amendments to REC and/or MHRA and 
approval dates…………...……………………………………………………91 
16. Table 16 – Adverse events during pulsed cyclophosphamide and methyl-
prednisolone therapy………………………………………………………..113 
17. Table 17 – Types of infections reported during pulsed therapy……………113  
	
							
2	
List of figures 	
1. Figure 1A – HRCT feature of UIP fibrosis, supine, inspiratory scan of lung 
base…………………………………………………………………………....6 
2. Figure 1B – HRCT feature of UIP fibrosis, prone, inspiratory scan of lung 
base……………………………………………………………………………6 
3. Figure 2 – Histological feature of UIP pattern fibrosis………………………10 
4. Figure 3 – Progressive anatomical disruption of the gastro-oesophageal 
junction as it relates to flap valve anti-reflux barrier………………………...16 
5. Figure 4 – Vitalojak cough recording device with 2 microphones (A- Air 
Microphone; B – Chest Sensor)……………………………………………...36 
6. Figure 5 – Cough recording device carried around waistline………………..36  
7. Figure 6 – Series of “spasms” of cough……………………………………...37 
8. Figure 7 – Example of 4 coughs where each of the explosive phases have been 
marked with a dotted line…………………………………………………….38 
9. Figure 8 – HRM plot of oesophagus, illustrating a normal swallow………...40 
10. Figure 9 – HRM plot of an abnormal peristalsis……………………………..41 
11. Figure 10 – Typical acid reflux event………………………………………..43 
12. Figure 11 – Consort diagram of patient screening and recruitment………….53  
13. Figure 12 – Scatterplot showing correlation between cough count and LCQ-
total score…………………………………………………………………….68 
14. Figure 13 – Scatterplot of cough count per hour and DeMeester score……...74 
15. Figure 14 – Scatterplot of cough count per hour and RSI score……………..75 
16. Figure 15 – Scatterplot of cough count per hour and GIQLI score………….76 
17. Figure 16 – Scatterplot of cough count per hour and DeMRQ score………...77 
18. Figure 17 – Average fitted quadratic curve for FVC (litres)………………..107 
19. Figure 18 – Average fitted quadratic curve for TLCo (mmol/min/kPa)……108 
20. Figure 19 – Change in FVC (litres) 6 months pre- and post-therapy……….109 
21. Figure 20 – Change in TLCo (mmol/min/kPa) 6 months pre-and post-therapy 
………………………………………………………………………………110 
							
3	
Chapter 1. Background to the Thesis 	
My thesis is based on the findings from 2 projects common to the theme of interstitial 
lung disease (ILD).  
 
The first relates to a single-centre randomised double-blinded placebo-controlled pilot 
trial of the proton pump inhibitor (PPI) omeprazole in idiopathic pulmonary fibrosis 
(IPF) (or the PPIPF study). The British Lung Foundation (BLF) funded the study. 
Professor John Simpson (Professor of Respiratory Medicine, Newcastle University) 
was the Chief Investigator; Dr Ian Forrest (Consultant Respiratory Physician, The 
Newcastle upon Tyne Hospitals NHS Foundation Trust) was the Principal 
Investigator; Dr Chris Ward (Senior Lecturer in Respiratory Medicine, Institute of 
Cellular Medicine, Newcastle University) and Professor Jacky Smith (Professor of 
Respiratory Medicine, University of Manchester) were Co-Investigators. I co-
ordinated the trial in my role as a BLF Clinical Research Fellow. 
 
The second project was a retrospective study to assess the efficacy of pulsed 
cyclophosphamide and methylprednisolone therapy in patients with progressive ILD. 
 
The two projects were common to my interest in ILD and addressed the relative lack 
of effective therapies. Working on these two parallel projects provided the 
opportunity to broaden my research experience while improving my understanding of 
advanced management of patients with ILD.  
Complying with the mandatory research regulations and initial teething problems of 
setting up a Clinical Trial of an Investigational Medicinal Product (CTIMP) meant 
delay in starting recruitment for the randomised controlled trial (RCT). Recruitment 
started in March 2014 (almost 6 months later than planned). In spite of several 
measures put in place to improve recruitment of participants to the PPIPF study this 
remained slower than expected (the initial plan was to recruit 60 participants over a 
period of 21 months). Therefore the decision was made to recruit for the study over an 
							
4	
extended period (until August 2016). In July 2015, I returned to my mandatory 
clinical training in Respiratory Medicine. Dr Wendy Funston, Clinical Research 
Fellow, kindly led further recruitment for the PPIPF study after I returned to clinical 
training. Being mindful of the MD programme timeline, my thesis is based on the 
baseline assessment of cough and reflux in patients with IPF, plus the 
cyclophosphamide study. In total 45 patients were recruited to PPIPF (last patient 
recruited in July 2016). The original intention was to recruit a minimum of 40 patients 
with complete data relating to the primary outcome measure, and this was achieved.  
Additionally, in keeping with the principles of a double-blinded clinical trial, the trial 
statisticians and the trial managers of the Newcastle Clinical Trials Unit (NCTU) 
managed data collected during study period/visits. At the time of writing, all the 
participants have completed their study visits and data is being collated.  Subsequent 
analysis can be performed only after further mandatory checks confirm satisfactory 
adherence to data collection regulations.  
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Chapter 2. Introduction: Idiopathic Pulmonary Fibrosis (IPF) 	
2.1 IPF: Background and pathogenesis 
 
IPF is the most common type of idiopathic interstitial pneumonia (IIP) (Bradley et al., 
2008; Raghu et al., 2011; Richeldi et al., 2017). In this condition, due to an as yet 
unknown aetiology, wide areas of healthy lungs are replaced by fibrotic tissue, which 
makes oxygen extraction difficult during respiration. Although the disease course is 
unpredictable, it tends to be chronically progressive with a median survival of 2-5 
years from time of diagnosis (Richeldi et al., 2017).  Patients predominantly suffer 
from breathlessness (on exertion and/or at rest) and cough, which can be debilitating. 
Till date there is currently no cure. Lung transplantation can improve survival but 
only a few patients are eligible given the complicated nature of the procedure and the 
subsequent follow up treatment regime. In recent years, two disease-modifying drug 
therapies (pirfenidone and nintedanib) have been approved for the treatment of mild 
to moderate IPF (Arai et al., 2013; King et al., 2014; Richeldi et al., 2014). Both 
drugs reduce the rate of decline in lung function in patients with IPF over a period of 
1 year but have little impact on symptoms of cough and breathlessness, which can 
cause significant impairment of quality of life. Hence there is continued focus on 
symptom-based treatment in patients with IPF. Cough associated with IPF is 
extremely difficult to manage and new approaches are required (Chung and Pavord, 
2008; Dicpinigaitis, 2008; Woodcock et al., 2010; Birring, 2011). 
2.1.1 Pathogenesis of IPF 	
IPF is not a common medical problem. According to the British Thoracic Society ILD 
Registry programme’s annual report of 2013/2014, it is estimated that there are 5000 
new cases of IPF every year in the UK or an incidence rate of 7 – 9 per 100,000 (the 
true incidence is not known). Prevalence was estimated to be 15 – 25 per 100,000 but 
increases with age. About 5000 patients with IPF die per annum in the UK probably 
accounting for the low recorded prevalence rate.  
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IPF more commonly affects males and they present mostly between the ages of 50 – 
70 years (the median age at diagnosis is 65 years) (Richeldi et al., 2017). 
The diagnosis of IPF is made on the basis of a distinct radiological and histological 
pattern of “usual interstitial pneumonia” (UIP) in the absence of other identifiable 
causes (King et al., 2011; Chung et al., 2015). High resolution computer tomography 
(HRCT) scans show characteristic reticular changes with secondary bronchial 
dilatation predominantly in the basal, peripheral and sub-pleural regions of the lungs. 
In advanced cases, clusters of cystic airspaces (typically 3 – 10mm in diameters) in 
between the interlobular septae known as “honeycombing” are seen, mainly at the 
basal and sub-pleural regions. These characteristic features in HRCT scans, in 
association with typical signs and symptoms, have been accepted world wide as 
diagnostic of IPF in day-to-day clinical practice (Richeldi et al, 2017). Currently, 
routine surgical lung biopsy (previously regarded as the diagnostic gold standard) is 
not advocated except in the presence of non-diagnostic or atypical HRCT scan and/or 
clinical features. 
 
The two HRCT scan images (Figure 1A and Figure 1B) below illustrate the 
radiological features of IPF: 
 
 
                                	
																																																																																																																													
	Figure 1: HRCT features of UIP 
 (A) supine, inspiratory scan of the lung bases. (B) prone, inspiratory scan of the lung bases.																																																																																																																																																																																																													    
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Figure 1A is an HRCT image of a patient in the supine position. It shows changes of 
fibrosis bilaterally at the bases of the lungs in peripheral and sub-pleural areas 
associated with honeycombing changes, as is typically seen in IPF. Figure 1B is an 
HRCT image from the same patient in the prone position. It shows persistent changes 
with change of position (anonymised images obtained from an HRCT scan of a 
patient with IPF under hospital follow up). 
The pathogenesis of fibrosis in IPF is not entirely understood but it involves a 
complex interaction between multiple inherent physiological and pathological 
processes. Previously, chronic inflammation of the lung leading to gradual fibrosis as 
a mechanism was proposed. However recent research suggests repeated alveolar 
epithelial injury in an aging lung (or in a genetically predisposed individual) in 
association with aberrant tissue repair leads to fibrosis in the lungs (King et al., 2011; 
Richeldi et al., 2017).  
 
Two types of alveolar epithelial cells (AEC) line the lung alveoli. AEC type 1 are the 
primary lining cells and cover up to 90% of the alveolar surface (King et al., 2011). 
They help with gas exchange during respiration. Type 2 AECs secrete surfactants and 
also help in renewal of type 1 AECs during homoeostasis and after lung injury. 
Damage or injury to the type 2 AECs caused by repetitive or persistent environmental 
insult(s) play a prominent role in the pathogenesis of IPF. Abnormal AEC2s and loss 
of AEC1s lead to dysregulated tissue repair and excess collagen production leading to 
fibrosis in the lungs.  
 
Repetitive lung injury causes damage and/or apoptosis to both AEC1 and AEC2 cells. 
Post injury AEC2 cells proliferate and migrate to attempt repair tissue damage. 
However, in patients with IPF, there is abnormal activation of AEC2 cells, which lead 
to increased secretion of a host of fibrosis-promoting growth factors and chemokines 
including transforming growth factor-β (TGF-β), platelet-derived growth factor 
(PDGF), tumour necrosis factor-α (TNF-α) (King et al., 2011). These chemicals 
promote migration, proliferation of fibroblasts and differentiation to myofibroblasts 
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[derived from residential mesenchymal cells, bone marrow derived fibrocytes, lung 
interstitium pericytes, circulating fibrocytes, epithelial-mesenchymal transition (EMT) 
and endothelial-mesenchymal transition (Richeldi et al., 2017)]. In particular, 
activation of latent TGFβ1 promotes EMT and differentiation of fibroblasts to 
myofibroblasts (King et al., 2011). EMT is the process by which epithelial cells 
transform and are capable of migration and secretion of extracellular matrix (acquire 
properties similar to mesenchymal cells), thereby increasing the number of fibroblasts 
and myofibroblasts at the site of alveolar injury. Activated myofibroblasts synthesise 
and deposit excess amounts of extracellular matrix (mainly type 1 collagen) 
contributing to fibrosis. 
In parallel, to abnormal extracellular matrix deposition, aberrant wound healing/repair 
leads to what is known as ‘bronchiolisation of alveolar tissue’. At the site of epithelial 
injury, aberrant repair process (due to deregulation of developmental pathways) leads 
to abnormal re-epithelialisation resulting in bronchiolisation of the alveolar space 
(King et al., 2011). 
Regeneration of AEC2 cells is impaired in IPF, leading to loss of AEC1 cells further 
preventing normal epithelialisation of damaged alveoli. 
  
In addition, both the extrinsic and intrinsic coagulation pathways are also activated in 
IPF leading to activation of Factor X, which promotes fibrosis, by stimulation of 
fibroblasts. Coagulation and fibrosis play a crucial role in homeostasis in health. An 
imbalance between coagulation and fibrinolysis have been demonstrated within the 
alveolar space in experimental animal models of fibrosis (Crooks and Hart, 2015). 
The risk of IPF associated with at least one prothrombotic state is significantly high 
(OR=4.78) and is associated with increased mortality (Navaratnam et al., 2014). 
Tissue injury leads to increased release of tissue factor (TF) from AEC2 cells, 
alveolar macrophages (and endothelial cells), which on exposure to plasma forms a 
TF-factor VIIa complex. This complex, ultimately leads to activation of factor X 
(FXa), which in association with activated factor Va leads to activation of thrombin 
and formation of a clot by converting fibrinogen to fibrin. The initial TF-factor VIIa-
FXa complex also activates factor IX, factor VIII, factor XI thereby triggering the 
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intrinsic coagulation cascade leading to persistent production of thrombin and 
sustaining coagulation. Increased levels of TF and Plasminogen activator inhibitor 
(PAI, an inhibitor of plasmin) have been demonstrated in the BAL fluid from patients 
with IPF, suggesting activation of coagulation and inhibition of fibrinolysis 
(Chambers and Scotton, 2012; Crooks and Hart, 2015).  
The cellular response of activated coagulation pathway is chiefly mediated by 
proteinases in conjunction with a family of proteinase-activated receptors (PARs), 
comprising of four members, PAR1 to PAR4 (Chambers and Scotton, 2012). 
Thrombin and factorVIIa-FXa complex are potent activators of PAR1. Increased 
expression of PAR1 is seen on epithelial cells, alveolar macrophages and fibroblasts 
in patients with IPF. Activation of PAR1 leads to increased release of inflammatory 
and fibrotic mediators like TNF, TGFβ, PDGF and PAI. PAI inhibits fibrinolysis 
while TGFβ, PDGF promote proliferation and differentiation of myofibroblasts. 
PAR1 stimulation also promotes collagen production by lung fibroblasts and their 
differentiation to myofibroblasts (Chambers and Scotton, 2012). 
 
Therefore, an abnormal epithelial cell (mainly AEC2) in association with abnormal 
extracellular matrix perpetuates dysregulated wound healing mechanism, which 
results in aberrant lung re-modelling. Re-epithelialisation of damaged alveolar 
epithelium is aberrant (in the absence of AEC1) and the rate of collagen deposition 
exceeds degradation, resulting in lung fibrosis, destruction of alveolar architecture and 
impairment of gas exchange during respiration. 
 
The microscopic features support the proposed new theory of repetitive epithelial 
injury in pathogenesis of IPF. Histology shows “typical UIP pattern” with temporal 
and spatial heterogeneity within the lungs. This means areas of normal lung alternate 
with areas of interstitial fibrosis, lung destruction and honeycombing in varying 
severity. An aggregation of fibroblasts and myofibroblasts within the extracellular 
matrix called “fibroblastic foci” are found adjacent to the fibrotic tissues which 
represent areas of active fibrosis. Fibroblastic foci is a diagnostic feature for 
histopathological diagnosis of UIP fibrosis.  
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Figure 2 demonstrates the histological features of UIP pattern essential for diagnosis 
of IPF 
 
	
	
Figure 2: Histological features of UIP pattern fibrosis.  
The picture on the left points to areas of fibrosis, honeycombing changes and fibroblastic foci. The image on the 
right demonstrates a fibroblastic focus at higher magnification. (Picture uploaded from Wikimedia.org after 
Internet search on google.co.uk) 
 
Mutations in the surfactant protein C gene (SFTPC) and protein A2 gene (SFTPA2) 
have been reported in some cases of familial pulmonary fibrosis (where two or more 
members of the same family have been affected) (Garcia C. K., 2011). These proteins 
are solely expressed by AEC2 cells and mutations in the genes result in accumulation 
of abnormal proteins which can cause persistent epithelial injury. 
 Terminal bronchi express MUC5B gene, which encodes for mucin 5B, a precursor 
protein that helps in mucus production.  A common variation in the MUC5B gene 
promoter region has been implicated as a genetic risk factor in the development of 
familial as well as sporadic cases of IPF. Overexpression of MUC5B lead to increased 
protein concentration causing impaired mucociliary clearance, retention of particles 
and repetitive epithelial injury. Alternatively, mucin play a vital role in innate 
immunity and immune dysregulation contributes to the development of lung fibrosis 
(Kaur et al., 2017).  
 Telomerase is an enzyme which promotes the addition of nucleotide to the terminal 
ends of the chromosomes. Telomerase reverse transcriptase (TERT) in association 
with telomerase RNA (TERC) preserve and maintain telomerase enzyme. Mutations 
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in the TERT and TERC genes have been demonstrated predominantly in familial 
pulmonary fibrosis (heterozygous mutation in TERT and/or TERC reported in 
approximately 15% of patients with familial pulmonary fibrosis). TERT mutation was 
the commonest genetic defect seen in familial pulmonary fibrosis (Garcia C. K., 
2011). 40% of TERT mutation carriers reported some symptoms of pulmonary 
fibrosis by the mean age of 51 years and died at an early age (average age at death for 
males 57.7 years and females 66.6 years). Mutations in TERT/TERC genes were also 
associated with other symptoms like aplastic anaemia, cirrhosis and premature 
greying. The pathogenesis of fibrosis is proposed to be due to progressive shortening 
of telomere lengths (to successive cell division) and premature consumption of 
progenitor cells, thereby compromising epithelial repair after tissue injury (Garcia C. 
K., 2011; Kaur et al., 2017).  
Interestingly, restricted telomere lengths have been demonstrated in a few patients 
with familial and sporadic IPF, in the absence of mutations in telomerase. Cronkhite 
et al. (2008) found short telomere lengths (less than 10 percentile when compared to 
healthy adults) in 24% and 23% of patients with familial and sporadic pulmonary 
fibrosis respectively, with no mutations in TERT or TERC genes. Radiological 
features consistent with IPF are often noted on CT scans of asymptomatic individuals, 
especially over the age of 75 years (King et al., 2011). Progressive shortening of 
telomeres has also been advocated as one of the possible mechanism in age-linked 
pulmonary fibrosis.  
Although growing evidence suggests genetic predisposition increases the risk of 
development of IPF no genetic factors have shown direct cause-effect relationship, 
especially in cases of sporadic IPF.  
 
Multiple environmental agents, namely cigarette smoking, exposure to 
organic/inorganic dust (metal and wood dusts, stone, silica) and viral infections (e.g. 
Epstein Barr Virus, Cytomegalovirus, Human Herpes Viruses 7 and 8) (Vannella et. 
al. 2008) have been implicated in the initiation and/or perpetuation of alveolar 
damage leading to pulmonary fibrosis. However no agent(s) have been consistently 
associated with development of IPF to establish a causal relation. 
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In recent years, the role of gastro-oesophageal reflux disease (GORD) and micro-
aspiration in the development of lung fibrosis has generated interest (Fahim et. al., 
2011; Raghu and Meyer, 2012; Lee et al., 2013). Recurrent aspiration of stomach and 
bile acids causing “repetitive alveolar cell injury” leading to progressive fibrosis has 
been proposed as a possible mechanism in the pathogenesis of IPF. This is discussed 
in further details in section 2.3. 
2.2 IPF and cough 
 
73-86% of patients with IPF suffer from cough (Crystal et al., 1976; Turner-Warwick 
et al. 1980; Key et al., 2010). It can be a presenting and a complicating feature of IPF. 
Cough is often non-productive and persistent with significant impact on quality of life 
(both social and physical). Key et al. (2010) objectively measured cough rates in 
patients with IPF and investigated the association between the objective and 
subjective measures of cough. Their study showed significantly higher cough counts 
in IPF patients (median cough rate of 9.4 per hour) compared to asthmatics and 
healthy volunteers (cough rate of less than 1 per hour). The study confirmed that 
cough is a major disabling symptom, with a strong correlation between objective 
cough assessment and cough-related quality of health measures in patients with IPF. 
 
Physiologically, cough is a protective reflex, which helps clear mucus, secretions and 
noxious substances from the airways (McGarvey et al., 2007). It is mediated by the 
afferent vagus nerve, which mainly innervate the central and proximal airways 
(Kilduff et al.,2014). Studies have shown heightened cough reflex sensitivity 
(measured by the concentration of inhaled capsaicin needed to induce 2 – 5 coughs) in 
patients with IPF (Doherty et al., 2000). This suggests up-regulation of sensory c 
fibres in the airways, which are sensitive to chemical stimulation. Similar increase in 
sensitivity of the cough reflex has also been reported in patients without IPF who have 
chronic cough and reflux disease. 
 
Patients with IPF express increased levels of neurotrophins in their lungs (Harrison et 
al., 2013). Induced sputum from IPF patients contains higher concentrations of nerve 
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growth factor (NGF) and brain-derived neurotropic factor (BDNF) compared to 
normal controls (Hope-Gill et al., 2003). Bronchoalveolar lavage (BAL) fluid from 
IPF patients contains higher levels of NGF than healthy controls (Jones R. M., 2012; 
Harrison et al., 2013). A single immunological study found enhanced expression of 
NGF and TrKA (neurotrophic tyrosine kinase receptor type 1) in the lungs of patient 
with IPF compared to other interstitial lung diseases (Ricci et al., 2007). The 
fibroblastic foci in particular showed immune staining for BDNF and TrKB 
(neurotrophic tyrosine kinase receptor type 2). Data show NGF can enhance both 
cough and airway obstruction via a mechanism that involves the activation of the 
TrKA receptor and TRPV1 (Transient Receptor Potential Vanilloid – 1) (Caterina et 
al., 1997; Caterina and Julius, 1999; Groneberg et al., 2004). 
 
Treatment of cough in IPF remains difficult. Current practice involving opiate-based 
anti-tussives (like codeine or low dose slow release morphine) has limited therapeutic 
benefits (Pavord and Chung, 2008). In a small uncontrolled, open label study, high 
dose steroids for a month were shown to reduce cough sensitivity to capsaicin and 
cough symptom score suggesting that cough in IPF should be amenable to 
pharmacological therapy.  In another open-labelled trial of oral interferon-α, five of 20 
patients reported improvement in cough symptoms (Lutherer et al., 2011). However, 
these are small open label studies and it is well known that cough as a symptom is 
highly influenced by placebo effect. Gabapentin has shown promise in refractory 
chronic cough, improving cough-specific quality of life compared to placebo after 8 
weeks of therapy (Ryan et al., 2012). However, patients in the study were chronic 
coughers with no active respiratory disease (i.e. IPF) or infection. Also, side effects 
occurred in 31% of patients, including nausea, fatigue and dizziness. 
 
A recently concluded double-blinded, two-treatment, two-period cross over trial 
comparing thalidomide with placebo showed beneficial effects on cough and quality 
of life as determined by questionnaires and visual analogue scale in IPF (Horton et al, 
2012). However study participants represented a small number of self-referred 
patients with mild IPF, who had other possible causes of cough (70% had reflux 
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disease and 30% were on angiotensin converting enzyme inhibitors (ACEi) for 
hypertension). In addition the side effect profile of thalidomide included constipation, 
dizziness, drowsiness, increased risk of infection and peripheral neuropathy, and 
hence thalidomide cannot be regarded as an ideal therapeutic option. 
 
Thus there is a need for better treatments for cough, which can only be developed 
through better understanding of the pathogenesis of cough in IPF (interestingly IPF, 
despite being a disease in the peripheries of the lung, causes disabling cough, a reflex 
typically mediated by nerves which are predominantly centrally located). 
2.3 IPF and Gastro-oesophageal reflux disease (GORD) 	
Recurrent aspirations secondary to gastro-oesophageal reflux have been postulated in 
the pathogenesis of IPF by perpetuating epithelial injury. As stated previously, the 
cough receptors are predominantly located proximally and the pathological changes in 
the lungs in IPF are predominantly peripheral. This raises a strong possibility of a link 
between gastro-oesophageal reflux disease, cough and IPF. 
2.3.1 Gastro-oesophageal reflux disease  	
Reflux of gastric contents into the oesophagus can be a physiological event 
(Bredenoord et al, 2013). In healthy adults reflux episodes can occur through out the 
day but are mainly postprandial. 
 
GORD disease is defined as reflux that causes distressing symptoms (typically 
heartburn and regurgitation) with or without mucosal injury to the oesophagus 
(Bredenoord et al., 2013). Patients with GORD often show oesophageal erosion, 
ulceration or intestinal metaplasia at endoscopy. However, by definition oesophageal 
lesions are not essential for a diagnosis of GORD and this subgroup of patients are 
generally said to suffer from non-erosive reflux disease. 
“The anti-reflux barrier” prevents reflux. It consists of three major components: 
1. The crural diaphragm 
2. The lower oesophageal sphincter (LOS) 
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3. The “anatomical flap valve” 
 
The right crux of the diaphragm forms a sling that surrounds the distal oesophagus, 
creating a teardrop shaped hiatal canal. This structure serves as an extrinsic sphincter 
and reinforces the high-pressure zone of the lower oesophageal sphincter. 
 
The LOS is a 3-4 cm segment of tonically contracted circular smooth muscle at the 
distal end of the oesophagus (manometry reveals this to be a high pressure area). It is 
also known as the “intrinsic sphincter”. In healthy individuals the resting tone of the 
LOS may vary from 10 – 35 mm Hg relative to intragastric pressure. The most 
common mechanism for reflux is transient lower oesophageal sphincter relaxations 
(TLOSRs). These are mediated by the vagus nerve in response to gastric distension to 
enable gas venting from the stomach. These are independent of swallows. On average, 
a TLOSR lasts for about 20 sec., which is significantly longer than the typical 
swallow-induced relaxation.	
 
In healthy individuals, the oesophagus enters the stomach at an acute angle called the 
angle of His. The “anatomical flap valve” is present at the oesophago-gastric junction 
and its primary functions are to maintain the angle of His and to retain the terminal 
part of the oesophagus in the abdomen. 
 
Both the intrinsic and extrinsic sphincters are weakened by disruption of the flap 
valve and migration of the LOS above the crural canal, contributing to reflux. Severe 
reflux disease occurs when the LOS is permanently displaced proximally above the 
diaphragm and swallow-associated reflux from the hiatal sac impairs oesophageal 
clearance. Endoscopically, the flap valve can be inspected and graded with the Hill 
classification (as shown in Figure 3). 
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Figure 3. Progressive anatomical disruption of the gastro-oesophageal junction as it relates to the flap valve 
anti-reflux barrier.  
Upper panels: 3-D endoscopic anatomy with endoscope retroflexed. Lower panels: endoscopic manifestations of 
the flap valve grade (Figure adapted from Bredenoord et al. Lancet 2013; 381:1934). 
 
Peristaltic dysfunction of the oesophageal body can predispose to reflux disease. 
Failed peristalsis and hypotonic peristaltic contractions can both result in incomplete 
emptying and prolonged mucosal exposure to refluxate. An extended period of acid 
exposure is known to cause oesophagitis and Barrett’s oesophagus.   
 
The “acid pocket” refers to a layer of unbuffered gastric acid that sits on top of the 
meal in the postprandial period. It is close to the gastric cardia and is facilitated by the 
absence of peristaltic contraction in the proximal stomach (and hence the potential to 
reflux easily). In patients with reflux disease, the acid pocket is located more 
proximally and could even extend beyond the manometrically located LOS. 
 
Physiological or pathological conditions that chronically increase intra-abdominal 
pressure augment the risk of reflux disease. The gastro-oesophageal pressure gradient 
is amplified in pregnancy, cough and obesity and plays a pivotal role in associated 
reflux symptoms. 
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Thus signs and symptoms of reflux can occur secondary to distal oesophageal acid 
exposure when frequency and volume of reflux is excessive or the oesophageal 
mucosa is hypersensitive and/or injured.		
2.3.2 IPF and gastro-oesophageal reflux disease 
 
GORD is detected in 10-20% of healthy western population (Fahim et al., 2011). 
GORD is a known cause of persistent cough (McGarvey et al., 2007; Chung and 
Pavord, 2008). A diagnosis is usually made after resolution of the symptoms 
following treatment with high dose anti-acid therapy, usually by a proton pump 
inhibitor (PPI) like omeprazole or lansoprazole. 
GORD has been associated with a number of chronic respiratory conditions. 62% of 
patients with severe chronic obstructive pulmonary disease (COPD) demonstrated 
pathological reflux disease in comparison to 19% of healthy controls (Casanova et al., 
2004). In a study by Terada et al., (2008), approximately 27% of COPD patients 
reported reflux symptoms compared to 12% of healthy volunteers and presence of 
reflux symptoms were significantly associated with exacerbation of COPD (p<0.01). 
Subsequently, Benson et al., (2015) also demonstrated a high prevalence of reflux 
disease in a large cohort of COPD patients (n=2135) and reflux symptoms with or 
without antacid therapy was associated with increased risk of exacerbation of COPD 
and hospitalisation (HR=1.58, 95% CI=1.35-1.86).  
Similarly, both symptomatic and silent reflux disease has been demonstrated in 
patients with non cystic fibrosis bronchiectasis (prevalence rate 26-75%) and cystic 
fibrosis patients (prevalence 35-81%) and seem to be associated with a more severe 
disease pattern (Lee et al., 2011; Robinson and DiMango, 2014).  
 
GORD is significantly more frequent in patients with IPF than in age- and sex-
matched controls. As early as the 1970s, Pearson reported 6 cases of pulmonary 
fibrosis with hiatus hernia (Pearson et al, 1971). Mays et al (1976) later demonstrated 
fluoroscopic evidence of gastro-oesophageal reflux in patients with IPF compared to 
age-matched controls. 
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In 1998, Tobin et al, demonstrated abnormal distal acid exposure in 16 out of 17 
patients with IPF compared to four out of eight controls, using ambulatory pH 
monitoring. Interestingly, only 4 of the IPF patients with reflux disease reported 
typical reflux symptoms. The study also showed that proximal supine reflux was 
common. Although this study had a small sample population, subsequent studies have 
reported similar findings. 
 
In a study by Raghu et al (2006), sixty-five consecutive patients with well-defined IPF 
were subjected to 24-hour pH monitoring and oesophageal manometry. A total of 133 
consecutive patients with intractable asthma and symptoms of GORD were used for 
comparison. The prevalence of abnormal acid GORD in IPF patients was 87%, with 
76% and 63% demonstrating abnormal distal and proximal oesophageal acid 
exposures, respectively. Abnormal acid GORD was significantly more common in 
IPF patients than in asthma patients. Only 47% of IPF patients experienced classic 
GORD-related symptoms. There was no correlation between IPF severity and acid 
GORD severity. In conclusion, abnormal acid gastro-oesophageal reflux is highly 
prevalent, but often clinically occult in patients with idiopathic pulmonary fibrosis. 
 
A recent study by Kilduff et al. (2014), on 18 subjects with IPF recorded a high 
proportion of proximal reflux events (mean 74.7%) and supine reflux events in the 
study cohort as a whole. Acid reflux events were noted to be within normal limits by 
the study but the size of the sample cohort was limited.   
 
Raghu et al in 2006 presented a retrospective review of the clinical outcomes of four 
patients with newly diagnosed IPF and increased acid reflux, who chose to be treated 
solely with anti-acid reflux therapy. Pulmonary function test (PFT) results in all four 
patients stabilized and/or improved while their conditions were maintained with 
adequate treatment for acid reflux. 
Studies have suggested that surgical correction of reflux in IPF reduces disease 
progression. Linden et al. (2006), compared post-operative lung function tests in 14 
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IPF patients on a transplant waiting list with reflux disease who underwent Nissen 
fundoplication, to 31 IPF patients who did not undergo anti-reflux surgery. Over an 
average period of 15 months follow up, patients who had undergone surgery 
maintained stable lung function and stabilisation in oxygen requirement was also 
noticed. 
In a retrospective study of 204 patients with IPF by Lee et al. (2011), therapy for 
reflux disease was an independent predictor of longer survival. In addition use of 
reflux medication was associated with lower radiologic fibrosis score. 
2.3.3 Reflux, Aspiration and IPF 	
Studies have demonstrated biomarkers of aspiration in the BAL fluid samples of 
patients with IPF. Savarino et al. (2013), reported that 40 consecutive IPF patients had 
significantly higher (p<0.01) oesophageal acid exposure, and number of weakly acidic 
and proximal reflux events, compared to 40 non-IPF ILD patients and 50 healthy 
volunteers. Patients with IPF had more bile acids and pepsin (p<0.03) in BAL fluid 
(62% and 67%, respectively) and saliva (61% and 68%, respectively) than non-IPF 
patients (25% and 25% in BAL fluid, and 33% and 36%, respectively, in saliva) and 
controls (0% and 0% in BAL fluid and saliva, respectively).	
 
In 2012, Lee et al. measured gastric pepsin levels in BAL fluid from 24 patients with 
acute exacerbation of IPF and compared this to 30 patients with stable disease. They 
detected measurable pepsin levels in most patients with stable IPF. On average the 
pepsin concentration in BAL fluid was higher in patients with acute exacerbation 
compared to stable controls (median level of 46.8 ng/ml in acute exacerbation versus 
35.4 nanogram/ml in controls). The study demonstrated pepsin level was an indicator 
of acute exacerbation status (p=0.04) in IPF. This was mainly driven by a subgroup of 
8 patients (in the acute exacerbation group) with markedly high pepsin concentration 
in their BAL fluid (greater than or equal to 70 ng/ml).  
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Therefore, findings from the above studies demonstrate a stronger association of 
GORD with IPF and suggest aspiration secondary to GORD may play an important 
role in the natural progression of IPF. 
 
The definitive treatment of reflux disease is surgery in the form of fundoplication. 
This is done under general anaesthesia and mechanical ventilation. The majority of 
patients with IPF also suffer from additional cardiovascular co-morbidities (like 
hypertension, diabetes mellitus, stroke, ischaemic heart disease) putting them at 
higher risk for adverse events relating to general anaesthetics. This means only a few 
IPF patients are suitable for surgery. In this context effective medical therapy may be 
more useful. International consensus recognises the potential relationship between 
reflux and IPF and agrees further research is necessary to improve care in IPF. 
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Chapter 3. Methods: PPIPF study  	
Based on the literature, both acid and non-acid reflux is common in patients with IPF. 
3.1 PPIPF study hypothesis 	
Therefore the hypotheses underlying the planned study were: 
1) Acid reflux causes cough in patients with IPF 
2) Acid suppression therapy will significantly ameliorate cough with immediate 
improvement in quality of life 
3) Acid suppression therapy by itself might be sufficient to reduce the rate of decline 
in IPF. 
3.2 Usefulness of the PPIPF study 	
The study aimed to  
1) Assess severity of cough and its impact on quality of life in patients with IPF 
2) Objectively measure both acid and non-acid reflux in patients with IPF.  
 
Anti-acid therapy blocks or neutralises gastric acid in the stomach but does not 
actually prevent reflux. The role of non-acid reflux in pathogenesis of cough and 
fibrosis is not clearly understood. Fibrosis of lung parenchyma can trigger up-
regulation of central cough receptors by mechanical distortion of the proximal 
airways thereby providing an alternative explanation for cough in IPF. Additionally, 
lung fibrosis can disrupt the anti-reflux barrier by altering the anatomical relation 
between LOS and crural diaphragm. Fibrosis can also impair oesophageal motility, 
which in turn will slow bolus clearance, increasing exposure time to reflux, thereby 
precipitating reflux disease frequently found in IPF patients. Hence there is a 
theoretical possibility that acid suppression therapy might not improve cough in 
patients with IPF. 
 
Even if anti-acid therapy in the trial failed to improve cough in IPF patients, the study 
is expected to provide further insight into role of non-acid therapy in IPF and inform 
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management strategies.  If the study showed significant improvement in cough with 
acid suppression therapy then it would provide robust scientific evidence for an 
inexpensive therapeutic option for a distressing symptom in IPF. This will help design 
further multi-centre definitive trials prior to routine clinical practice. Long term 
antacid therapy is potentially associated with increased risk of infection (like 
pneumonia) due to alteration of the normal gut organism. Our study was planned to 
assess adverse events associated with antacid therapy. Either way the study was 
expected to generate new knowledge to guide future treatment for IPF patients. 	
3.3 Study drug: Omeprazole - drug class and licensed indication 	
Omeprazole is a widely used acid suppressant medication belonging to the class of 
drugs commonly referred to as proton pump inhibitors (PPI). It is a selective inhibitor 
of the hydrogen/potassium-adenotriphosphatase (H+/K+-ATPase) enzyme system 
found on the surface of gastric parietal cells, which is responsible for secretion of 
hydrogen ions or protons in the gastric lumen (the acid/proton pump). Omeprazole 
therefore inhibits both basal and stimulated acid secretion by reversibly inhibiting the 
final step of gastric acid production (Robinson, M., 2004).  
 
Omeprazole is available over the counter and prescribed in [Vanderhoff and Tahboub, 
2002; Summary of product characteristics (SmPC): omeprazole, version 4, 2013, 
Bristol Laboratories Ltd]: 
 
1. Treatment and prevention of relapse of gastric ulcers 
2. Treatment and prevention of relapse of duodenal ulcers 
3. Treatment and/or eradication of Helicobactor pylori-induced peptic ulcer 
disease (in combination with antibiotics) 
4. Treatment and prevention of non-steroidal anti-inflammatory drug (NSAID)-
induced peptic ulcer disease 
5. Treatment of reflux oesophagitis. 
 
Long-term omeprazole therapy is employed in the management of: 
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1. Zollinger-Ellison syndrome 
2. Symptomatic gastro-oesophageal reflux disease 
3. Healed reflux oesophagitis. 
	3.3.1 Dose and duration 	
Omeprazole 20 mg daily is usually prescribed for the management of peptic ulcer 
disease and symptomatic reflux disease. In most patients with duodenal ulcers healing 
occurs in 2 weeks whereas gastric ulcers may take up-to 4 weeks to heal. Patients with 
inadequate response or incomplete healing are often prescribed 40mg omeprazole 
(higher dose) daily for an extended period (SmPC: omeprazole, version 4, 2013, 
Bristol Laboratories Ltd). 
 
Omeprazole is acid-labile and hence is administered orally as enteric-coated capsules 
or tablets. Absorption of omeprazole is rapid via the small intestine and achieves peak 
plasma concentration in 1-2 hours post-ingestion (Vanderhoff and Tahboub, 2002). In 
patients with duodenal ulcer once a day 20 mg omeprazole will maintain an intra-
gastric pH >/= 3 over a mean time of 17 hours in a 24 hour period (Miner Jr et al., 
2003; SmPC: omeprazole, version 4, 2013, Bristol Laboratories Ltd).  
 
For these reasons a twice daily dosing schedule of omeprazole 20 mg was chosen for 
the study. 
3.3.2 Clinical pharmacology 	
Omeprazole is a weak base. It is concentrated and converted to active form in the 
gastric parietal cells. It is completely metabolised by the hepatic cytochrome P450 
enzyme system. It is mainly excreted via the urine (80%) while the rest is excreted via 
the faeces (Welage and Berardi, 2000;Vanderhoff and Tahboub, 2002).  
 
Omeprazole is a competitive inhibitor of CYP2C19 and CYP3A4 enzymes (Arnold, 
R., 1994;Reilly, J.P., 1996;Welage and Berardi, 2000). This raises the risk of 
							
24	
interaction with other medications that are metabolised by these hepatic enzymes. In 
addition, the half-life of omeprazole is prolonged in patients with hepatic disease due 
to delayed metabolism. For these reasons patients with documented hepatic cirrhosis 
(or advanced hepatic disease) and patients with current drug therapy with warfarin, 
phenytoin, diazepam or azoles (anti-fungal medications) were excluded from the 
study (Reilly, J. P., 1996;Vanderhoff and Tahboub, 2002). 
In addition, recent evidence suggests warfarin is associated with more adverse events 
in patients with IPF hence patients on warfarin therapy were excluded from the study 
(Noth et al., 2012). 
Patients on anti-fungal therapy could be included in the study on completion of 
therapy. 
	3.3.3 Adverse effects 	
Omeprazole is a commonly prescribed anti-acid therapy. The overall incidence of side 
effects is reported to be less than 5% (Arnold, R., 1994;Reilly, J.P., 1996; Welage and 
Berardi, 2000). Commonly reported side effects are headache, abdominal pain, 
constipation, diarrhoea, flatulence, nausea and vomiting (occurring in between 1-10% 
of patients). Prolonged periods (greater than equal to 3 months) of omeprazole 
therapy have been associated with hypomagnesaemia and increased risk of fractures 
(hips, wrist, spine). Rare (frequency > 1/10,000 to < 1/1,000) documented side effects 
associated with omeprazole therapy include hypersensitivity reactions, 
hyponatraemia, leukopenia, thrombocytopenia, skin rashes and interstitial nephritis. 
	3.3.4 Administration schedule 	
Participants were prescribed omeprazole 20 mg twice a day for 3 months.  
	3.3.5 Manufacture and supply 	
Omeprazole and matched placebo were supplied by Victoria Pharmaceuticals, Royal 
Hospitals, Belfast BT12 6BA. 
 
 
							
25	
3.4 PPIPF study design 	
The study was a prospective, randomised double-blinded, placebo-controlled single-
centre, pilot trial of omeprazole in patients with IPF. The study was designated as a 
“pilot trial” as it sought to provide proof of concept of reduction in cough with anti-
acid therapy in patients with IPF. Therefore major focuses of the study were rate of 
eligibility, participant recruitment and retention, and yield and quality of data, 
especially with regards to the proposed secondary outcomes (Johnson et al., 2005). 
This will help design further multi-centre definitive studies in future. 
3.4.1 Patient population/Recruitment 	
Patients were recruited from the specialist ILD clinic at the Royal Victoria Infirmary 
(RVI) in Newcastle. RVI is the regional tertiary specialist centre for ILD. Eligible 
patients from across the region are routinely referred to the RVI clinic for initiation of 
anti-fibrotic therapy (i.e. pirfenidone and/or nintedenib) in IPF. 
 
I regularly attended the Tuesday afternoon clinic to recruit participants for the study. I 
screened patients with a diagnosis of IPF aged between 40 and 85 years. Cases with 
an incident or prevalent diagnosis of IPF were recruited. 
3.4.2 Sample size 	
This was a pilot trial. The analysis of data was expected to be mainly descriptive, 
hence no formal sample size was calculated (Hertzog 2008). Good practice guidelines 
recommend 20-30 participants per treatment arm should provide sufficient 
information to adequately assess feasibility and distribution of data, and to estimate 
the standard deviation of major study parameters (Lancaster et al., 2002; Schelling 
2003). Therefore the aim of the study was to recruit 60 IPF patients in total 
(approximately 30 patients in the omeprazole arm and 30 patients in the placebo arm). 
This was expected to ensure at least 20 patients per treatment arm completing study 
follow up, allowing for an attrition rate of up to 33%. 
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3.4.3 Inclusion criteria 	
Patients who fulfilled all of the following criteria were recruited for the study:  
• The ILD multidisciplinary team (ILD-MDT) at Newcastle considered IPF as 
the most likely diagnosis  
• The patient had a history of cough, with or without exertional breathlessness 
• The presence of predominantly basal, sub-pleural honeycombing changes on 
high resolution computed tomography (HRCT) scan of the chest  
• The presence of bilateral basal crepitation on auscultation of chest 
• Lung function tests consistent with a restrictive ventilatory pattern, with vital 
capacity (VC) <90% predicted and/or transfer factor capacity of the lung for 
carbon monoxide (TLco) <90% predicted 
• Age between 40 – 85 years. 
	
Patients with evidence of emphysema on their scan were also eligible for the study as 
long as IPF was the predominant feature and all of the above criteria were met.  
	
In the event of no clear consensus as to the diagnosis in the ILD-MDT, the plan was 
to include patients in the study only if 2 external experts (from outside the region) in 
ILD ratified the diagnosis of IPF as being mostly likely. 	
 
Patients already on anti-acid therapy (i.e. PPI) at screening were potentially eligible 
for recruitment to the study. In those patients, the indication for PPI therapy was 
reviewed. Patients who had been on PPI for a short period (e.g. 2 months) were 
eligible after a month of cessation of anti-acid therapy. Patients on PPI therapy for 
prolonged periods were also eligible after discontinuation of PPI unless they had a 
clear indication for prolonged therapy. Apart from Zollinger-Ellison Syndrome (ZES), 
there are only a few medical conditions that require prolonged therapy with PPI. 
Hence, I reviewed each patient’s history and case notes and/or contacted his/her 
general practitioner (GP). If there was no known diagnosis of ZES or history of 
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significant gastro-intestinal bleed or dyspepsia, I requested patients to consider a trial 
of supervised discontinuation of PPI therapy. 
 
I contacted the respective GPs of patients who expressed a wish to take part in the 
study but were on long-term PPI therapy. If they were in agreement, the patient signed 
a consent form to agree to discontinue PPI therapy for a period of 2 weeks. If patients 
developed any symptoms during the supervised 2-week period then they re-started 
therapy and were excluded from the study. If however they remained asymptomatic 
(without their usual PPI therapy) for the 2-week period, they were recruited for the 
study. Similarly, patients on antacids like raft alginates and/or pro-kinetics were also 
potentially eligible for the study if they remained well off the treatment for a period of 
at least 2 weeks. 	
3.4.4 Exclusion criteria 	
Patients were excluded from the study if they fulfilled any of the following criteria: 
• Documented allergy to omeprazole or any other PPI  
• Concurrent therapy with warfarin, diazepam, phenytoin or azole therapy (like 
ketoconazole) 
• Requirement for regular therapy with antacids such as PPI, raft alginates 
and/or prokinetics like metoclopramide (especially during the trial period) 
• History of exacerbation of IPF and/or history of upper or lower respiratory 
tract infection within the prior 4 weeks of starting the study drug 
• Treatment started specifically for IPF (e.g. prednisolone, pirfenidone, 
nintedanib, N-acetylcysteine) in the 4 weeks before starting the study drug 
• Documented history of hepatic cirrhosis or advanced liver disease 
• Pregnancy and/or breast feeding  
• ILD not considered to be IPF by the regional ILD-MDT (i.e. patient’s ILD 
was considered to be related to other conditions like rheumatoid lung disease, 
systemic sclerosis, sarcoidosis, asbestosis) 
• Simultaneous participation in another CTIMP for IPF. 
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3.4.5 Intervention 	
Patients were randomised 1:1 either to receive omeprazole 20mg twice daily or 
matching placebo. Medication was taken orally before food for 3 months. 
3.4.6 Primary outcomes 
Primary efficacy outcome 	
The frequency of objectively measured cough from baseline i.e. from beginning of the 
study to the end of treatment (or within the last 2 weeks of completion of treatment) 
between the omeprazole and the placebo group.   
Primary feasibility outcomes 
 
• Assess eligibility rate, recruitment, randomisation and study completion rate 
•   Assess feasibility and acceptability of study-related procedures. 
3.4.7 Secondary outcomes 	
The key focus behind the proposed secondary outcomes was analysis of data 
collection and data quality. The plan was to assess the following efficacy outcomes:  	
		
• Change in subjective assessment of cough at the end of treatment period as 
measured by a validated cough questionnaire 	
• Change in subjective assessment of reflux symptoms at the end of treatment as 
measured by validated reflux questionnaires 	
• Change in acid and non-acid reflux at the end of treatment 	
• Change in VC and TLco at the end of treatment	
• Change in 6 minute walk test at the end of treatment	
• Concentrations of cytokines (such as interleukin-8 and transforming growth 
factor beta) and bile salts/acids in BAL fluid at the end of treatment as 
evidence of on-going lung inflammation 	
• Infection in BAL fluid at the end of treatment 	
• Adverse events as reported by patients. 	
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3.5 PPIPF study procedures 
 
3.5.1 Screening 	
IPF patients attending the dedicated ILD clinic at RVI were screened and recruited for 
the study if they fulfilled the inclusion criteria and consented. I attended the clinic 
regularly every Tuesday. I reviewed the medical records of the patients attending or 
due to attend the clinic. I then provided information relating to the study either in 
person (when they attended the clinic appointment), or by letter to the eligible 
patients. I also made it clear to the patients that they may take as long as they liked to 
consider the information provided, and could contact if they had any further queries. 
Patients who were on an antacid therapy were also considered as outlined in sub-
section 3.4.3. 
 
I then followed up the potential patients with a phone call or at their next clinic review 
(whichever was earliest). I answered any questions and clarified any doubts or 
concerns with regards to the study or related procedures.  
3.5.2 Consent 
 
I was responsible for requesting consent from each participant. Participants were 
randomised and entered into the trial only after they had received information relating 
to the study and signed a written consent form. Once patients expressed interest in the 
study project, and had read the patient information, they were requested to sign the 
study consent form. I requested written consent from the participants in the ILD clinic 
and retained a copy of the form in the case report form. A copy of the consent form 
was filed in the patient’s clinical records, and the patient kept another copy. A letter 
was sent out to the GP informing him/her of the patient’s participation in the study. 
Copies of the GP letter were filed in each patient’s medical notes and in the case 
report form.  
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Patients were aware that they could withdraw from the study at any time without any 
prejudice. Data recorded up to the point of withdrawal were included in the study 
analysis, unless patients withdrew consent to use the collected data.    
 
3.5.3 Randomisation 
 
Participants were randomised via a secure password-protected web site administered 
by the NCTU. It was available 24 hours a day. The web address of the randomisation 
site was https://apps.ncl.ac.uk/random/.  
 
Participants were either randomised to the omeprazole arm or the placebo arm in a 1:1 
ratio using random permuted blocks of size twelve. To ensure concealment of 
allocation, a statistician who had no other involvement with the study generated the 
randomisation schedule. Randomisation generated a unique 3 digit “Study ID 
number” for each participant. This unique number was entered on to the prescription, 
which was then delivered to the Clinical Trials Pharmacy at RVI. Randomisation also 
generated a unique “Trial patient number (pack number)” for the medication pack 
held at Pharmacy. The Study ID number matched the Trial Patient number, hence 
allocation to either omeprazole or the placebo group was double-blinded (i.e. both the 
participant and the research team were blinded to the allocation). 
3.5.4 Drug termination criteria 	
The study drug (omeprazole or placebo) was stopped if any one of the following 
conditions were met at any time during the study period (criteria were agreed pre-
trial):  
• Completed the stipulated 90 days of treatment  
• The patient suffered an adverse event deemed related to the study drug 
• The patient needed regular treatment with an antacid on clinical grounds (as 
decided by the patient’s usual clinical team or GP)  
• The patient declined to continue and/or complete the study 
• Death or a clinical decision to discontinue routine medical treatment.  
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3.5.5 Process of unblinding 	
An agreed protocol (between the trial team and the pharmacy) was put in place prior 
to beginning the trial for emergency unblinding, if such a situation arose. If it was 
deemed essential to know the treatment allocation of a participant, I could be 
contacted via the RVI switchboard or via a 24-hour mobile number (both numbers 
were provided to the participants and were also printed in the PIS). I would then 
contact the clinical trials pharmacist at RVI (during working hours) or the on-call 
pharmacist for The Newcastle upon Tyne Hospitals NHS Foundation Trust (if out of 
working hours) for emergency unblinding. I would then record (at the earliest 
opportunity) the date, time and reason for unblinding in the case report form.   
 
3.6 PPIPF study assessments 	
Participants who consented for the study had the following information collected and 
underwent the following study procedures. 
3.6.1 Demographics 	
I recorded patients’ age, gender, smoking history, medical co-morbidities and current 
list of medication. In addition, baseline observations including height, weight, body 
mass index (BMI), pulse rate, blood pressure, oxygen saturations and respiratory rate 
were recorded. This information helped in assessing patients for suitability of study 
procedures and later in stratification during analysis of study results.	
3.6.2 Questionnaires 	
I used the following 4 questionnaires to assess the impact of cough and reflux on 
health and daily activities of study participants. Questionnaires were administered via 
the chest clinic at RVI during study visit day 1 (pre–treatment) and study visit day 4 
(post-treatment).  
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Leicester Cough Questionnaire (LCQ) 
	
This is a fully validated 19-item cough-related questionnaire (Birring et al., 2003). It 
is divided into 3 domains (physical, social and psychological) to assess the overall 
impact of cough in day-to-day life and also to assess any improvement after 
intervention. It has a 7-point Likert response scale and the total score is calculated by 
adding the domain scores (ranges from 3-21). Each domain score is derived by 
dividing the total score from items within the domain by the number of items in the 
domain (ranges from 1-7). A higher score implies better quality of life.  
LCQ is easy to administer, reproducible and responsive to change [questionnaire was 
developed with help from patients with chronic cough (Birring et al., 2003)]. Birring 
et al. (2003) indicated that a change of 2.56 in the total LCQ score is likely to be 
clinically significant. Yousef et al. (2011) in their study of assessment of quality of 
life in patients with acute cough demonstrated LCQ-acute and it domains were highly 
responsive and the minimal important difference (MID) for total LCQ was 2.5. 
However Raj et al. (2009) demonstrated a LCQ MID of 1.3 for patients with chronic 
cough. 
Although LCQ was not specifically designed for patients with IPF, it is a well 
established cough-related quality of life questionnaire. It has been frequently used in 
longitudinal studies objectively assessing severity of cough and studies assessing 
efficacy of anti-tussives. 
 
Reflux Symptom Index (RSI) 
	
This is a fully validated 9-item questionnaire to assess the possibility of laryngo-
pharyngeal reflux (Belafsky et al., 2002). Each item is rated on a scale of 0 – 5 (0 = 
no problems, 5 = severe problems). Possible scores range from 0 – 45. A composite 
score of 10 or below is taken as normal (Cohen et al., 2005), while scores above 13 
suggest significant reflux disease (Belafsky et al., 2002). Lower scores imply better 
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health. RSI questionnaire is highly reproducible and widely used in clinical practice 
for diagnosis and management of laryngo-pharyngeal reflux disease.  
 
Gastro-Intestinal Quality of Life Index Questionnaire (GIQLI) and De-Meester 
Reflux Questionnaire (DeMRQ) 
 
These two questionnaires are designed to assess quality of life in patients with gastro-
intestinal disease in clinical practice and in clinical studies. 
 
GIQLI is a 36-item questionnaire relating to symptoms attributable to gastro-intestinal 
disease (Eypasche et al., 1995). There are 5 possible options or responses to each 
question with 4 points allocated to the “most desirable option” and 0 points allocated 
to the “least desirable option”. Possible score range from 0 – 144 with higher score 
indicating better quality of life. Healthy individuals have a mean score of 122.6 +/- 
8.5 (Yano et al., 2009). This is an exhaustive questionnaire comprising of a set of core 
questions applicable to patients with any gastro-intestinal disease and several organ 
specific questions. Therefore it is not a specific questionnaire for gastro-intestinal 
reflux disease.  However it is validated, reproducible and is a comprehensive measure 
of patient’s perception of impact of disease (and related treatment) on his/her life.  
 
The DeMRQ questionnaire has been previously used in our research group. This is a 
short 3-item questionnaire to assess health-related quality of life in patients with 
reflux disease (DeMeester et al., 1976). The 3 items/questions relate to symptoms 
usually associated with reflux disease (i.e. heartburn, regurgitation, dysphagia). Each 
item is rated on a scale of 0 – 3 depending upon frequency and severity of occurrence 
(0 = no/none, 3 = severe). Possible scores range from 0 – 9 with low scores indicating 
better quality of life. This questionnaire has not been extensively used in clinical trials 
or research previously. However it is easy to administer and included in the study due 
to earlier experience in our research group.  
							
34	
3.6.3 Lung function tests 
 
Lung function tests are often performed in patients with IPF as part of their routine 
clinical assessment. Hence IPF patients are familiar with the procedure. It is well 
known that early changes in vital capacity (VC) are associated with progression in 
IPF. Also, exploring various secondary end-points is one of the main reasons for 
conducting a pilot trial (Johnson et al., 2005). Therefore spirometry [Forced 
expiratory volume in 1 second (FEV1) in litres and Forced vital capacity (FVC) in 
litres] and gas transfer factors [Transfer factor of lung for carbon monoxide gas 
(TLco) in mmol/min/Kpa) and Transfer factor coefficient of lung for carbon 
monoxide gas (Kco) in mmol/min/Kpa/litres] were assessed for the purpose of this 
trial. Lung function tests were performed by the specialist physiologists at the Chest 
Clinic in RVI, using an Nspire body plethysmograph as per standard international 
guidelines (Miller et al., 2005;Macintyre et al., 2005). 
3.6.4 Six minute walk test (6MWT) 
 
6MWT measures the distance that a patient can walk on a flat, hard surface in 6 
minutes. It is an useful measure of exercise capacity in various cardio-pulmonary 
diseases. Short term reproducibility of 6MWT is excellent when performed by the 
same person or technician [American Thoracic Society (ATS) statement: guidelines 
for the six minute walk test, March 2002]. The median distance walked by healthy 
men and women in 6 minutes was 576 m and 494 m respectively (Enright et al., 
1998). Reidelmeier et al., (1997), reported that a minimal difference of 54 m in 
6MWT distance was associated with subjective change in exercise capacity in stable, 
severe COPD patients.  
 
6MWT is commonly undertaken in patients with IPF to assess overall functional 
capacity. In a study of 123 IPF patients by Swigris et. al., (2010), 6MWT distance did 
not change significantly from baseline over a period of 12 months and the MID for 6 
minutes walk distance was estimated to be approximately 28 m. However the study 
included only a small number of moderately severe IPF patients and data from 
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patients who died or who were unable to perform 6MWT were not included in the 
analysis. Du Bois et. al., (2010), assessed validity, reliability and responsiveness of 
6MWT in a large group of IPF patients (n=826). They determined an MID of 24-45 
m. They also demonstrated that a decline of more than 50 m in 6 minutes walk 
distance over 24-weeks was associated with 4 fold increased risk in mortality in 1 
year (p<0.001). Therefore, both the studies concluded 6MWT is a valid and reliable 
measure of disease condition in IPF. The later study suggested 6MWT is an important 
prognostic marker and can be used as a key endpoint for clinical trials in patients with 
IPF. 
 
I performed the 6MWT at the Chest Clinic in RVI as per standard international 
guidelines. Two points (distance between which is known or measured prior to the 
test) are marked on a level surface and the patient walks between the points for a 
period of 6 minutes. The patient can stop and/or rest at any point if they are too 
breathless to continue or have other symptoms such as joint pains, chest pain etc. The 
total distance managed is calculated at the end of 6 minutes and any change in 
symptoms or reason for early discontinuation of test is recorded.  
3.6.5 Twenty-four hour cough recording 
 
I am grateful to Prof Jacky Smith (Co-Investigator, University of Manchester) and her 
team for their continued help and support with the 24-hour ambulatory cough 
recording. I have visited Manchester (Cough Research Centre) on multiple occasions 
to learn setting up of cough monitors, securing electronic transfer of cough recording 
(to Manchester), and formatting of the recording data cards. They provided the cough 
recorders and the cough sensors for the study.  
 
The cough recorder objectively measures cough frequency over a period of 24 hours 
(McGuiness et al., 2012). It involves participants wearing a CE marked lightweight 
digital sound recording device Vitalojak (Vitalograph Ltd, Birmingham, UK) for 24 
hours while performing their day-to-day activities. There are two microphones 
attached to the recorder – the first is an Air Microphone, which can be clipped to a 
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lapel or collar (of the shirt or jacket of the participant) and records all sounds. The 
second is a Chest Sensor, which is attached to the skin over the top of the sternum and 
records sounds from the chest wall. The device has an internal 4GB data card on 
which the sound is recorded. The device is inserted in a small bag, which is then 
secured around the waistline with help of an adjustable belt with self-locking clips (as 
shown in Figure 4 and Figure 5). 
 
 
 
 
 
Figure 5: Cough recording device carried around 
waistline in a bag (adapted from “cough count 
training” power point presentation provided by the 
cough research team at Manchester). 
 
The procedure is well tolerated with no major discomfort reported by previous 
research participants (McGuiness et al., 2012). On completion of recording, 
anonymised sound recording is transferred electronically via a File Zilla application to 
a secure server at the University of Manchester. The actual cough count is calculated 
from the 24-hour recording with help of a specially developed, fully validated 
software programme (CoolEdit 2000, Syntrillium Software Corp., USA). Cough is 
counted manually, hence the 24-hour recording is cut down and compressed by the 
custom-made software by removing background noises, silent periods and the 
majority of speech, with the aim of retaining only the coughs. This generates 24 tracks 
or files each representing 1 hour of real time. An expert cough counter in Manchester 
then listens to all the files and electronically tags all the cough sounds thereby 
Figure 4: Vitalojak cough recording device with 
the 2 microphones.  
A: Air Microphone; B: Chest Sensor 
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generating a report of cough counts per hour (including daytime and night time cough 
rates). The reports were then returned to us.  
 
The act of coughing involves the intake of a large volume of air followed by rapid 
expulsion associated with an explosive sound. A typical cough consists of an 
“explosive phase”, an “intermediate phase” and a “voiced phase”.  
 
Figure 6 demonstrates a series of coughs with the explosive and the voiced phases 
marked (adapted from “cough count training” power point presentation provided by 
the cough research team at Manchester). 
 
	
	
Figure 6: Series or “spasms” of coughs. Arrows point to the explosives and voiced phases of each cough 
(adapted from “cough count training” presentation provided by the cough research team at Manchester) 
During manual cough counting, every “explosive cough sound” heard is tagged. 
Sounds from throat clearing or sneezing can be mistakenly marked. The microphone 
and chest sensor are synchronised during compression of the files and are reviewed 
together – this helps to confirm that the cough tagged has come from the participant 
being studied (cough from another person nearby is not recorded or registered in the 
chest sensor). 
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Figure 7 shows an example where each explosive phase of cough is tagged with a 
dotted line thereby representing 4 coughs (adapted from “cough count training” power 
point presentation provided by the cough research team at Manchester): 
 
Figure 7: Example of 4 coughs where each of the explosive phases have been marked with a dotted line 
(adapted from “cough count training” presentation provided by the cough research team at Manchester). 
For this study, Prof Smith and her team (which consists of 3 experts in cough 
counting) performed all the cough counting. The same cough counter performed the 
majority of the counts (and all the recordings from any particular individual), to 
reduce the likelihood of inter-operator variability. In addition 10% of the cough 
recordings were randomly selected for re-count by a second counter. Differences 
between the two cough counters were deemed acceptable as long as the difference 
was within 95% limits of agreement based on previously collected data analysed by 
the most experienced cough counters. 	
3.6.6 Gastro-intestinal physiology study 	
I am most grateful to Mr Rhys Jones (Clinical Research Fellow, Upper GI Surgery 
Department, RVI) from whom I learnt to perform and interpret GI physiology studies. 
I am also grateful to Rachel Colver (Specialist GI Nurse), with whom I have worked 
closely at the Northern Oesophago–Gastric Unit, for her help and support in 
performing the GI studies. 
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I also attended a 3-day course in the Netherlands to consolidate my experience in the 
performance and interpretation of GI studies. I performed and analysed the majority 
of the GI studies undertaken by the participants. The tests were performed in the 
Endoscopy Unit, RVI.  	
The GI physiology element was designed to detect and assess the severity of reflux 
disease. It consisted of two parts: 
 
1. High Resolution Manometry – oesophageal study 
2. 24-hour ambulatory pH - impedance study 
High Resolution Manometry – oesophagus (HRM) 
 
The peristaltic function of the oesophagus and the integrity of the LOS are assessed 
by the HRM study. It was performed with a 20-channel oesophageal catheter using an 
MMS Solar Gastric water-perfused high-resolution manometer. The 20 channels are 
actually pressure sensors, which assess the function of the oesophageal body and 
relaxation of the LOS with the help of 10 “wet” swallows (10 x 5 ml of water). The 
catheter is inserted via the nose and secured in place once the LOS is localised (with 
help of pressure tracing on the monitor). Patients are then instructed to swallow water 
(at least 10 times). This generates pressure waves (as the liquid bolus propagates 
through the oesophagus towards the stomach), which are recorded as graphs. With the 
development of a colour topographic technique, different colours could be assigned to 
different pressures generated across the oesophagus. Therefore the huge volume of 
recorded pressure traces (during the 10 swallows) can be easily represented as 
coloured plots. Any variation from the typical or normal swallow pattern can be easily 
identified, thereby facilitating detection of abnormal oesophageal and/or LOS 
function (Figure 8).  
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Figure 8: HRM plots of oesophagus, illustrating a normal swallow.  
A: anatomical landmarks identified with HRM; B: LOS relaxation assessment; C: identification of peristaltic 
landmarks using isobaric contours lines; D: assessment of peristaltic function (adapted from the open access 
journal “clinical application of oesophageal impedance monitoring and high resolution-manometry” Current 
Gastroenterology Reports, June 2002, volume 14, issue 3, 197-205). 	
Figure 9 below shows a HRM plot of an abnormal peristalsis during swallow. It 
shows a “large break” in peristalsis in the oesophageal body (marked by the large 
rectangle). The marked smaller rectangle depicts LOS relaxation (adapted from power 
point presentation provided at the HRM training course in Netherlands, April 2014) 
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 Figure 9: HRM plot of an abnormal peristalsis.  
A “large break” (marked by the large rectangle) in the oesophageal body is illustrated by the large rectangle 
(adapted from power point presentation provided at the HRM training course in Netherlands, April 2014).  
 
HRM techniques can assess both the oesophageal body and LOS at the same time (as 
opposed to conventional manometry methods) and is better at localising the LOS and 
detecting peristalsis abnormality, hence HRM was used for our study. Analysis was 
performed according to the Chicago classification system (Brendenoord et al., 2012).   
 
HRM study was always performed prior to the 24-hour pH-impedance study for the 
following 3 reasons: 
1. The study localises the LOS and guides subsequent accurate placement of the 
pH-impedance catheter  
2. The study assesses the peristaltic function of the oesophagus, which influences 
subsequent decisions relating to anti-reflux surgery 3. The study helps exclude additional oesophageal motility disorders (such as 
non-obstructive dysphagia).	
Twenty-hour hour pH-impedance study 
 
This test was performed to objectively quantify reflux disease. The test was 
performed using a multichannel (8) intraluminal combined pH-impedance catheter by 
MMS Ohmega Systems. 
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The catheter was inserted transnasally and placed 5 cm above the LOS (localised 
during the preceding HRM study) and connected to a data box. Regurgitation of 
gastric contents into the oesophagus is recorded over a period of 24 hours while the 
patient carries on his/her daily activities as far as possible. The patient is requested to 
record symptom episodes by pressing a button on the data recorder (data box) so that 
symptom-event correlation can be assessed. 
 
The 8 metal rings in the catheter allow measurement of electric resistance or 
“impedance” across 6 oesophageal segments. The attached pH catheter records the pH 
of the refluxate. The baseline resting impedance is that of the oesophageal mucosa. 
Resistance (or impedance) increases with the passage of air and decreases with the 
passage of food/liquid through oesophagus. Hence, depending on timing, change of 
measured impedance, direction and extent, any reflux events can be detected. The 
nature of reflux can also be characterised as acidic (pH < 4), weakly acidic (pH 4-7) 
or non acidic (pH >7). 
 
Over a period of 24 hours the number, duration and proximal extent of reflux is 
recorded and results are compared with values recorded from studies of healthy 
volunteers (Zerbib et al., 2005). 
 
Figure 10 shows a typical acid reflux event recorded during 24-hour pH-impedance 
study (an episode is marked by vertical lines with small squares on top). Impedance 
decreases initially at the distal channels (starts at channel 6) followed by the proximal 
channels. Impedance returns to baseline first at the proximal channels (channel 1) and 
then at the distal channels. A drop in impedance is associated with drop in pH to 
below 4 (as shown by the pH catheter tracing) thereby signifying an acid reflux event 
with proximal extension (adapted from pH-impedance study of Trial patient 003). 
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Figure 10: Typical acid reflux event.  
Impedance decreases in a distal to proximal direction and then returns to baseline from proximal to distal direction. 
This is associated with a drop in pH below 4 (adapted from pH-impedance study of Trial Patient 003). 
 
I have attached an illustration (Table 1) of the main results available from the 24-hour 
pH-impedance study (particularly those we planned to record for the purpose of the 
research study). This report format was initially designed by Mr Rhys Jones and 
reproduced with his kind permission. 
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Table 1: Proposed layout of data/results to be recorded from the 24-hour pH-
impedance study for the research study. 
 
Trial patient: XXX 
 Normal 
range  
Pre – study 
drug 
Post – study 
drug 
pH assessment 
% time pH<4 <4.2    
Number of pH drops to <4 <50    
Number of long reflux episodes > 5 
mins 
<4.0    
Longest reflux episode 2.2    
DeMeester score <14.72    
Impedance assessment 
Total number of reflux episodes 25-58    
Bolus clearance time (s) 8-13    
Symptom-event correlation 
Symptom-associated probability (%) <95    
 
The DeMeester score refers to a commonly used composite score with which to 
quantify acid reflux based on pH monitoring. It takes account of the four pH 
measurements also listed in Table 1.  
 
Bolus clearance time is the mean duration of oesophageal bolus exposure.  Bolus 
exposure is defined as the interval between an impedance drop to <50% of the 
baseline and recovery of the impedance level to 50% of the baseline value for ≥5 
seconds. 
 
The symptom-associated probability is a statistical analysis of the correlation between 
reflux events (as recorded by pH or impedance monitoring) and patient-reported 
symptom episodes. In symptomatic individuals, such symptom analyses are useful in 
deciding whether a patient’s symptoms are related to reflux.  
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3.6.7 Bronchoscopy and BAL assessment 
 
I am competent in performing bronchoscopy and BAL (these are mandatory clinical 
skills for a respiratory trainee). Dr Ian Forrest performed bronchoscopy during the 
early phase of the study (to teach specific principles of research bronchoscopy), after 
which I performed the procedures. 
 
I am thankful to Dr Gail Johnson and Kasim Jiwa at the Sir William Leech 
Respiratory Research Centre for my training in processing BAL samples. I have 
processed lavage samples obtained for separate on-going research studies under their 
supervision and have counted archived cytospin samples. I have processed BAL 
samples at the William Leech Research Laboratory, and centrifuged these for 
retention of supernatant at -80°C for future analysis of various cytokine 
concentrations in batched samples in Prof Simpson’s	 laboratory at Newcastle 
University. 
Bronchoscopy 
 
Bronchoscopy was performed in the Endoscopy Unit at RVI according to standard 
practice and international guidelines.  The procedure was performed usually under 
sedation (with intravenous midazolam) with topical anaesthesia provided by 2% 
lignocaine throat spray. Patients received supplemental oxygen via nasal prongs. 
Electrocardiogram (ECG) tracing and oxygen saturations were continuously 
monitored throughout the procedure. Previous HRCT scans were reviewed and where 
possible BAL samples were taken from a segment with changes of IPF but without 
advanced honeycombing, in order to minimise the small theoretical risk of 
pneumothorax. Three aliquots of saline, each of 60 ml, were instilled and aspirated as 
BAL sample. The patient was monitored for at least 2 hours after the procedure. 
Patients who had sedation were advised not to drive, work, drink alcohol, operate 
moving machinery (including drills etc. at home), or sign legal documents for the 
remainder of the day, and had to return home accompanied by a responsible adult.  
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BAL assessment 
 
The quantity of BAL fluid aspirated was recorded. An aliquot of BAL fluid (at least 5 
ml) was sent to the NHS Microbiology Laboratory (Freeman Hospital) for culture 
(and sensitivity if positive) of commonly known respiratory pathogens. 
  
The rest of the sample was transferred to the research laboratory on ice. The BAL 
sample was processed as per established standard operating procedures (Standard 
Operating Procedures; BAL processing SOP Index S 01.version 3, Sir William Leech 
Centre, Freeman Hospital). 
 
The sample was centrifuged at 1250 rpm (183g) for 6 minutes at 4oC. The supernatant 
was decanted in centrifuge tubes. The cell pellet was reconstituted in 1-50 millilitres 
of Dulbecco’s Phosphate-Buffered Saline solution (to generate an opaque 
suspension), and total cell count was estimated using an Improved Neubauer counting 
chamber. Up to 12 cytospins (using Shandon cytospin) were prepared on glass slides 
and air-dried. One cytospin was stained with Giemsa stain to perform a differential 
cell count. The rest of the cytospins were stored at -20oC for future examination 
and/or research.		
	
The decanted supernatant was centrifuged at 2500 rpm (734g) for 6 minutes at 4oC. 
The supernatant was then divided into 600 microlitre aliquots and stored at – 80oC. 
After completion of preparation of cytospin, the cell suspension was re-centrifuged at 
1250 rpm (183g) for 6 minutes at 4oC. The supernatant was discarded and the cells 
were re-suspended in Dulbecco’s Phosphate-Buffered Saline to achieve a 
concentration of 2 -3 million cells/ml. A maximum of 6 x 1 ml aliquots was retained 
and centrifuged at 3000 rpm (325g) for 4 minutes. The supernatant was discarded and 
cell pellets were stored at – 80oC for future research studies. 
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The stored supernatant could be assessed in future for markers of inflammation and 
aspiration including (but not limited to) IL-8, transforming growth factor beta, pepsin 
(Stovold et al. 2007), and bile salts. 
 
3.6.8 Patient visits for study assessments 
 
Patients visited hospital and/or clinic for 6 days in total as summarised in Table 2 
below. Patients attended for 3 consecutive days on 2 occasions.  
 
On the first day (Visit 1) patients were consented (once eligibility confirmed) and 
baseline demographics recorded. Health related quality of life questionnaires were 
administered. They underwent lung function tests, 6MWT and then 24-hour 
ambulatory cough recording were commenced. Patients returned the cough recorder 
the next day (Visit 2) and 24-hour ambulatory pH-impedance study were commenced. 
On the third day (Visit 3) patients were randomised and issued with trial drug 
(omeprazole or placebo) and patient diary card (after completion of 24-hour pH-
impedance study). 
 
Patients were instructed to take study medication for 90 days and further study visits 
were planned for day 88-day 90. 
 
Visit 4 was on day 88 for similar assessments as in Visit 1 (except consent and 
demographics). GI physiology study was repeated on day 89 (Visit 5).  
Patients underwent bronchoscopy on day 90 (visit 6). 
 
Patients took the last dose of medication on the evening of Day 90 and returned the 
empty IMP bottle the next day (or within 2 weeks). 
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Table 2: PPIPF study visits 
	
 Days -7 to 0 
(ie any 3 days 
in the lead up 
to starting 
study 
medication 
Days 1-87 Days 88-90 
§§ 
Confirm 
eligibility 
*       
Consent *       
Demographics *       
VC and TLco *    *   
6 minute walk 
test 
*    *   
Cough 
questionnaire 
*    *   
Reflux 
questionnaire 
*    *   
Commence 
24h 
cough 
monitoring 
*    *   
Commence 
24h 
oesophageal 
physiology 
tests 
 *    *  
Randomization   *     
Issue 
omeprazole or 
placebo 
  *     
Issue adverse 
event diary 
*       
Take study 
medication 
   * * * * 
Bronchoscopy 
and BAL 
      * 
 
§§ - the tests scheduled for “days 88-90”: some participants had tests performed within the 2 weeks prior to 
completion of omeprazole/placebo (this was pre- agreed in the study protocol). (Adapted from the PPIPF study 
protocol, version 4.0, 3.7.14). 
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3.7 PPIPF study pharmacovigilance/safety monitoring 	
During the trial period safety of participants was prioritised. The trial complied with 
all the mandatory regulations and principles set out in the Research Governance 
Framework and The Medicines for Human Use (Clinical Trials) Regulations 2004 and 
subsequent amendments. A favourable ethical opinion from a NHS Research Ethics 
Committee [NRES Committee Yorkshire & The Humber - Leeds West granted 
approval for the study on 20.09.2013 (Ref 13/YH/0284)] and a Clinical Trial 
Authorisation (CTA) from the MHRA were obtained prior to initiation of the trial 
(granted on 13.09.2013). In addition, the sponsor, The Newcastle upon Tyne 
Hospitals NHS Foundation Trust (NuTH) requires all clinical trials of investigational 
medicinal products (CTIMPs) to be managed through a registered Clinical Trials Unit, 
hence Newcastle Clinical Trials Unit (NCTU) monitored this trial. I completed Good 
Clinical Practice (GCP) training. 
3.7.1 Data Monitoring and Safety Committee (DMSC)/ Trial Steering Group (TSG) 
appointment 
 
A 3-member, independent DMSC was established for the trial. The committee 
consisted of 2 clinicians and 1 independent statistician. The panel members were Dr 
A. M. Wilson (chair), Senior Clinical Lecturer in Respiratory Health, University of 
East Anglia, Norwich; Dr Owen J. Dempsey, consultant chest physician, Aberdeen 
Royal Infirmary, Aberdeen; and Evie Gardner, Senior Biostatistician, Northern 
Ireland Clinical Trials Unit, The Royal Hospital, Belfast. I drafted the trial-specific 
DMSC charter (based on guidelines set by NCTU), which was approved and accepted 
by all members. The first DMSC meeting was held on 23/6/14. Subsequently, the 
DMSC convened roughly every 3 months during the trial period (DAMOCLES study 
group, 2005).  
	
A 3-member independent TSG was also established for the trial. The members 
consisted of 2 clinicians and 1 lay patient member (not a study participant). The 
members of the steering group were Dr Michael Gibbons, consultant chest physician, 
Royal Devon and Exeter Hospital; Dr Helen Palfrey, consultant chest physician, 
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Papworth NHS Foundation Trust and Mr Ian Perry (lay patient member). Dr Gibbons 
was the chair. I drafted the trial-specific TSG charter, which was approved by the 
chair. The first TSG meting was on 31/10/14 and subsequent meetings were held 
every 6 months. 
 
In addition, I designed the trial-specific Serious Adverse Event Form based on a 
template from NCTU. Also the SOHO66 system (a secure password-protected web 
based system) was set up for reporting of serious adverse events in accordance with 
NCTU guidance. 
3.7.2 Patient diary card 	
I designed a “patient diary card” for the study participants (attached Appendix 5). 
This was a symptom diary card that was issued to participants so that they could 
record any symptoms or illness while participating in the study. This helped in 
assessment of drug compliance and safety of the investigational medicinal product 
(IMP) during final analysis.  
 
3.7.3 Data collection 
 
In accordance with suggestions by NCTU, research data were collated via an 
electronic Case Report Form (CRF). Data were uploaded via a password-protected 
secure website: www.macro.inferomed.com/NewcastleCTU/ 
 
I designed the paper CRF on which the electronic CRF was based. My study involved 
multiple hospital visits for study participants. Study procedures were performed at 
different departments – the Chest Clinic, Endoscopy Unit, and the laboratory – hence 
access to the electronic CRF (via internet) was difficult at times. Hence, being 
pragmatic I collected data on paper CRFs and then uploaded the data at the earliest 
possible opportunity.  
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3.7.4 Regulations, Ethics, Governance 
 
 
Ethics: NRES Committee Yorkshire & The Humber - Leeds West granted approval 
for the study on 20.09.2013 (Ref 13/YH/0284). 
MHRA approval for the study was granted on 13.09.2013.  
Trust R&D approval: The Newcastle upon Tyne NHS Hospitals Foundation Trust 
granted final R&D approval on 11.02.2014 (Ref 6754). 
 
There was a considerable interval between initial REC, MHRA approval and final 
R&D approval. The reason is outlined in details in Section 13. In summary, our initial 
submission (to REC and MHRA) was reviewed by NCTU, who suggested an 
amendment to the protocol (no change to proposed study outcomes were suggested). 
Hence a request for substantial amendments was filed for approval to REC and 
MHRA. R&D approval was delayed pending favourable opinion (after re-submission) 
from both REC and MHRA. 
 
The Ethics Committee approved amendments on 10.01.2014. 
The MHRA approved amendments on 15.01.2014. 
Hence the study started recruitment in March 2014. 
The first patient was randomized on 28.03.2014. 
 
My research project was accepted as an NIHR portfolio study. 
The study is registered with clinicaltrials.gov (NCT02085018) and ISRCTN 
(ISRCTN07139948). 
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Chapter 4. Results 
 
Prior to returning to clinical training (July 2015), I had recruited 33 participants for 
the PPIPF study. I am grateful to Dr Wendy Funston who further recruited and 
randomised 12 participants. In total 45 participants were enrolled for the study. Study 
closed to recruitment on 19/11/2016.  
 
I am grateful to the NCTU, Vicky Ryan (senior trial statistician) and Helen Mossop 
(trial statistician) for their help with the collected data which was securely stored via 
the electronic website. Vicky and Helen kindly provided the “raw data” from the 
secure website. The results presented for the thesis are based on the baseline 
assessments (i.e. pre drug treatment) of cough and reflux of the participants. They 
provide an account of recruitment, completed study procedures and baseline 
characteristics of the participants of PPIPF study. Some of the results have already 
been presented at the mandatory DMSC and/or the TSG open progress reports for the 
PPIPF study (which I have helped Vicky and her team to prepare). 
4.1 Screening and recruitment 
 
The following figure (Figure 11) is a CONSORT diagram outlining screening, 
eligibility and recruitment of IPF patients for the study: 
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Figure 11: Consort diagram of patient screening and recruitment to study 
 
 
 
 
 																													 																							
 
 
 
In summary, 280 IPF patients were identified and screened for the study. Of the total 
patients screened, 125 (45%) were excluded based on the study inclusion and 
	
IPF patients assessed for eligibility/screened, n= 280 
Excluded at point of initial 
screening (based on study 
inclusion/exclusion criteria), n= 
125 
Consent to trial off PPI, n= 25 
Number of patients consented and randomised, n = 45 
(29% of the eligible/potentially eligible patients) 
Number of eligible/potentially eligible patients, 
n= 155  
(55% of the patients identified at initial screening) 
Eligible/potentially eligible, but did 
not take part in the study, n= 101 
(65% of eligible/potentially eligible) 
[Declined, n= 64 
Unsuitable due to clinical reasons, n= 
34 
Unknown/unable to contact, n=3] 
No return of 
symptom, n= 
16 
Return of 
symptoms 
(hence 
excluded), n= 9 
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exclusion criteria. I have outlined the reasons why identified IPF patients at initial 
screening were excluded from the study in Table 3 below.  
 
155 patients were eligible or potentially eligible (based on current use of PPI and/or 
antacid, prokinetics). Of them 34 patients were excluded on clinical grounds i.e. 
history of GI bleed, gastrectomy surgery for cancer, fundoplication surgery, recent 
diagnosis of malignancy or patient deemed a candidate for palliative care in view of 
end stage pulmonary fibrosis (I have outlined the reasons and the number of potential 
participants excluded on clinical grounds in Table 3 and discussed in further details 
later in this section). 
  
Therefore 118 IPF patients were invited to take part in the study (we were unable to 
contact and/or receive communication from 3 IPF patients identified at screening). 
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Table 3: Why identified IPF patients were excluded from the study based on 
inclusion/exclusion criteria, clinical grounds and/or other reasons: 
 
Reasons Number of 
patients 
Percent (1) 
(Rounded)  
 
 
 
 
 
Not fulfilling 
inclusion criteria, n= 
59 
ILD-MDT did not considered 
IPF as the likely diagnosis 
 
9 3.2 
Patient has no cough 24 8.6 
No honeycombing on CT scan 5 1.8 
No bilateral basal fibrosis on 
CT scan 
1 0.4 
No restrictive defect on lung 
function 
2 0.7 
Age > 85 years 18 6.4 
 
 
 
 
 
Fulfilling exclusion 
criteria, n= 66 
Unable to stop concurrent 
PPI/antacid therapy 
34 12.1 
Previous known allergy or 
intolerance to omeprazole or 
other PPI 
3 1.1 
Concomitant use of interacting 
drugs (2) 
23 8.2 
History of liver disease 
(cirrhosis) 
4 1.4 
Concomitant enrolment in 
other trials 
2 0.7 
 
Clinically unsuitable, 
n= 34 
Clinical co-morbidities 22 7.9 
Patient for palliative care only 7 2.5 
Died (during screening for 
example due to lung cancer) 
5 1.8 
 
Declined (after 
invitation to 
participate), n= 64 
 
Travel/work 
commitments/study procedure 
17 6.1 
Unwell/frail 6 2.1 
Other reasons 6 2.1 
Reason unknown 35 12.5 
Unable to contact, n= 
3 
 3 1.1 
Return of symptoms 
off PPI, n= 9 
 9 3.2 
 Total 235 83.9 
 
(1) Percentage calculated with total number of IPF patients screened (n=280) as the denominator; (2) Concomitant 
drugs included warfarin (n=20); diazepam (n=1); phenytoin (n=2). 
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64 eligible IPF patients declined to participate (17 cited travel commitments with 
study procedures related reasons, 6 felt too unwell/frail for the study, 6 patients were 
not keen to discontinue their long term antacid therapy and/or were concerned about 
placebo, while no particular reason known for the other 35 patients).  
 
25 patients who were on long term PPI consented for 2-week period of supervised 
discontinuation of PPI therapy. 16 patients successfully completed the “period of 
supervised discontinuation” and were randomised for the study. 9 patients had 
symptoms off PPI hence excluded.  
 
In total 45 (29 % of the eligible or potentially eligible) patients were consented and 
randomised for the study (achieving a mean recruitment rate of 1.5 participant per 
month). 
 
4.2 Patient characteristics at baseline or randomisation 	
During screening baseline demographics, co-existing medical illness and current drug 
therapy were recorded.  
 
Table 4 below shows patient’s demographics at baseline (prior to initiation of drug 
therapy). 
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Table 4: Baseline patient demographics (n=45) 
 
Baseline Characteristic 
Number (%) 
Cohort 
N= 45 
Gender  
    Female 10 (22.2) 
    Male 35 (77.8) 	 	
Ethnicity  
    Caucasian 45 (100) 	 	
Smoking History  
   Never smoked 10 (22.2) 
   Ex smoker 34 (75.6) 
   Current smoker 1 (2.2) 	 	
Continuous Baseline Characteristic 
 
Cohort 
N= 45 
Mean (SD) [Range] 
 
Age (years) 
 
71.2 (6.9) [56.0-85.0] 		 	
Physical examination 
 
				BMI (kg/m2) 29.2	(5.0)	[22.7-50.2]		 		 				Blood Pressure (mmHg) 	
      Systolic 123.3 (14.5) [90-153] 	 	
      Diastolic 71.8 (11.5) [50-107] 	 	
   Heart rate (beats per minute) 76.0 (13.8) [51-107] 
  
   Respiratory rate (per minute) 
 
   Oxygen saturation (%) 
22.0 (3.6) [14-28] 
 
95.0 (2.1) [89-99] 			 	
Lung function tests 
 
	
   FEV1 (litres) 
   FEV1 (% predicted) 
2.04 (0.55) [0.67-3.14] 
77.67 (16.79) [46-122] 
   FVC (litres) 2.54 (0.71) [1.55-4.32] 
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   FVC (% predicted) 75.49 (17.34) [44-122] 
   TLCO (mmol/min/kPa) (n=44)(1) 
     TLCO (% predicted) 
3.99 (1.46) [1.53-7.16] 
49.00 (15.67) [19-87] 
   KCO (mmol/min/kPa/litre) (n=44)(1) 1.11 (0.27) [0.56-1.66] 
   KCO (% predicted) 
 
6 minute walk test 
 
   Distance walked (m) (n=44)(2) 
85.25 (21.33) [45-128] 
 
 
 
373.26 (115.53) [50.0(3)-550.0] 	 	
 
(1) Participant ID 014 – gas transfer factors were not possible to measure due to sub-optimal technique; (2) 
Participant ID 027 – had above knee amputation hence 6MWT was not performed; (3) Participant attended in 
wheelchair, 6MWT was difficult to perform. 
Participants recruited for the study were predominantly male IPF patients between the 
age group of 65-84 years (with 5 patients between 40-64 years and 2 patients who 
were 85 years old). Mean smoking history of approximately 20 pack years (data 
available from 31 participants only). On an average each participant suffered from 3 
or more additional medical illness and were prescribed 7 or more medications (for 
regular and/or “as needed” use). 
 
Table 5 below shows the extent of co-existing medical illness among the participants 
at screening. A table of pre-specified comorbidities was listed in the CRF to be 
recorded routinely. I have also documented the other medical conditions that were 
most commonly reported in addition to the listed conditions. 
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Table 5: List of co-existing medical illness among participants (n=45): 
 
 
Medical comorbidities 
 
Number of patients 
 
Percent (%) 
Hypertension 19 42.2 
Diabetes Mellitus 10 22.2 
Hyperlipidaemia 1 2.2 
Stroke 3 6.7 
Heart failure 5 11.1 
Atrial Fibrillation 2 4.4 
Ischaemic heart disease 13 28.9 
Osteoarthritis 7 15.6 
Osteoporosis 3 6.7 
Peripheral vascular disease 1 2.2 
Malignancy - Prostate 3 6.7 
Gout 6 13.3 
Hypothyroidism 4 8.9 
Chronic kidney disease 3 6.7 
Asthma 2 4.4 
Emphysema 2 4.4 
Increased BMI 6 13.3 
 
 
Table 6 below is a list of concomitant medications that the participants were taking at 
screening. The list is not exhaustive; I have reported the most frequently prescribed 
medications among the participants. 
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Table 6: List of concomitant medication at screening (n=45): 
 
 
Drug 
 
Number of patients 
 
Percent (%) 
Aspirin 20 44.4 
Pirfenidone 18 40.0 
Simvastatin 13 28.9 
Atorvastatin 10 22.2 
Paracetamol 10 22.2 
Lansoprazole 9 20.0 
Levothyroxine 9 20.0 
Losartan 9 20.0 
Amlodipine 8 17.8 
Carbocisteine 8 17.8 
Omeprazole 7 15.6 
Codeine 6 13.3 
Glyceryl trinitrate spray 6 13.3 
Alendronic acid 5 11.1 
Allopurinol 5 11.1 
Bendroflumethiazide 5 11.1 
Bisoprolol 5 11.1 
Colecalciferol and calcium carbonate 5 11.1 
Isosorbide mononitrate 5 11.1 
Metformin 5 11.1 
Prednisolone 5 11.1 
Salbutamol inhaler 9 20.0 
Furosemide 4 8.9 
Oxygen 4 8.9 
Ramipril 4 8.9 
 
 
As outlined previously, 34 potentially eligible IPF patients were not included in the 
study due to “clinical reasons”. These patients were eligible for the study (based on 
study inclusion and/or exclusion criteria) but were not recruited due to clinical and/or 
technical considerations as explained below. 
2 patients had already undergone gastric surgery (1 fundoplication for reflux disease 
and 1 gastrectomy surgery for cancer) hence it would not be possible to perform GI 
physiology study with them. Patients with previous history of significant GI bleed 
were deemed unsafe to discontinue antacid (PPI) therapy (considered risky for trial of 
“ 2 week period of supervised discontinuation of PPI therapy”). 5 patients with IPF 
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died (for example, due to lung cancer, acute exacerbation of fibrosis) during screening 
period. 7 patients with advanced disease (who were unsuitable for specific anti-
fibrotic therapy) preferred palliative care on a domiciliary basis precluding them from 
participation in the study (which entailed multiple hospital visits for study related 
procedures). Therefore, often it has been a challenge to recruit potential IPF patients 
with end stage disease for the trial due to the inherent nature of the study.  
 
4.3 Subjective assessment of cough and gastro-oesophageal reflux disease in 
patients with IPF 
 
The impact of cough on daily life of the participants was assessed by the LCQ. LCQ 
was primarily developed for use in patients with chronic cough (hence “normal score” 
for healthy individuals is not known). Subsequently it has been validated to assess 
impact of cough severity in various respiratory conditions like bronchiectasis (Murray 
et al., 2009) and COPD (Berkhof et al., 2012).  
Participants filled the questionnaire on the first day of study visit prior to initiation of 
drug therapy. Table 7 below summarises impact of cough on quality of life as 
reported by patients at baseline (assessed by the LCQ). 
 
Table 7: Impact of cough on quality of life at baseline (n=45) 
 
Cough related quality of life questionnaire at 
baseline 
 
Cohort 
N=45 
Mean (SD) [Range] 
 
Leicester Cough Questionnaire  
[possible range: 3-21; higher score indicate 
better quality of life] 
 
                  LCQ – Total 
                  LCQ – physical domain 
                  LCQ – psychological domain 
                  LCQ – social domain 
 
 
 
 
 
 15.22 (3.18) [7.92-20.63] 
 05.13 (1.01) [2.63-6.75] 
 4.93 (1.27) [2.29-7.00] 
 5.16 (1.17) [1.75-7.00] 
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The above results suggested impairment of quality of life in patients with IPF due to 
cough across all domains (physical, social, psychological).  
 
The impact of reflux symptoms on health and day-to-day life of the participants was 
assessed by the RSI, GIQLI and demesster reflux questionnaires (DeMRQ). In 
addition to the LCQ, participants were requested to fill the reflux related quality of 
life questionnaires on the first day of study visit prior to initiation of drug therapy. 
Table 8 below summaries impact of reflux on quality of life as reported by patients at 
baseline as assessed by the above mentioned questionnaires.  
 
Table 8: Impact of reflux on quality of life at baseline (n=45) 
 
Reflux related quality of life questionnaires 
at baseline 
 
Cohort 
N=45 
Mean (SD) [Range] 
	 	
Reflux Symptom Index Questionnaire 
[possible range: 0-45; lower score indicate  
better quality of life] 
 
 15.69 (9.30) [0-33] 
    
Gastro-Intestinal Quality of Life Index 
Questionnaire 
[possible range: 0-144; higher score indicate 
better quality of life] 
 
 
105.56 (17.66) [62-135] 
  
De-Meester Reflux Associated Questionnaire 
[possible range: 0-9; lower score indicate 
better quality of life] 
 
Score = 0 
Score = 1 
Score = 2 
Score = 3 
Score = 5 
 
1.16 (1.15) [0-5] 
 
 
 
16 (35.6%) 
13 (28.9%) 
11 (24.4%) 
  4 (8.89%) 
  1 (2.22%) 
 
Overall high RSI score (mean 15.69) would suggest increased incidence of gastro-
oesophageal reflux disease in our study population. Accordingly the GIQLI score 
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(mean 105.56) also suggest some impairment of quality of life possibly due to reflux 
disease in our study cohort. However the DeMRQ score (mean 1.16) suggest better 
health in majority of the participants. 
The main reason for the disparity is not entirely clear but may be related to the 
inherent nature of the questionnaires, the disease condition studied and the complex 
interaction between cough and breathlessness in patients with IPF. RSI is designed to 
assess the possibility of laryngo-pharyngeal reflux in patients presenting with cough 
(with or without throat symptoms) thereby prompting further definitive investigations. 
GIQLI is an extensive questionnaire developed to assess quality of life in patients 
with gastro-intestinal diseases. They are sensitive hence might have identified patients 
with mild reflux disease (associated with no or minimal symptoms) among the study 
participants. DeMRQ was not developed to be used in IPF patients and it is possible 
that it does not truly reflect impact of reflux disease in these patients.  
Breathlessness and cough are predominant symptoms in IPF. Reflux disease in turn 
can cause cough (specially after meals or lying down), throat and/or choking 
sensation, heartburn, chest tightness leading to sensation of breathlessness. Therefore 
symptoms (cough and breathlessness) could be attributed to both IPF and/or reflux 
disease. Patients with self-reported cough were enrolled for the study. Hence it is 
possible that patients have marked high scores on the following items of the RSI 
questionnaire (attached Appendix 1): presence of “troublesome cough”, “breathing 
difficulty or choking sensation”, “ cough after meals or on lying down”, “throat 
clearing” (difficult/unable to distinguish between cough and breathlessness related to 
IPF or reflux disease). Further, DeMRQ is a short questionnaire (attached Appendix 
1) comprising of 3 items associated with a typical reflux symptom i.e. heartburn, 
regurgitation, dysphagia (no cough or breathlessness related item or question). As 
outlined previously, it is well established from published literature that there is 
increased prevalence of reflux disease in IPF patients compared to healthy population 
and patients with other chronic respiratory diseases but only a minority of these 
patients suffer/report classical reflux related symptoms.  	
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4.4 Objective assessment of cough in patients with IPF 
 
Objective assessment of cough severity in participants was performed with help of a 
24-hour cough recording device as outlined in the section 3.6.5. Dr J Smith and her 
team provided us with the “cough count” data. I have attached an example (Table 9 
below) of 24-hour cough count result (of participant ID 003 at baseline) as provided 
by colleagues at Manchester for the purpose of our study. 
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Table 9: Example of 24-hour cough count data at baseline (participant ID 003) 
 
General 24-Hour Cough Report
General 24-Hour Cough Report, Version 1, 17-Jul-2014 Page 1 of 2
T:\Newcastle\IPF/&/Omeprazole/Study\PPIPF_027\PPIPF_027_V1
Study Newcastle/IPF/&/Omeprazole/Study
Subject ID PPIPF_027
Visit number 1
Randomisation number
Report date 31BJulB14
Hour 0 cough count 6
Hour 1 cough count 2
Hour 2 cough count 7
Hour 3 cough count 24
Hour 4 cough count 6
Hour 5 cough count 21
Hour 6 cough count 14
Hour 7 cough count 8
Hour 8 cough count 3
Hour 9 cough count 26
Hour 10 cough count 20
Hour 11 cough count 6
Hour 12 cough count 6
Hour 13 cough count 0
Hour 14 cough count 0
Hour 15 cough count 0
Hour 16 cough count 0
Hour 17 cough count 0
Hour 18 cough count 0
Hour 19 cough count 0
Hour 20 cough count 4
Hour 21 cough count 17
Hour 22 cough count 5
Hour 23 cough count 0
Total coughs (Awake) 171
Total coughs (Asleep) 4
Total coughs 24 hr 175
Coughs per hour (Awake) 10.34
Coughs per hour (Asleep) 0.54
Coughs per hour (24 hr) 7.29
Sleep start (sample points) 348093422
Sleep end (sample points) 563005038
Sleep start (hh:mm:ss) 12:05:12
Sleep end (hh:mm:ss) 19:32:56
Initials
Processed by KH
Tagged by CG
Reported by KH
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The data show total number of coughs recorded over a period of 24 hours with the 
help of which the final cough count per hour is calculated (total number of 
coughs/total recording time in hours). In the above example cough frequency is 7.29 
per hour. It also shows daytime cough rate [cough per hour (awake)] and night-time 
cough rate [cough per hour (asleep)] which are 10.34/hr. and  
0.54/hr. respectively.  
 
Table 10 below summarises 24-hour cough frequency (cough count/hour) of the 
participants at baseline. Table also includes daytime and nocturnal cough counts.  
   
Table 10: Baseline cough frequency (cough/hour) of participants (n=45) 
 
Objective cough assessment at baseline 
(cough/hour) 
 
Cohort 
N=45 
Mean (SD) [Range] 
 
24-hour cough frequency 
 
11.99 (10.18) [1.63-52.29] 
 
Daytime cough frequency 
 
15.68 (13.72) [2.52-75.10] 
 
Nocturnal cough frequency 
 
4.62 (5.74) [0.00-21.00] 
 
Total duration of cough recording (hours) 
 
23.55 (0.92) [19.03-24.00] 
 
24-hour cough recording data show mean cough frequency of 11.99/hour. Diurnal 
cough count is significantly higher than nocturnal cough counts (15.6/hr. compared to 
4.6/hr.). These suggest IPF patients, who participated in our study, could cough up to 
12 times in an hour. Their cough was particularly worse through out the day when 
they are awake. Good quality recording over 24-hour period was obtained from 
majority of the participants. 
Hsu et al., (1994) studied cough frequency and diurnal variation in cough in 12 
normal subjects, 21 stable asthmatics and 14 patients with chronic cough. They 
demonstrated only 0-16 coughs over 24-hour period in the normal subjects compared 
to median cough of 282 (range 45-1577) in asthma patients and median cough of 794 
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(range 64-3639) in patients with chronic cough. They also demonstrated cough most 
frequently occurred between 11:00 am – 02:00 pm and least between 02:00 am – 
05:00 am (less than 3% in total). Cough during sleep was equally reduced in 
asthmatics and chronic coughers. Similar low cough counts (less than 2 per hour) in 
healthy individuals and diurnal variation in cough have been shown in further studies 
with patients suffering from chronic cough (Birring et al., 2006) and asthma (Marsden 
et al., 2008)  
Key et al., (2010) measured significant high cough count (median 9.4/hr., range 1.5–
39.4) in 19 IPF patients when compared to healthy subjects and asthmatics but similar 
to patients with chronic cough. Day-time cough rate (median 14.6/hr.) in these 
patients was much higher than night-time cough rate (median 1.9/hr.). 
Diurnal variation in cough frequency among young adults during common cold was 
noted by Kuhn et al., (1982). Suppression of cough during sleep in patients with 
chronic bronchitis was demonstrated by Powers et al., (1984). The exact mechanism 
of cough suppression during sleep in not well known. Cough is a defence reflex 
therefore reduced exposure to stimuli in association with decrease cough reflex 
sensitivity at night might account for reduced cough during sleep (Lee et al., 2010). 
 
The cough frequency noted in our study participants are significantly higher and 
consistent with previously published data. 	
4.4.1 Relation between subjective and objective assessment of cough 
 
Previous studies have shown strong correlations between objective cough counts and 
cough related quality of life questionnaires (i.e. LCQ) in patients with chronic cough 
(Key et al, 2010; Kelsall et al., 2011). A high cough frequency negatively correlates 
with LCQ (high score implies better health quality). 
 
Figure 12 below shows scatterplot (with regression) of cough frequency (cough 
count/hour) and LCQ-total score of our study patients (n=45). Analysis was 
performed with Minitab 17 statistical software. 
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Figure 12: scatterplot showing negative correlation between cough count per hour and LCQ-total score (R – Sq.= 
14.9%). Data points in blue represent cough counts (per hour) of our study participants. 
In keeping with published literatures, data from our study show negative correlation 
between objective cough counts and LCQ-total score in patients with IPF. 
 
4.5 Objective assessment of gastro-oesophageal reflux disease in patients with 
IPF 
 
13 (28.9%) of the total recruited 45 participants consented for the GI physiology 
studies but baseline assessments were performed only on 9 (69.2% of those who 
consented) participants.  
 
1 participant declined GI study during initial visit. Procedure was abandoned in 3 
participants, as 2 were unable to tolerate manometry and/or pH-impedance catheter 
(for the tests to be completed), while I was not able to insert GI catheter in 1 
participant. 
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All the participants who underwent GI physiology assessment successfully completed 
both the HRM and the 24-hour pH-impedance studies. Table 11 below summarises the 
findings on HRM oesophagus study at baseline. 
 
Table 11: HRM oesophageal study at baseline (n=9)  
 
Patient ID HRM – oesophagus results 
001 Normal study 
002 Normal study 
003 Normal study 
005 Oesophago-gastric junction outflow obstruction 
013 Oesophago-gastric junction outflow obstruction 
020 Normal study 
022 Ineffective oesophageal motility 
030 Normal study 
032 Oesophago-gastric junction outflow obstruction 
 
 
In summary, 4 (44%) out of the 9 patients with IPF demonstrated oesophageal 
motility disorder in the HRM study. HRM study is usually performed prior to pH-
impedance study to assess integrity of oesophageal peristalsis and to exclude 
additional oesophageal motility disorder. The study results influence further decisions 
regarding anti-reflux surgery in patients with significant reflux disease. Presence of 
oesophageal dysmotility in IPF patients can predispose to reflux disease. Alternatively 
fibrosis of the lung itself can cause oesophageal motility disorder (disruption of 
normal anatomy by mechanical stretching) which in turn slows bolus clearance, 
increases exposure time to refluxate thereby accounting for increased prevalence of 
reflux disease in IPF patients. 
I have listed the individual ambulatory pH-impedance test results of the participants in 
the table below (Table 12). The data presented is corrected for 24-hour study [i.e. raw 
data x (time on study in hours/24 hours)]. 
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Table 12: Baseline data of 24-hour pH-impedance study (n=9) 
 
Study 
parameters 
(normal values/ 
range) 
Patient ID 
 001 
 
002 003 005 013 020 022 030 032 
Time pH <4 
(<4.2%) 
6.4 12.8 7.6 8.4 1.0 4.2 0.7 22.4 1.6 
Number of times 
pH <4 
(<50) 
36.0 71.0 54.1 51.0 13.0 23.0 11.0 65.0 14.0 
Number of long 
reflux episodes 
(<4.0) 
4.0 6.0 4.0 7.0 0.0 2.0 0.0 8.0 0.0 
Longest reflux 
episodes  
(2.2 min) 
25.2 33.0 14.6 13.1 3.2 26.3 1.7 16.9 4.0 
Number of acid 
refluxes  
(10-35) 
35.0 48.0 23.0 36.0 15.0 29.0 1.0 18.6 12.0 
Number of weak 
acid refluxes  
(5-18) 
24.0 17.0 15.0 9.0 38.0 5.0 58.0 2.7 19.0 
Number of 
proximal reflux 
events 
(4-17) 
10.0 13.0 2.0 20.0 13.0 21.0 13.0 17.0 3.0 
DeMeester score 
(<14.72) 
18.4 46.4 22.9 25.4 3.8 17.6 3.0 57.8 4.2 
Total number of 
reflux episodes 
(25-58) 
73.1 65.9 38.0 46.0 55.0 36.0 61.0 30.8 31.0 
Bolus clearance 
time  
(8-13 s) 
9.0 10.0 13.0 12.0 8.0 13.0 14.0 16.0 11.0 
Symptom 
associated 
probability  
( <95%) 
0.0 99.9 99.9 0.0 0.0 0.0 0.0 0.0 0.0 
	
The numbers highlighted (or in bold) represent values that are above the known normal range for the particular 
study parameter.	
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24-hour pH-impedance study confirmed presence of gastro-oesophageal reflux 
disease in most of the participants (6 out of the 9 patients) as evidenced by high 
DeMeester scores (mean score: 22.1, range: 3.0, 57.8). I have highlighted the elevated 
DeMeester scores in the table above. Data also show higher number of weak acid 
reflux events among the participants (mean number of weak acid reflux events: 21.0, 
range 5.0, 58.0). Participants 013 and 022 suffered from significantly higher episodes 
of weak acid reflux events (number of events highlighted in the table above) although 
their DeMeester scores were within normal range. 3 out of the 6 patients (whose 
DeMeester scores were also elevated) demonstrated significant numbers of proximal 
reflux events (highlighted in the table above).  
Interestingly only 2 patients (participant ID 002 and 003) with objective evidence of 
reflux disease reported clinical symptoms, which indicate symptoms, were related to 
reflux disease (SAP 99.9%). None of the other patients (with evidence of reflux in pH 
and/or impedance study) including those with significant amount of proximal reflux  
reported any symptoms during the study period suggesting silent or asymptomatic 
reflux disease in most of the patients.  
Therefore, the 24-hour pH-impedance study data confirmed presence of significant 
reflux disease in majority of the participants within this study cohort.  
 
However acceptability of GI physiology studies was low amongst the study 
participants. Although our study primarily focussed on cough, less than 30% of the 
participants consented for the GI studies. The invasive nature of the tests compounded 
by mandatory, multiple hospital visits and pre-existing medical co-morbidities made 
the tests undesirable among study participants. In addition, GI physiology assessments 
can be technically demanding both for patients and clinicians. 1 patient failed GI 
catheter insertion and 2 patients were unable to tolerate catheter in situ for completion 
of study. Therefore, even a smaller number of patients completed GI studies (9 out of 
13 patients who initially consented, 1 participant declined during initial visit). I have 
discussed further regarding low rate of consent and completion of GI studies in 
subsequent section (section 5.3).  
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4.6 Relation between cough and reflux disease in patients with IPF 
 
Only 9 out of 45 participants underwent formal GI physiology study hence it is 
difficult to establish any significant correlation between subjective and objective 
assessment of reflux disease. For similar reasons it is difficult to explore any 
association between increased cough count and presence of reflux disease in this 
cohort of IPF patients. 
The following table (Table 13) compares baseline GI physiology studies of those 9 
participants with their respective cough counts (per hour) and reported quality of life 
scores.  
Table 13: Baseline GI physiology studies with respective cough counts (per hour) and 
reported quality of life scores (n=9) 
 
Patient 
ID 
GI test:HRM 
24-hour pH-
impedance 
(DeMeester 
score) 
Cough 
count  
(per hour) 
LCQ – 
score 
(total) 
RSI 
- 
score 
GIQLI - 
score 
DeMRQ - 
score 
001 HRM: normal 
DeMeester: 
18.4 
8.67 18.70 04 129 0 
002 HRM: normal 
DeMeester: 
46.4 
10.67 10.50 28 62 2 
003 HRM: normal 
DeMeester: 
22.9 
8.77 15.60 14 119 1 
005 HRM: O-GJO* 
DeMeester: 
25.4 
19.38 15.40 06 120 0 
013 HRM: O-GJO* 
DeMeester: 3.8 
15.55 13.38 24 102 0 
020 HRM: normal 
DeMeester: 
17.6 
23.33 13.68 17 120 0 
022 HRM: IOM** 
DeMeester: 3.0 
3.33 19.36 4 111 2 
030 HRM: normal 
DeMeester: 
57.8 
14.56 14.85 4 100 1 
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032 HRM: O-GJO* 
DeMeester: 4.2 
2.00 17.73 11 96 1 
*O-GJO: Oesophago-gastric junction outflow obstruction 
**IOM: Ineffective oesophageal motility 
 
Patients who recorded high DeMeester score (above the accepted normal score of 
14.7) on 24-hour pH-impedance study also demonstrated increased cough frequency 
on 24-hour ambulatory cough recording. Participants ID 005, 020, 030 demonstrated 
significantly greater cough frequency (above the calculated mean cough rate of 
11.9/hr. in this study) also recorded comparable higher DeMeester score. This trend 
provides further support to well-accepted theory that acid reflux disease can cause 
persistent/chronic cough. The RSI score was appropriately raised in 3 participants 
with objective evidence of reflux disease (participants ID 002, 003 and 020) but no 
positive correlation demonstrated in other participants. Based on the data above, no 
significant trends were identified with regards to the GIQLI and DeMRQ quality of 
life scores when compared to GI physiology studies. This might reflect higher 
incidence of “silent reflux” disease in our study population but it is difficult to draw 
any firm conclusions given the limited number of studies performed. 
 
Given the small number of studies available, no meaningful and/or valid relations 
might be demonstrated, however, exploring various plausible correlations is one of 
the main reasons for undertaking a research study. Therefore to explore further, I have 
plotted (scatter plot with regression) cough count (per hour) against DeMesster scores 
and reflux related health questionnaire scores. Analysis was performed with Minitab 
17 statistical software. 
 
Figure 13 below shows scatter plot with regression of cough count (per hour) and 
DeMeester scores of our study participants (n=9). 
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Figure 13 : scatterplot showing no significant correlation between cough count (per hour) and DeMeester scores 
(R-Sq=100%). Data points in blue represent cough counts (per hour) of our study participants. 
Scatterplot does not show any significant correlation between cough frequency and 
DeMeester scores, as opposed to the well known fact that reflux causes cough. 
However, data were available only from 9 participants hence it is difficult to draw any 
firm conclusion. Conversely, it is possible that cough can also be induced by non-acid 
reflux. DeMeester score (which is a composite score taking into account pH 
measurements) will not be high in patients with predominantly non-acid reflux 
disease.  
 
Figure 14 below shows scatter plot with regression of cough count (per hour) and RSI 
scores of our study participants (n=9). 
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Figure 14: scatterplot showing no significant correlation between cough count (per hour) and RSI scores (R-
Sq=84%). Data points in blue represent cough counts (per hour) of our study participants 
Scatterplot does not show any significant positive correlation between cough 
frequency and RSI scores, as was expected. This is difficult to explain, but might be 
related to the limited amount of data available. In addition, RSI was not developed to 
be used in patients with IPF and it is possible that it does not actually reflect the 
impact of cough in these patients. 
 
Figure 15 below shows scatter plot with regression of cough count (per hour) and 
GIQLI scores of our study participants (n=9). 
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Figure 15: scatterplot showing no significant correlation between cough count (per hour) and GIQLI scores (R-
Sq=98%). Data points in blue represent cough counts (per hour) of our study participants 
 
Figure 16 below shows scatter plot with regression of cough count (per hour) and 
DeMRQ scores of our study participants (n=9). 
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Figure 16: scatterplot showing no significant correlation between cough count (per hour) and DeMRQ scores (R-
Sq=44%). Data points in blue represent cough counts (per hour) of our study participants 
Scatterplots for both the GIQLI and DeMRQ scores show unexpected trends. It shows 
a trend towards a positive correlation between cough frequency and GIQLI scores and 
a trend towards a negative correlation between cough frequency and DeMRQ scores. 
Higher GIQLI score implies a better health status, conversely lower DeMRQ score 
imply better health status. Therefore, high cough frequency should negatively 
correlate with GIQLI scores and positively correlate with DeMRQ scores. This 
discrepancy is difficult to explain by the limited amount of data available. This could 
be related to the high incidence of asymptomatic or silent reflux disease in our study 
cohort. Also, these questionnaires were not developed to be used in IPF patients and it 
is possible that this does not really capture the impact of cough in IPF patients. 
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4.7 Bronchoscope and BAL samples 
 
13 (28.9%) out of the recruited 45 participants consented for bronchoscopy at 
randomisation. Of them 8 (61.5%) had procedure performed. 
 
1 participant was withdrawn from the study (prior to completion of assessments) 
while another participant was not keen to discontinue his regular anticoagulant 
medication prior to bronchoscopy test. 2 participants were unable to attend on the 
planned date (1 due to accidental fall leading to severe back pain, 1 was admitted to 
hospital due to an unrelated illness). Procedure was not performed on 1 participant 
due to low resting oxygen saturations levels (procedure deemed unsafe on clinical 
grounds).  
 
Table 14 below shows results of bronchoscopy and BAL sample analysis. It outlines 
the macroscopic features, the total and differential cell counts and the microbiology 
culture (for bacteria, acid fast bacillus, fungus) results. 
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Table 14: Results of bronchoscopy and BAL samples analysis (n=8) 
 
Patient 
ID 
Bronchoscopy Total cell 
count (104/ml 
BAL) 
Differential count 
[count (%)] 
Microbial 
cultures 
003 Normal 
appearance 
12.4 Macrophages: 490 
(98%) 
Neutrophil: 006 
(1.2%) 
Lymphocytes: 004 
(0.8%) 
Eosinophils: 000 (0%) 
Ciliated epithelial: 
001 (0.2%) 
Metaplastic epithelial: 
011 (2.1%) 
No pathogens 
005 
 
 
 
 
 
 
 
 
Normal 
appearance 
301.8 Macrophages: 086 
(17.2%) 
Neutrophil: 398 
(79.6%) 
Lymphocytes: 016 
(3.2%) 
Eosinophils: 000 (0%) 
Ciliated epithelial: 
004 (0.8%) 
Metaplastic epithelial: 
000 (0%) 
Pseudomonas 
aeruginosa 
013 Normal 
appearance 
24.5 Macrophages: 197 
(39%) 
Neutrophil: 241 (48%) 
Lymphocytes: 062 
(13%) 
Eosinophils: 000 (0%) 
Ciliated epithelial: 
009 (2%) 
Metaplastic epithelial: 
015 (3%) 
Staphylococcus 
aureus 
016 Normal 
appearance 
83.0 Macrophages: 359 
(72%) 
Neutrophils: 091 
(18%) 
Lymphocytes: 050 
(10%) 
No pathogens 
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Eosinophils: 000 (0%) 
Ciliated epithelial: 
022 (4%) 
Metaplastic 
eplithelial: 005 (0.9%) 
020 Normal 
appearance 
17.3 Macrophages: 344 
(69%) 
Neutrophils: 126 
(25%) 
Lymphocytes: 030 
(6%) 
Eosinophils: 000 (0%) 
Ciliated epithelial: 
006 (1.2%) 
Metaplastic epithelial: 
004 (0.8%) 
No pathogens 
030 Bronchitic 
mucosa 
36.3 Macrophages: 490 
(98%) 
Neutrophils: 001 
(0.2%) 
Lymphocytes: 009 
(1.8%) 
Eosinophils: 000 (0%) 
Ciliated epithelial: 
005 (1%) 
Metaplastic epithelial: 
001 (0.2%) 
No pathogens 
032 Normal 
appearance 
14.8 Macrophages: 462 
(92.4%) 
Neutrophils: 033 
(6.6%) 
Lymphocytes: 004 
(0.8%) 
Eosinophils: 001 
(0.2%) 
Ciliated epithelial: 
015 (2.9%) 
Metaplastic epithelial: 
000 (0%) 
 
No pathogens 
044 Normal 
appearance 
27.3 Macrophages: 492 
(98%) 
Neutrophils: 002 
(0.4%) 
Lymphocytes: 006 
No pathogens 
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In summary, bronchoscopy was macroscopically normal in all patients except 
participant ID 030. As expected, BAL samples showed leucocytosis with 
macrophages being the predominant cells. Only 2 patients (participant ID 005, 013) 
showed increased neutrophil counts in their BAL, both have shown bacterial 
pathogens on cultures probably indicating on-going chest infection. Only a limited 
number of patients in the study underwent bronchoscopy test hence it is difficult to 
draw any firm conclusions from the above results with regards to the differential cell 
counts and the rate of infection in patients with IPF. 
 
Similar to the GI physiology study, bronchoscopy was not favoured by the study 
participants. Less than a third of the patients consented to undergo the procedure and 
only 8 completed the assessment. The procedure was undesirable amongst the 
participants due to the invasive nature of the test, associated mandatory hospital 
attendance and associated risks especially with lung fibrosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1.2%) 
Eosinophils: 000 (0%) 
Ciliated epithelial: 
002 (0.4%) 
Metaplastic epithelial: 
000 (0%) 
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Chapter 5. Discussion 
 
 
This study was designed to comprehensively assess impact of cough and reflux in 
patients with IPF. Advanced techniques were used to objectively assess cough and 
reflux disease. The trial focuses on a current major health problem and if the results 
are positive, is likely to provide further evidence in favour of a commonly used drug 
(omeprazole) treatment for the unmet health problem.  
 
As outlined in the Consort diagram (Figure 11), I have screened a considerable 
number (n=280) of identified IPF patients to successfully recruit 45 participants for 
the study. Long-term PPI therapy was one of the predominant barriers to patient 
recruitment. I have discussed difficulties/challenges relating to screening and 
recruitment in details in the following sections. Despite multiple measures (as 
described in the subsequent sections) to improve recruitment remained below 
expected through out the study period. Approximately 2 participants were randomised 
every month.  
In addition, acceptance of study related procedures was lower than expected. Of the 
recruited 45 participants, 13 (approximately 29%) consented for the GI physiology 
and/or bronchoscopy studies at baseline but GI study and bronchoscopy was actually 
performed only in 9 (69%) and 8 (61%) participants respectively. I have already 
outlined clinical and/or practical constraints regarding performing GI and 
bronchoscopy procedures in Chapter 4 (sections 4.5, 4.7). I have discussed 
“acceptance of study procedures” among the participants in further details in 
subsequent sections. 
 
Participants recruited for the study had a secure diagnosis of IPF (history, radiology, 
and lung function test reviewed in the regional ILD-MDT and clinic at RVI). The 
majority of the patients suffered from moderate severity of disease (based on baseline 
patient characteristics) and were male, and consistent with the gender prevalence in 
IPF.  
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Consent and completion rate of non-invasive assessments among the study 
participants was high (one patient was unable to perform gas transfer factor tests due 
to poor technique and another patient, who had above knee amputation, were unable 
to perform 6MWT). All the participants completed baseline quality of life 
assessments (questionnaires) and 24-hour ambulatory cough recording. Participants 
tolerated the ambulatory cough recording well through out the study period with no 
major problems reported or identified.  
 
Baseline data demonstrated significantly high cough frequency in IPF patients (mean 
11.99/hour, range 1.63 – 52.29). Daytime cough frequency was markedly elevated 
than nocturnal cough frequency (Table 10). The cough rate in IPF patients 
demonstrated in our study is slightly higher than that published in a previous similar 
study (9.4/hour). (Key et. al. 2010).  
 
Cough was associated with significant impairment of daily lives of patients with IPF 
as indicated by the LCQ-total score (mean15.22, range 7.92-20.63). Low scores were 
seen across all domains of LCQ providing further evidence that cough is a disabling 
symptom in patients with IPF with huge physical and social impact. Data also 
suggested a negative correlation (as expected) between subjective (LCQ-total score) 
and objective assessment of cough (cough count per hour) in patients with IPF. 
 
Reflux related health quality questionnaires (RSI, GIQLI and DeMRQ) demonstrated 
interesting results. The RSI (mean score 15.69) suggested an increased incidence of 
reflux disease in our study cohort. The GIQLI (mean score 105.56) further confirmed 
impaired quality of life, possibly due to reflux disease in these patients. In contrast, 
DeMRQ (mean score 1.16) suggested a better health in the majority of the patients. 
The reason for this discrepancy is not entirely clear, but I have already discussed 
possible explanations in the previous chapter (Chapter 4).   
 
Only a small proportion of patients consented for GI physiology and bronchoscopy 
studies for the inherent “invasive” nature of the procedures. I have briefly discussed 
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“acceptability” of these procedures among the study participants in the previous 
chapter. I have further discussed regarding the low rate of consent and completion of 
GI studies and bronchoscopy in the following section. 4 out of the 9 patients with IPF 
demonstrated peristaltic disorder in HRM study of the oesophagus (Table 11). 6 out of 
the 9 participants showed objective evidence of significant reflux study in 24-hour pH 
impedance study. In addition to acid reflux, considerable numbers of weak acid reflux 
events were noted in the impedance studies (Table 12). Participants ID 013, 022, 032 
(with normal DeMeester score) showed high number of weak acid reflux events. 3 
patients with objective evidence of reflux disease (in the pH-impedance study) 
demonstrated a significant number of proximal reflux events. Patients who showed 
evidence of reflux disease also demonstrated raised cough count on ambulatory cough 
recording (Table 13).  
 
However only 2 participants with reflux disease reported associated clinical 
symptoms. No definite correlation was noted between the reflux related quality of life 
questionnaires in patients with evidence of reflux disease on impedance study. 
 
Overall results suggest increased incidence of reflux disease among the IPF patients in 
our study (as evidenced by impedance study). Presence of reflux disease was 
associated with higher cough frequency. Majority of patients (with objective evidence 
of reflux in impedance study) did not report any symptoms suggesting increased 
incidence of “silent” or asymptomatic reflux disease in our patients. However these 
observations (regarding GI studies, cough, reflux related questionnaires) are based on 
only small numbers of studies and/or participants hence it is not possible to draw any 
firm conclusions. 
 
Similarly limited bronchoscopy studies were performed. As expected, BAL samples 
showed leucocytosis with macrophages predominant. Only 2 participants showed 
signs of possible infection hence it is difficult to comment on BAL cell count or rate 
of infections (in relation to IPF and/or trial drug therapy).  
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In future, further BAL sample analysis can be performed to look for markers of 
inflammation and aspiration (as outlined in Chapter 3, section 3.6.7) and comparison 
made with GI physiology study and cough counts. This could provide further 
evidence in favour of reflux-associated cough in patients with IPF. 
 
Given the interesting baseline findings, I am looking forward to the final analysis of 
the trial data especially relating to cough. In total 45 patients were recruited. We have 
achieved our initial aim of randomising at least 40 participants for the study. I believe 
trial results will provide useful information with regards to the role of antacid therapy 
in patients with IPF and cough. If results are positive, it will help plan further multi-
center definitive trials, If not it will guide future researches in treatment and 
pathogenesis of IPF. 
 
5.1 Difficulties/challenges encountered in the PPIPF study 	
The initial study plan was to recruit 60 patients over a period of 21 months (starting 
from August 2013), which meant a target recruitment rate of 3 participants per month. 
At the time of my appointment in August 2013, Ethics Committee and MHRA 
approvals for the study were already in place. The Research Ethics Committee (REC) 
and MHRA granted approval for the study by September 2013. 
 
Newcastle Clinical Trials Unit subsequently scrutinised the submission again, and 
noted that some of the original submission was based on a template used by a 
different Clinical Trials Unit (CTU). For internal consistency and clarity, they 
suggested that improvements could be incorporated around sections on patient 
recruitment, randomisation, statistical analysis, pharmacovigilance, and reporting of 
adverse events during the study period.  Therefore the requested changes were made. 
The overall study design and the end-points to be assessed did not change. This meant 
substantial amendments, and all other related documents e.g. Patient Information 
Sheet and Consent Forms had to be amended to coincide with changes in the protocol 
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and re-submitted to Ethics and MHRA. As a result recruitment for the study was 
delayed until March 2014 (recruitment commenced 6 months later than initially 
planned). 
 
Up until July, recruitment was slower than expected (only 5 patients randomised for 
the study procedure by the end of July 2014). Feedback from eligible participants 
highlighted that multiple hospital visits and invasive tests (namely GI 
studies/bronchoscopy) were the main things dissuading them from taking part. 
 
In addition, with the new aero-digestive approach to patient management of IPF and 
the recently concluded Characterisation Study (a separate study of the biology for 
reflux in IPF patients), a number of eligible patients had already undergone research-
based GI studies and/or bronchoscopy examination. 
 
Due to unforeseen circumstances, TEVA changed the colour of their omeprazole 
capsules. In order to maintain blinding, Victoria Pharmaceuticals had to source an 
alternative UK-licensed generic omeprazole capsule to match the yellow placebo 
capsules for the study.  Hence a second notice of substantial amendments had to be 
filed for approval to MHRA.  
5.2 Action/Measures put in place 	
Listening to feedback from eligible participants and following recommendations from 
the DMSC chair, a range of measures was put in place to address the low rate of 
recruitment to the study. The main things were: 	
1. Alterations to the Patient Information Sheet (PIS):  The patient information 
sheet was amended to make it clear to the participants that the only parts of the study 
that were essential were taking the study drug and having the (non-invasive) cough 
monitoring performed twice. The more invasive tests were optional. A short summary 
of the study was added on page 1 of the PIS and the “cough monitoring and drug 
only” part of study on page 3 was highlighted (attached Appendix 4). 
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Again, the overall study design and the end-points to be assessed did not change. 
An application was made to the REC for approval of these amendments. 
 
2. Addition of Participant Identification Centre (PIC) sites: We identified and 
added 3 PIC sites namely Sunderland Royal Hospital, James Cook University 
Hospital in Middlesbrough and North Tees Hospital in Stockton-on-Tees. Over the 
preceding 12 months, an increasing number of IPF patients were referred to our 
regional ILD clinic at RVI from these hospitals, especially for pirfenidone therapy. 
However the patients referred represent a selected group (considered eligible for 
pirfenidone therapy) and represent only a small proportion of IPF patients, hence 
inclusion of these centres as PIC sites was expected to “unlock” further IPF patients 
potentially eligible for the study around the North East region. Eligible patients were 
identified and invited to take part in the study by clinicians involved in their usual 
care. I followed up those who expressed interest in the study. Amendments were 
made in the study protocol (attached Appendix 2) to allow inclusion of the PIC sites. 
5.3 Challenges in recruitment to the study 
 
Recruitment to the study remained slower than expected or initially estimated in spite 
of the above-mentioned measures.  In addition, the BLF granted us a 12-month no-
cost extension to achieve target recruitment. While these measures gave access to 
more IPF patients across the region, recruitment to the study remained challenging 
throughout, for the following reasons (in my view): 
5.3.1 IPF patients prescribed PPI therapy 	
Of the 280 patients screened (Consort diagram), 150 (54%) were already on long-term 
PPI therapy. Indications for the therapy were peptic ulcer disease (with or without GI 
bleed), upper GI endoscopy (performed for dysphagia, dyspepsia) showing signs of 
gastritis/oesophagitis assumed secondary to reflux disease, and/or Barrett’s 
oesophagus. However a major proportion of patients were started on PPI therapy 
either empirically for possible gastro-oesophageal reflux disease or as secondary 
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prophylaxis for drug-induced gastritis (because they had trial therapy of high dose 
prednisolone for their ILD or in a few cases non-steroidal anti-inflammatory drugs as 
analgesics). In most cases, PPI therapy continued even after withdrawal of 
corticosteroids and/or analgesics. Once established on therapy it is difficult to take 
patients off PPI therapy for research, especially when they are suffering from a 
chronic progressive disease with no cure. 
Of the patients on long term PPI therapy, 25 agreed to come off PPI for a “period of 2 
weeks of supervised discontinuation” for the purpose of the research. Of these, 16 
participants consented and were randomised for the study while 9 had recurrence of 
symptoms and were excluded from the study. 
Despite few indications for long term PPI therapy, a significantly high proportion of 
IPF patients were prescribed prolonged antacid therapy. Often it has been difficult to 
discontinue antacid therapy in these patients, which remained one of the predominant 
reasons for persistent slow recruitment. 
5.3.2 IPF severity and comorbidities 	
IPF is a chronic progressive disease. Often there are associated significant 
cardiovascular and other systemic co-morbidities (for example diabetes mellitus, 
osteoarthritis, stroke). Although a median survival of 3 to 5 years from diagnosis is 
often quoted, a subgroup of patients has a rapidly progressive course with shortened 
survival. Also 5-20% of patients suffer from episodes of “acute exacerbation” where 
they suffer from rapid progression of the disease without any identifiable cause i.e. 
infection, infarction, heart failure, embolism etc. Poor lung function at diagnosis, 
resting oxygen saturation and walk- distance are some of the markers for poor 
prognosis, but these are not reliable predictors for these events in any given 
individual. 
Of the patients I screened for research (this is not a definitive list but a few 
representative examples): 
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“Participant Screen 124” was reviewed and started on treatment with pirfenidone in 
October 2014, consented, and study visits were booked on 24.2.15. However the 
patient was admitted to hospital on 17.2.15 and died most probably secondary to an 
episode of acute exacerbation. 
“Participant Screen 107” had advanced disease by the time of review in the clinic, 
was referred for lung transplant assessment, and had undergone lung transplant within 
2 months of referral. The participant had expressed interest in our research. 
“Participant Screens 115 and 153” both expressed interest in the research, however 
both suffered from rapid progression of disease and were accepted on the active lung 
transplant list (both were prescribed PPI therapy due to the possible link between 
reflux and IPF). 
Hence, in spite of initial expression of interest and/or consent, I was not able to 
actually enrol the above patients for the research study, as a result of the inherently 
progressive nature of the condition being studied. 
As tabulated in the Consort diagram, “Patients considered unsuitable for study 
specific procedures due to clinical reasons” includes some of the potential participants 
with progressive/advanced IPF who were deemed appropriate for symptomatic or 
palliative treatment. 
Therefore, often it has been a challenge to recruit IPF patients with severe and/or 
advanced disease. However, our study population is comparable to most of the IPF 
patients enrolled in other clinic trials in terms of mean age and baseline 
characteristics, although we recruited a higher proportion of male participants than 
usual. 
5.3.3 Study procedure-related 	
The study was planned to provide an assessment of the prevalence of acid and non-
acid reflux in patients with IPF and of the role of acid suppression therapy in 
management of these patients. The study entailed 6 visits to the RVI chest clinic (for 2 
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x 24 hour ambulatory cough monitor studies, 2 x GI physiology studies, 1 x trial 
medication-related and 1 bronchoscopy study). 
Feedback from the eligible/potentially eligible participants was that the invasive 
nature of the GI studies and the bronchoscopy, as well as the number of visits, had put 
them off the study. This was compounded by the fact that most of the patients had 
other significant medical co-morbidities and they often had to travel a considerable 
distance (e.g. from Morpeth, Hexham, Cleveland, Middlesbrough or Darlington). 
In addition, as stated above, patients were often on PPI therapy. 
Also, a few of the IPF patients (10 in total) in our clinic had already undergone GI 
studies with bronchoscopy as part of a recently concluded Characterisation Study 
(looking into the incidence and nature of reflux in IPF patients) as part of a new Aero- 
Digestive MDT approach towards managing ILD patients. Subsequent to their study 
they were advised to take PPI therapy if reflux was present. Those without evidence 
for reflux were understandably not keen for a repeat study. 
Hence, consent and completion rate of GI studies and bronchoscopy remained low 
through out the study period. Also, our study primarily focused on cough (and the 
impact of antacid and/or placebo on cough) in IPF patients. Nonetheless, data 
suggested invasive tests are not desirable among IPF patients. 
5.3.4 Mandatory compliance with regulatory framework around clinical trials with 
an IMP 	
As outlined earlier, working through the necessary regulatory paperwork and sorting 
out the initial teething problems of setting up a clinical trial meant a delayed start to 
the study (by 6 months). After starting, the study underwent 3 Major Amendments 
and 1 Minor Amendment. I have tabulated the reasons, and the timeline of the filing 
and approval of the amendments (Table 15). 
 
							
91	
Table 15: Dates of submission of amendments with reasons and approval dates: 
Protocol 
version 
Amendment Details Date of 
approval 
1.0, dated 
22/07/2013 
Original 
submission 
 REC – 
20/09/2013 
(conditional) 
MHRA – 
13/09/2013 
2.0, dated 
15/09/2013 
Protocol 
changes 
Changes made for unconditional 
REC favourable opinion – 
updated correct Funding Ref. 
REC only 
20/09/2013 
3.0, dated 
20/11/2013 
Protocol 
changes 
Amendments to update protocol 
for internal consistency as 
suggested by NCTU. 
Amendments made in sections 
of Patient Recruitment, 
Randomisation, Statistical 
Analysis, Pharmacovigilence, 
Adverse Event Report 
Reporting. 
Also updated contact numbers of 
study members. 
New document added:  
Patient Diary Card – to help 
assess adverse events in 
participants, 
Patient Information Sheet, GP 
information letters, Consent 
Forms: updated with appropriate 
changes in version number and 
date to coincide with amended 
protocol. 
REC – 
10/01/2014 
MHRA – 
15/01/2014 
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4.0, dated 
03/07/2014 
Protocol 
changes 
Amendments in protocol to 
allow inclusion of PIC sites to 
help improve recruitment for 
the study. 
Also a summary page was 
added to the Participant 
Information Sheet to make it 
plain to participants that the 
only essential part of the study 
was cough monitoring and 
taking the drug. All other tests 
were non-essential. 
Amendments in the CTA form 
due to changes in colour of the 
TEVA omeprazole capsules. 
To maintain blinding Victoria 
Pharmaceuticals had to source 
an alternative generic UK-
licensed omeprazole for the 
study. 
Consent Forms and PIS were 
updated to correspond changes 
in Protocol. 
REC – 
26/08/2014 
MHRA – 
02/09/2014 
R&D – 
11/09/2014 
4.0, dated 
03/07/2014 
(Nil changes in 
protocol) 
 
Minor 
Amendment: 
PIS: version 
3.0 dated 
1/10/14 
GP letter: 
version 2.0 
dated 1/10/14 
Consent 
Forms: 
version 3.0 
dated 1/10/14 
 
A participant was prescribed 
regular antacid (PPI) by his 
general practitioner during the 
study period when the 
participant was taking trial 
medication. Neither the patient 
nor his doctor informed the 
study team. This was picked up 
by the study team on review of 
notes prior to booking his 
subsequent study visits. 
Participants cannot be on a 
regular PPI as this is a double- 
blinded trial comparing 
omeprazole with placebo. As a 
result of this, after discussion 
with the Sponsor and NCTU, 
modification was made in the 
PIS and GP letter to make it 
clear to patients and their GPs 
that they should not be 
prescribed regular PPI or 
REC – 
acknowledgem
ent 12/11/2014 
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antacid while they are in the 
trial. If prescription of PPI or 
antacid was necessary for 
clinical reasons they should 
contact the trial team prior to 
the start of medication. Prof 
Simpson (CI) confirmed with 
the Chair of the REC that these 
modifications should be minor 
amendments. Consent Forms 
were updated to correspond to 
changes in the PIS. 
5.0, dated 
07/03/2016 
Substantial 
Amendment 
Dr. Forrest was listed as co-
investigator  
Change of Senior Trial 
Manager – Dr. Lesley Hall 
replaced Dr. Jennifer 
Wilkinson  
Change of Trial Manager – Mr. 
Mark Palmer replaced Jessica 
Qian.  
New Clinical Research Fellow 
– Dr. Wendy Funston replaced 
me. 
Changes to randomisation 
section were made to bring in 
line with current procedures. 
Addition of reference to 
Summary of Product 
Characteristics (SmPC) in 
section 3.5 of Protocol. 
Update to increase clarity in 
section 5.3 (Withdrawal of 
Consent of Protocol) and to 
include 2 options for 
withdrawal. 
Addition of Expectedness as 
per section 7.3 in Protocol. 
Addition of nintedanib to list 
of active trial of treatment in 
exclusion criteria. 
REC – 
12/07/2016 
 
After starting recruitment I attended the following mandatory meetings relating to the 
study (until July 2015): 
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1. TMG meeting – every month  
2. DMSC meetings – 4  
3. TSG meetings – 1 
The NCTU monitored the study twice during the corresponding period: once at the 
start (informally) and then in January 2015 (formally). 
Subsequently, the sponsor (NuTH) also audited the trial in March 2015 (mandatory 
for clinical trials with an IMP). 
These regulations are in place to ensure patient safety, to ensure clinical 
trials/research are conducted in accordance to mandatory guidelines, and to ensure 
research yields high quality data/results. They are also to ensure that any problems 
relating to the study are identified early and measures put into place as appropriate. 
The suggested amendments to my trial were sensible, positive and in one instance 
unavoidable (the change in colour of TEVA omeprazole capsules). Unfortunately 
filing amendments, preparation, organisation of meetings (with which I had 
invaluable help from NCTU) and managing the trail of paperwork subsequently 
generated (in addition to the mandatory paperwork directly related to study and 
recruitment i.e. amendments/consent forms/screening logs/randomisation logs/trial 
files/SAE logs etc.) did take up considerable amounts of effort and time. In a trial like 
mine (limited by time) on occasions it proved difficult to prioritise screening and 
recruitment of potential patients while keeping “the momentum going” (the dilemma 
of whether to keep trying to recruit more participants or whether to keep mandatory 
paperwork up-to-the-minute/file more paperwork to help recruit). 
This is not a criticism of any department or individual, but rather a realisation that the 
current statutes regulating conduct of clinical trials can result in time pressures felt by 
clinical researchers. 
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Interestingly, the Association of British Insurers has guidelines for healthy volunteers 
as well as patients considering taking part in clinical trials. In summary the guidelines 
advise potential participants to inform their insurers about clinical trials they are 
interested in taking part in, as there are implications for their travel, income, critical 
illness and private medical insurance covers. I have copied a paragraph outlining an 
insurer’s advice with regard to clinical trials and travel insurance from the 
association’s published guidelines (taken from the internet – Google search). 
“If you are not a healthy volunteer the cover you could get will depend on the type of 
insurance and what is wrong with you 
Travel insurance 
You might get cover if you take part in a clinical research trial of established
2 
drugs, 
research, imaging studies or comparisons of established surgical interventions (to 
identify which treatment is better in certain circumstances) that are prescribed by 
your doctor. 
It is unlikely that you would get cover if you take part in a clinical research trial of: 
Drugs that are in the experimental/unproven phase, even if you are healthy with no 
pre-existing conditions3 
New or innovative surgical procedures.” 
In the above context, “getting cover” often means an increase in the premium. Also, 
Participant ID 012 informed me that his usual insurer refused him travel insurance 
while in the study. Understandably he was not impressed. 
I was not aware of this issue prior to initiation of the study. Subsequently, I had to 
inform potential participants about their insurance implications, especially if they had 
travel plans while on the trial IMP. 
There is no doubt that the issues illustrated above make recruitment to any clinical 
trial challenging. Some of them are unavoidable but some can be modified. Hopefully 
with sanction of the proposed new EU Clinical Trials Regulations (May 2014) a 
single clinical trials approval will replace the current separate approvals from REC, 
MHRA etc. This should ease and expedite negotiation of mandatory regulations. 
							
96	
5.4 Strengths and weaknesses of the study 	
5.4.1 Strengths 	
This was a carefully designed pilot randomised controlled trial to assess cough and 
reflux in patients with IPF. State of the art techniques were utilised to accurately 
assess cough and quantify reflux in patients. The diagnosis of IPF in the study 
population was well defined as they undergo robust assessments (including lung 
function tests, high resolution CT scans, and very occasionally surgical biopsy if 
indicated) by the regional ILD team at RVI, as part of their clinical care. Patients 
recruited for the study are comparable to the IPF patients enrolled in other clinical 
trials. All the participants completed ambulatory 24-hour cough recording without any 
major problems (the primary focus of the trial was cough and the change of cough 
with omeprazole and/or placebo therapy).  
 
The study provided a detailed characterisation of both acid and non-acid reflux in 
patients with IPF. In addition it assessed the impact of omeprazole therapy in 
improving cough and reflux in patients. If the final analysis of the study shows that 
omeprazole does significantly improve cough in a safe manner, then it will provide 
further evidence for an effective and inexpensive solution to a long-standing unmet 
health problem. It will help plan further multi-centre definitive trials. If omeprazole 
does not improve symptoms, the study will provide new insights into the role of non-
acid reflux in pathogenesis of IPF and/or symptoms in IPF. This will help determine 
future researches into treatment and pathogenesis of IPF. Therefore the study should 
provide practical benefits either way. 
5.4.2 Weaknesses  	
As discussed previously recruitment to the study was challenging throughout. The 
majority of the patients were already established on empirical anti-acid therapy. In 
addition, the study population mostly included elderly patients with multiple co-
morbidities, which limited their suitability for multiple invasive procedures. 
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Patients with subjective and/or clinical symptoms of reflux (as opposed to those with 
no symptoms or “silent reflux”) are more likely to consent for the study procedures. 
Multiple study visits and study procedures had the potential to introduce selection bias 
towards a “less severe” disease group. Hence the study population may mostly 
comprise patients with mild to moderate IPF and/or patients with gastro-oesophageal 
reflux disease. However, given the nature of the diagnostic tests for reflux disease, 
and those involved in the study project, the potential for recruitment bias were 
unavoidable. Moreover, patients who could not tolerate discontinuation of antacid 
therapy were excluded from the study.  
 
Omeprazole is a widely used acid suppressant therapy. It achieves excellent 24 hour 
acid suppression, especially with the twice daily regime. Therefore, 3 months duration 
of twice daily omeprazole therapy (for the treatment arm) was chosen for the trial 
mostly for practical reasons. However, omeprazole could reduce circulating 
pirfenidone levels in IPF patients as it induces hepatic enzymes. Study participants 
were informed of the potential drug interaction prior to recruitment. For future trials 
(depending on the final analysis of this study data) alternative PPIs and/or antacid 
therapy should be considered to avoid such drug interaction.   
 
Research conducted in association with patients and/or their representatives to address 
specific clinical needs are more likely to yield results that can improve health and well 
being. Researchers can design relevant, patient-friendly trials by taking account of the 
patient’s and/or their relative’s unique insight into their condition. The potential 
benefits of involving patient and public in clinical research/trials have long been 
identified and currently increasingly a funder requirement. Patients and/or relatives 
can be involved early as a “driving force” or co-researcher (pre-approval and design 
stages) to help ensure efficient trial design, help raise funds and address issues 
regarding recruitment and compliance. They can also be engaged later in the study as 
a “reviewer”, “advisor”, “information provider” and “research subject” to help smooth 
delivery of clinical trials (adapted from Patient Partner, Patient involvement in clinical 
research, a guide for sponsors and investigators, produced by the Patient Partner 
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project funded by the 7th Framework Programme of the European Commission, taken 
from the internet – Google search).  
No patient and/or public was involved in our trial study design (to the best of my 
knowledge). I am grateful to Mr. Ian Perry (lay patient member) for his help and 
advice with the trial as an independent TSG member (involved as a reviewer, advisor 
and information provider). As outlined previously, recruitment to our study has been 
slower than expected in spite of multiple measures put in place. In retrospect, early 
involvement of patients and their relatives could have been helpful to address some of 
the identified issues.   
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Chapter 6. Efficacy of pulsed cyclophosphamide and 
methylprednisolone therapy in patients with progressive interstitial 
lung disease (ILD) – a retrospective study 	
6.1 Background 	
ILDs diffusely affect lungs and are often relentlessly progressive with healthy lung 
tissue replaced by fibrous tissue, which reduces lung compliance leading to 
breathlessness and hypoxia on exertion and/or rest, ultimately leading to respiratory 
failure. The exact mechanism of progression of ILD is not known but a current 
accepted theory is that a hyperactive immune stimulation (often due to an unknown 
trigger) leads to inflammation and fibrosis. Lung fibrosis is generally considered 
irreversible, hence therapeutic strategies aim to reduce inflammation. 
However, therapeutic options are limited, as no pharmacological agent has shown to 
significantly reduce mortality in ILD. Despite this it is often difficult to withhold 
potential treatments in a seriously ill, deteriorating patient due to lack of robust 
evidence to suggest any individual therapy. 
The drug cyclophosphamide is an alkylating agent that prevents cell division by 
inhibiting intracellular DNA synthesis (Fleer et al, 1982). It is also a potent 
immunosuppressant. Its beneficial immunomodulatory effects are mediated via 
cytotoxic effects on both resting and dividing lymphocytes. Cyclophosphamide 
therapy induces reduction in the numbers and functions of T and B-lymphocytes 
thereby impairing both cellular and humoral immunity, which potentially helps to 
reduce lung injury, and therefore theoretically may inhibit further fibrosis and decline 
in lung function (Cupps et al, 1982). 
Intravenous pulsed cyclophosphamide therapy in association with methylprednisolone 
is employed as a therapeutic strategy in selected centres, especially in a setting of 
rapidly progressive ILD, as a few studies have shown small improvements in lung 
function with this therapy, especially in ILD associated with systemic sclerosis 
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(Griffiths et al, 2002; Hoyles et al., 2006; Poormoghim et al., 2012) and in some 
cases of non specific interstitial pneumonia (NSIP) (Naki et al, 2002; Kondoh et al., 
2005; Brummaier et al, 2013)]. 
However cyclophosphamide therapy is potentially associated with significant side 
effects namely bone marrow suppression, worsening of liver and kidney function, 
haemorrhagic cystitis (Monarch et al., 2010) and increased risk of infections. 
In our centre, cyclophosphamide therapy is administered via a dedicated 
Rheumatology Day Unit at Freeman Hospital (with Dr. Bridget Griffiths, Consultant 
Rheumatologist, as clinical lead). Therapy has been given to patients with a wide 
variety of rapidly progressive ILD. It was considered important to review whether the 
treatment had overall beneficial or detrimental effect. 
Therefore, I undertook a retrospective case series study to assess the outcome of 
cyclophosphamide therapy in patients with ILD, regardless of aetiology. 
6.2 Treatment protocol 	
Usually, patients receive 6 pulses of intravenous (IV) methylprednisolone 10 mg/kg 
and IV cyclophosphamide 15 mg/kg. The first 3 pulses are given at 3 weekly intervals 
and the last 3 pulses at 4 weekly intervals. The dose of IV methylprednisolone is 
usually reduced in patients with diabetes mellitus or known osteoporosis. The dose of 
IV cyclophosphamide is reduced if the patient is over 70 years of age to 10 mg/kg and 
if they have renal impairment. The patients receive Mesna 400mg orally 3 times on 
the day of IV cyclophosphamide to reduce the risk of haemorrhagic cystitis, co-
trimoxazole 960mg Monday, Wednesday and Friday, a proton pump inhibitor and 
bone protection therapy. If a patient is on oral prednisolone, then this is gradually 
reduced according to response with each IV pulse. Depending upon a patient’s 
response, they may receive an additional 3 pulses of treatment (i.e. 9 pulses in total). 
After completing the course of IV methylprednisolone and cyclophosphamide, 
patients are usually started on maintenance immunosuppressant therapy in the form of 
mycophenolate mofetil. 
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6.3 Study aims 	
The primary aim of the study was to assess the change in lung function between the 3-
6 months pre-therapy and the 3-6 months post-therapy (up to 12 months pre- and post-
therapy if results were available). 
The secondary aims of the study were to: 
1. Assess the rate of change in lung function 3-6 months pre-therapy to that in the 3-6 
months post-therapy (especially in patients who had not responded, or who had shown 
deterioration in lung function) 
2. Assess any significant change in oral prednisolone dose before and after pulsed 
therapy. 
3. Assess any significant change in weight post-pulsed therapy. 
4. Assess any significant change in oxygen requirement post-pulsed therapy. 
5. Any cyclophosphamide-related side effects, in particular bone marrow suppression, 
haemorrhagic cystitis, and infection. 
6. Review the most recent pre-therapy chest CT scans to assess for the predominant 
radiological features regardless of the working/clinical diagnosis. 
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Chapter 7. Methods and data collection 
 
7.1 Patient identification 
A database of patients receiving pulsed intravenous cyclophosphamide therapy is 
maintained by the Rheumatology Department at Freeman Hospital, as part of routine 
clinical care. Patients were identified from the database and data were collected from 
the identified patients’ case notes. My aim was to study all patients with ILD who had 
received cyclophosphamide therapy from January 2010 to August 2014. 
7.2 Data collection 
Data were collected in an anonymised audit proforma sheet. With help from my 
supervisors and Dr Bridget Griffiths I designed the audit proforma and also prepared a 
study protocol mainly to set study parameters and outcome definitions to help guide 
data collection and subsequent analysis. 
7.3 Pre-determined study parameters and outcome definitions for data analysis 	
The study team agreed on the following definitions (especially with regards to 
changes in lung function) prior to data collection to help guide subsequent 
interpretation/analysis: 	1.		Primary aim/outcome definitions:  
a) Response or improvement to therapy: if post-treatment lung function increased 
by more than or equal to 10% when compared to pre-treatment lung function 
b) No Response to therapy or Static: if post-treatment lung function was 
unchanged, or if it improved but by less than 10%, or if declined but by less 
than 10% when compared to pre-treatment lung function 
c) Deterioration despite therapy: if post-treatment lung function declined by 
more than or equal to 10%. when compared to pre-treatment lung function 
2. Secondary aim/outcome definitions: 
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a) If the rate of decline in post treatment lung function was reduced by more than 
or equal to 10% – “significant decline prevented by the therapy” 
 
b) If the rate of decline in post treatment lung function reduced but by less than 
10%, or if the rate of decline increased – “no significant decline induced by 
the therapy” 
3. Echocardiogram study: results of echocardiography performed up to 6 months pre 
or post therapy were recorded.  
4.	Blood tests for autoantibodies: results from the most recent panel (pre-therapy) 
were accepted. Results from diagnosis headings in clinic letters were included as well, 
if no autoantibody results could be found in the notes or on electronic records.  
5. Definition of impaired liver function tests: bilirubin, alanine transaminase (ALT), 
alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT) enzyme levels >/= 
3 times the normal limit. 
6. Definition of impaired renal function: creatinine above the normal range for age/wt. 
or increase of more than 10% from baseline (last test prior to starting therapy). 
7. Definition of bone marrow suppression: any from haemoglobin less than 9.0 g/dl 
(new onset), neutrophil count< 2.0x10
9
/L (new onset), lymphocyte count <0.6x10
9
/L 
(new onset), platelet count < 140x10
9
/L (new onset).	 	
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Chapter 8. Results 	
Leo Mansell, an undergraduate Pharmacy student in Newcastle University showed 
interest in taking up the cyclophosphamide audit for his mandatory research topic. 
Prof Simpson was happy for me to lead Leo’s supervision. 
Unfortunately, complying with Research/Information Governance guidelines meant 
Leo was not allowed direct access to NHS clinic notes, records or tests. Also, given 
the limited time allotted for him to complete the project it was deemed not practical to 
get a “research passport” sorted. Hence I collected all the data in the anonymised 
audit proforma and then he analysed the data (using Minitab 17 statistical software). 
He has submitted his dissertation. Some of the results presented here have been taken 
from his work. 
The collected data were scrutinised further with the help of Dr. Peter Avery (Senior 
Lecturer, Institutes of Statistics and Mathematics, Newcastle University) to extract 
further evidence with regard to the administered therapy (as a host of other 
information was collected i.e. change in prednisolone therapy, change in weight, 
cyclophosphamide dosing schedule). He has kindly helped me with the statistical 
analysis especially relating to the assessment of change of lung function pre- and 
post-pulsed cyclophosphamide and methylprednisolone therapy. 
In addition, Dr. Anna Beattie, Dr. Sylvia Worthy (Consultant Thoracic Radiologists at 
Royal Victoria Infirmary) and Prof John Simpson reviewed chest CT scans of the 
patients.  
Results of the study were presented as a poster at the British Thoracic Society Winter 
Meeting on 02/12/2015 (Efficacy of pulsed cyclophosphamide and 
methylprednisolone therapy in patients with progressive interstitial lung disease). 
8.1 Patient demographics 	
60 patients were identified from the database. Of these 53 patients’ notes were 
available and transcribed.  
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The median age of patients was 60 years (range 39 – 81 years); 29 (55%) were male. 
53% of the patients were either former or current smokers (ex-smokers 26, current 
smokers 2, non smokers 22, unknown 3). 
 
In addition to the primary diagnosis of ILD, the major co-existing medical conditions 
were diabetes mellitus in 10 (19.2%) patients, hypertension in 13 (25%), ischaemic 
heart disease in 7 (13.2%), heart failure in 2 (3.8%) and osteoporosis in 3 (5.7%). 1 
patient had previously had a stroke. 
 
Echocardiography data were available from 27 patients. Of these, 10 showed right 
ventricular enlargement with mild impairment of right ventricular function in 4 
patients, moderate impairment of function in 9 patients and severe impairment in 3 
patients. 
8.2 Diagnosis of ILD at initiation of therapy 	
Diagnosis at initiation of therapy included connective tissue disease related – ILD 
(CTD-ILD 21, 40%), idiopathic NSIP (12, 23%), chronic hypersensitivity 
pneumonitis (8, 15%), IPF (6, 11%), unclassifiable ILD (6, 11%). 
Of the 21 patients with CTD – ILD, the nature of the underlying connective tissue 
disease was: Undifferentiated CTD (8), systemic sclerosis (7), rheumatoid arthritis 
(2), inflammatory arthritis (2), polymyositis (1), primary Sjogren’s syndrome (1). 
8.3 Dosage of cyclophosphamide and methylprednisolone delivered and follow on 
immunosuppression 	
The median number of cyclophosphamide and methylprednisolone pulses received by 
patients was 6 (range 1 – 23). This meant a median cumulative dose of 7085 mg of 
cyclophosphamide (min 840mg; max 25000 mg, N=50) received by patients. 42 
(79%) out of the 53 ILD patients received at least 6 pulses of therapy. 12 (23%) 
received upto 9 pulses.  
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The dose of methylprednisolone therapy was reduced (less than 10mg/kg) in 19 
patients, mostly due to diabetes mellitus. Eight patients had a reduced dose of 
cyclophosphamide therapy (10 mg/kg) due to age (most common reason) and/or renal 
impairment or thrombocytopenia at presentation. 
 
As per the protocol, all patients received Mesna (to prevent haemorrhagic cystitis) 
during pulsed cyclophosphamide and methylprednisolone therapy. 
46 (87%) patients were prescribed co-trimoxazole prophylaxis during therapy. 2 
patients were already on azithromycin therapy, 2 patients had previously documented 
allergy/adverse reaction to co-trimoxazole and 1 patient suffered from deterioration of 
liver function during therapy – hence they were not prescribed additional co-
trimoxazole (data were missing on 2 patients). 
 
After completion of cyclophosphamide and methylprednisolone therapy, 41 (77%) 
patients received follow on immunosuppressive therapy in the form of mycophenolate 
mofetil (37), azathioprine (2) or rituximab (2). 
8.4 Assessment of change in lung function post-therapy 	
I am extremely grateful to Dr Peter Avery for his help with the statistical analysis 
with regards to the rate of change of lung function pre- and post-therapy.  
 
Lung function data (including spirometry and gas transfer data) were collected up to 
12 months (or even up to 24 months if available) prior and subsequent to completion 
of cyclophosphamide therapy. Forced vital capacity (FVC) is the volume of air that 
can be forcibly expired after a full inspiration. It is measured in litres. Transfer factor 
of lung for carbon monoxide (TLco) test determines the extent to which diffusible gas 
passes from lung alveoli to blood. It is measured with the help of carbon monoxide 
gas and expressed in mmol/min/kPa 
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Previous studies have shown that FVC and TLco are the two best predictors to 
determine any subtle progression in ILD, hence those two parameters were chosen for 
analysis. 
 
Statistical analysis was done with Minitab 17 software. Rate of decline of lung 
function pre- and post-cyclophosphamide therapy was compared using a random 
intercept model. 
Figure 17 shows data plots and average fitted quadratic curve for FVC of patients who 
received pulsed cyclophosphamide and methylprednisolone therapy 
 
	
 
Figure 17: Average fitted quadratic curve for FVC; FVC (litres);                                                                      
Time relative to start of treatment (months); p=0.0004 
The graph shows a mean decline in FVC from 2.9 litres to approximately 2.4 litres 
over a period of 20 months prior to start of therapy. This means a decline in lung 
volume of more than 400 ml in absolute terms (i.e. more than 10% decline from 
baseline). This is considered clinically significant, as this would suggest a reduced life 
expectancy. Post-therapy there is a significant reduction in the rate of decline of FVC 
(highly significant quadratic term in time p=0.0004). 
Figure 1-showing data lots and average fitt  quadratic curve for FVC of patients 
who received IV Cyclophosphamide therapy  
!
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Figure 18 below shows data plots and average fitted quadratic curve for TLco of 
patients who received pulsed cyclophosphamide and methylprednisolone therapy 
 
	
Figure 18: Average fitted quadratic curve for TLCO; TLco (mmol/min/kPa);                                                
Time relative to start of treatment (months); p = 0.00015 
Similar to FVC, the above graph shows a decrease in the rate of decline of TLco post-
cyclophosphamide and methyl-prednisolone therapy, the quadratic term in time is 
highly significant p=0.00015.  
 
Not all patients who received therapy (at least 1 pulse of cyclophosphamide and 
methyl-prednisolone) had lung function tests performed at regular intervals post- 
therapy (due to death, advanced disease or other reasons as outlined below).  
 
1 patient underwent lung transplantation after receiving 2 pulses of therapy. Only 1 
lung function test (at 3 months post-therapy) was available for him. Another patient 
who was switched to mycophenolate therapy after a couple of pulses (poorly tolerated 
pulsed therapy) struggled to perform lung function tests post-therapy. 1 patient, who 
had previously received 6 pulses of therapy but died 11 months post-therapy due to 
malignancy of gynaecological origin, had only 1 lung function test (4 months after 
therapy) available for analysis. Another patient who died 16 months after receiving 6 
pulses had only one lung function test performed 8 months post-therapy.  
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In total, 13 patients (at the time of review) had died during or after completion of 
pulsed therapy. Of them 7 had no post-therapy lung function tests performed.  
Therefore the data available from the study was randomly clustered or grouped at 
different time intervals. Hence the random intercept model with average fitted 
quadratic curve (process of constructing a curve that approximately/best fits the data) 
was chosen for analysis of the collected data (as advised by Dr Peter Avery).   
 
In a selected group of patients (who had 0 – 6 months pre- and post-therapy lung 
function tests available) rate of decline in lung function was assessed before and after 
therapy.  
Rate of decline was calculated for each patient by dividing their total decline pre- or 
post-therapy by the number of months over which the decline took place.  
(This work was carried out by Leo Mansell and reproduced with his kind permission) 
 
Figure 19 shows change in rate of decline in FVC 6-0 months pre-therapy to 0-6 
months post-therapy (data available from 17 patients).  
 
	
Figure 19: Change in FVC 6 months pre- and post-therapy: FVC (litres), Time relative to start of treatment 
(months). The red line depicted on the graph connects the mean FVC of each time period (paired t test, n=17, 
p=0.002). 
The graph shows steady decline in FVC of 17 patients pre therapy (mean decline of 
0.303 litres in 3 – 6 months pre-therapy).  There was significant reduction in rate of 
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Secondary Aim 1:  Assess the rate of change in lung function 0-6 months pre-therapy to that 
in the 0-6 months post-therapy 
 
 
Figure 18: Decline of FVC 6-0 months pre therapy to 0-6 months post therapy. The patients 
appear in each PFT time period (n=17) 
Figure 18 depicts the decline of the 17 
patients who had complete 0-6 months pre 
and 0-6 months post PFT data. The red 
superimposed line connects the mean FVC 
of each time period. Much like Figure 4, 
which displays the trend of the cohort, an 
initially steep decline is seen between 3-6 
months and 0-3 months pre therapy 
(0.303L decline in mean). The 0-3 and 3-6 
months post therapy decline is much 
flatter (0.003L). Additionally there is an 
inclining trend between 0-3 months pre 
and 0-3 months post therapy (0.272L 
increase in mean FVC).  
Tables 13 and 14 show the statistical 
analysis performed on the rate of decline 
pre and post therapy. Rate of decline was 
calculated for each patient by dividing their 
total decline pre or post therapy by the 
number of months over which the decline 
took place (6). 
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decline of FVC in 3 – 6 months post-therapy (mean decline of 0.003 litres, p=0.002, 
paired t test).  
Significant decline in FVC was prevented in 13 out of 17 patients (defined as greater 
than or equal to 10% reduction in the rate of decline in secondary outcome/aim 
definition) after therapy. 
 
Figure 20 shows change in rate of decline in TLco 6-0 months pre-therapy to 0-6 
months post-therapy (data available from 10 patients). 
 
	
Figure 20: Change in TLco 6 months pre- and post-therapy: TLco (mmol/min/kpa), Time relative to start of 
treatment (months). The red line depicted on the graph connects the mean TLco of each test time period (paired t 
test, n=10, p=0.001). 
 Similar to FVC, this graph shows steep decline in TLco of 10 patients in 3 – 6 
months pre-therapy (mean decline of 1.53 mmol/min/kpa). Following therapy, TLco 
shows a small amount of incline, which continued upto 3 – 6 months, post-treatment 
(mean increase in TLco by 0.27 mmol/min/kpa).  
Significant decline in TLco was prevented in 8 out of 10 patients after therapy 
(p=0.001, paired t test).   
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Table 13: Statistical analysis on rate of decline of FVC pre and post therapy 
 
Table 14: The response of the 17 patients in Secondary Aim 1 analysis FVC 
Effect of CPM on FVC Rate of Decline Number of Patients 
Decline Not Prevented (≥10% Increase in 
Decline) 4 
Decline Prevented (≥10% reduction in 
Decline 13 
Total Number of Patients 17 
  
Basic Statistics 
Rate of Decline 6-0 Months Pre 
Therapy (L/Month) 
Rate of Decline 6-0 Months Post 
Therapy (L/Month) 
N 17 17 
Mean 0.0505 0.0 51 
Median 0.367 0.01333 
Statistical Test Paired t Test 
P Value 0.002 
3-6 Months Post Therapy0-3 Months Post Therapy0-3 Months Pre Therapy3-6 Months Pre Therapy
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Decline of TLCO 6-0 and 0-6 Months Pre and post Therapy
Figure 19 : Decline of TLCO from 6-0 months pre therapy to 0-6 months post therapy. The same patients 
app ar in each PFT time period (n=10) 
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8.5 Assessment of any significant change in pre-therapy maintenance 
prednisolone dose 	
Post-therapy, the dose of oral prednisolone was decreased in 15 patients but increased 
in 6 patients. 28 patients had no change.  
Mean dose of prednisolone pre-therapy was 11.5 mg compared to 7.5 mg post- 
therapy. Wilcoxon signed rank test was performed as data were non-parametric but 
symmetrical. 
	
• Wilcoxon	Signed	Rank	Test:	C3		
• Test of median = 0.000000 versus median ≠ 0.000000 
•  
•         N for   Wilcoxon         Estimated 
•      N   Test  Statistic      P     Median 
• C3  49     25      242.5  0.032      1.000 
	
 4 patients were not included in the test as pre- and post-data (for prednisolone dose) 
were not available. The test showed a p value of 0.032 when comparing prednisolone 
dose pre- and post-therapy, implying a significant reduction in maintenance 
prednisolone dose post-cyclophosphamide and methylprednisolone therapy. 
8.6 Assessment of any change in weight post-therapy 
	
	
46 patients were included in the analysis as a full set of data was not available in 7. 
Paired t test was performed as the data were normally distributed. Mean weight of the 
patients pre-therapy was 83.4 kg compared to 83.5 kg post therapy. 
 
• Paired	T-Test	and	CI:	C5	(pre	therapy),	C6	(post	therapy)		
• Paired T for C5 - C6 
•              N    Mean  StDev  SE Mean 
• C5          46   83.44  20.74     3.06 
• C6          46   83.50  19.32     2.85 
• Difference  46  -0.063  6.374    0.940 
• 95% CI for mean difference: (-1.956, 1.830) 
• T-Test of mean difference = 0 (vs ≠ 0): T-Value = -0.07  P-Value = 
0.947 
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The test shows a p value of 0.947, implying no significant change in weight post 
cyclophosphamide and methylprednisolone therapy.  
8.7 Assessment of any significant change in oxygen prescription post-therapy 		
6 patients had a documented increase in oxygen therapy while 1 patient had a 
decrease in oxygen therapy (from 3 litres/min to 2 litres/min). Data were missing in 
11 patients. 
 
Many of the patients who have received therapy were referred to the regional 
Newcastle ILD clinic from surrounding district general hospitals. Usually, the local 
oxygen team manages the oxygen therapy and there is often a delay in documentation 
and/or notification of update in prescription. Patients (who are often significantly ill 
and undergoing toxic treatment) might not always recollect their oxygen use 
accurately (i.e. use as short burst therapy and/or ambulatory only or long-term oxygen 
therapy). 
 
Given these limitations and the low numbers, no statistical test has been carried out. 
There appeared to have been no change in oxygen prescription in 35 patients (this 
included patients who never had oxygen prescribed prior or at end of therapy).  
8.8 Adverse events during therapy 
	
Table 16 below outlines adverse events suffered by patients whist on pulsed 
cyclophosphamide and methyl-prednisolone therapy. 
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Table 16: Adverse events during pulsed cyclophosphamide and methyl-prednisolone 
therapy 
 
Adverse events Number of patients Percentage (%) 
Bone marrow suppression 8 15 
Impaired liver functions 4 7 
Impaired renal functions 3 6 
Infections (any) 27 51 
Microscopic haematuria 1 2 
 
32 episodes of infection (assessed from medical notes) were reported in 27 ILD 
patients’ receiving pulsed therapy. Majority (21, 66%) were of respiratory origin. 
Table 17 below outlines sites of infections reported (in addition to chest infections) 
whilst on therapy. 
 
Table 17: Types of infection reported during pulsed therapy  
 
Site/type of infection Number of episodes Percentage (%) 
Chest/Respiratory 21 66 
Urinary tract infection 4 13 
Fungal nail infection 2 6 
Tooth abscess 1 3 
Oral candidiasis 1 3 
Viral infection (flu) 1 3 
Tonsillitis 1 3 
Ear infection 1 3 
 
In total, 13 episodes of hospital admission were documented amongst the patients 
during therapy. Of these 8 were considered likely to be related to cyclophosphamide 
therapy (with pneumonia being the most common diagnosis). Other causes of hospital 
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admission were chest pain (leading to a diagnosis of pulmonary embolism), bleeding 
from gastric ulcer, deep venous thrombosis, hyperkalemia and exacerbation of ILD. 
 
25 (71%) of the 35 patients who suffered from an adverse event were able to complete 
the therapy. 
 
8.9 Review of pre-therapy chest CT scan features 	
Prof John Simpson, Dr Sylvia Worthy and Dr A Beattie independently reviewed the 
most recent pre-therapy chest CT scans of the patients who received the 
cyclophosphamide therapy to assess the predominant radiological feature blinded to 
the clinical diagnosis. I assessed the concordance/agreement between the chest 
physician and the radiologists’ interpretation (based on pre determined 
categories/descriptors on CT scan features: a) predominant fibrotic changes with 
secondary bronchial dilatation; b) predominant ground glass changes; c) predominant 
fibrotic changes with honeycombing).  
 
Chest CT scans showed predominant fibrotic changes with secondary bronchial 
dilatation in 30 (58%) patients; predominant ground glass changes in 16 (31%) 
patients and predominant fibrotic changes with honeycombing in 6 (11%) patients. 
(scans were not available for one patient). 
 
There was concordance between the members on most occasions (44 out of the 52 
scans reviewed). 
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Chapter 9. Discussion 	
This was a single centre, retrospective study. It showed pulsed intravenous 
cyclophosphamide and methylprednisolone therapy was associated with stabilisation 
of lung function in a mixed cohort of patients with progressive ILD. There was a 
significant reduction of maintenance steroid dose post therapy but no significant 
change in weight. Adverse events were common, most frequently in the form of 
respiratory tract infections. The adverse events were however transient and managed 
with dose reduction and/or delay in the schedule of cyclophosphamide and methyl-
prednisolone therapy. After completion of therapy the majority of patients were able 
to continue with follow on immunosuppression therapy in the form of mycophenolate 
mofetil.	
An inherent issue in retrospective studies are missing data. This study was not an 
exception especially in regard to oxygen therapy, echocardiography studies and on 
occasions lung function tests (as previously outlined in section 8.4). 
 
A minority of patients declined to continue with cyclophosphamide therapy and in a 
few patients therapy was discontinued due to clinical reasons (due to adverse events 
or due to rapid decline in lung disease necessitating palliative measures). In addition, 
patients with severe ILD often find it difficult to perform a full set of lung function 
tests. 7 patients who received therapy (at least one pulse) had no post-therapy lung 
function test performed. A further 7 patients had only 1 post therapy lung function test 
performed after completion of therapy. Therefore, it has been challenging to account 
for these “dropped out” lung function tests in the analysis and assess what effect they 
would have had on the overall study results. In theory, it is possible that the study 
results have been positively influenced by the patients who were able to tolerate the 
therapy better (i.e. complete treatment as per protocol thereby inducing “survivor 
bias”). 
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However subsequent scrutiny/analysis of data (where both pre- and post-therapy lung 
function tests were available at stipulated intervals) showed pulsed cyclophosphamide 
and methyl-prednisolone therapy was associated with stabilisation of lung function in 
a mixed cohort of patients with rapidly progressive ILD (although the number of 
patients/test results available were low, as detailed in section 8.4). 
Some of the patients showed significant improvement (greater than 10%) in their lung 
function post-therapy. Given the nature of the study, it is difficult to predict the 
“phenotype” of the patients who would benefit the most from therapy. 
  
The study is in concordance with previously published papers showing small 
improvements in lung function with the therapy in patients with ILD (as outlined in 
section 6.1). I hope the study has provided further important evidence for the team at 
the Newcastle regional ILD clinic, contributing to improvements in the clinical care 
of patients with progressive ILD.  
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Appendix 1: PPIPF study: Questionnaires 	
            PPIPF STUDY: RCT of Omeprazole/Placebo in IPF 
            (PI: Prof John Simpson, Rec: 13/YH/0284) 
 
            Subject Initial:_________        Study ID/Trial ID________     Date:___/___/______ 
 
 
LEICESTER COUGH QUESTIONNAIRE (LCQ) 
 
 
This questionnaire is designed to assess the impact of cough on various aspects of 
your life.   
 
Read each question carefully and answer by CIRCLING the response that best applies 
to you.  
Please answer ALL questions, as honestly as you can.  
 
 
1. In the last 2 weeks, have you had chest or stomach pains as a result of your 
cough? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of the 
time 
None of 
the time 
 
2. In the last 2 weeks, have you been bothered by sputum (phlegm) production 
when you cough? 
 
1 2 3 4 5 6 7 
Every 
time 
Most 
times 
Several 
times 
Some 
times Occasionally Rarely 
Never 
 
         
3. In the last 2 weeks, have you been tired because of your cough? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of the 
time 
None of 
the time 
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4. In the last 2 weeks, have you felt in control of your cough? 
 
1 2 3 4 5 6 7 
None of 
the time 
Hardly 
any of the 
time 
A little of 
the time 
Some of 
the time 
A good 
bit of the 
time 
Most of 
the time 
All of the 
time 
 
5. How often during the last 2 weeks have you felt embarrassed by your 
coughing? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of the 
time 
None of 
the time 
 
6. In the last 2 weeks, my cough has made me feel anxious. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
7. In the last 2 weeks, my cough has interfered with my job, or other daily tasks. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
8. In the last 2 weeks, I felt that my cough interfered with the overall enjoyment 
of my life. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
9. In the last 2 weeks, exposure to paints or fumes has made me cough. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
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10. In the last 2 weeks, has your cough disturbed your sleep? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
11. In the last 2 weeks, how many times have you had coughing bouts? 
 
1 2 3 4 5 6 7 
All of the 
time 
(continuously) 
Most 
times of 
during 
the day 
Several 
times 
during 
the day 
Some 
times 
during 
the day 
Occasionally 
through the 
day 
Rarely None  
 
12. In the last 2 weeks, my cough has made me feel frustrated. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
13. In the last 2 weeks, my cough has made me feel fed up. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
14. In the last 2 weeks, have you suffered from a hoarse voice as a result of your 
cough? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
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15. In the last 2 weeks, have you had a lot of energy? 
 
1 2 3 4 5 6 7 
None of 
the time 
Hardly any 
of the time 
A little of 
the time 
Some of 
the time 
A good 
bit of the 
time 
Most of 
the time 
All of the 
time 
 
16. In the last 2 weeks, have you worried that your cough may indicate a serious 
illness? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
17. In the last 2 weeks, have you been concerned that other people think 
something is wrong with you, because of your cough? 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
18. In the last 2 weeks, my cough has interrupted conversation or telephone calls. 
 
1 2 3 4 5 6 7 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly any 
of the time 
None of 
the time 
 
19. In the last 2 weeks, I feel that my cough has annoyed my partner, family or 
friends 
 
1 2 3 4 5 6 7 
Every 
time I 
cough 
Most 
times 
when I 
cough 
Several 
times 
when I 
cough 
Some 
times 
when I 
cough 
Occasionally 
when I cough Rarely Never 
 
 
 
Thank you for completing this questionnaire. 
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    PPIPF STUDY: RCT of Omeprazole/Placebo in IPF 
    (PI: Prof John Simpson, Rec: 13/YH/0284) 
 
    Subject Initial:_________        Study ID/Trial ID________     Date:___/___/______ 
 
 
   The Reflux Symptom Index (RSI) 
 
 
 
  Reflux Symptom Index Scale Test: Rate the following items on a  
  scale of 0-5.  
 
  The Reflux Symptom Index 
 
 Within the past month, how did the following affect you? 
  0 = No problem 5 = Severe problem 
 (Please put a tick in the score box as applicable to your symptom) 
 
 
Hoarseness or a problem with your voice? 0 1 2 3 4 5 
Clearing your throat?       
Excess throat mucus or postnasal drip?       
Difficulty swallowing food, liquids or pills? 
 
      
Coughing after you ate or lie down? 
 
      
Breathing difficulties or choking episodes? 
 
      
Troublesome or annoying cough? 
 
      
Sensations of something sticking in your throat or 
a lump in your throat? 
 
      
Heartburn, chest pain, indigestion, or stomach 
acid coming up? 
 
      
 
 
Thank you for completing the questionnaire. 
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         PPIPF STUDY: RCT of Omeprazole/Placebo in IPF 
         (PI: Prof John Simpson, Rec: 13/YH/0284) 
 
         Subject Initial:_________        Study ID/Trial ID________     Date:___/___/______ 
 
Gastrointestinal Quality of Life Index Questionnaire (GIQLI) 
 
This questionnaire is designed to assess the impact of GI symptoms on various 
aspects of your life.  
 
Read each question carefully and answer by circling the response that best applies to 
you.  
 
1. How often during the past 2 weeks have you had pain in the abdomen? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
2. How often during the past 2 weeks have you had a feeling of fullness in the 
upper abdomen? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
3. How often during the past 2 weeks have you had bloating (sensation of too 
much gas in the abdomen)? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
4. How often during the past 2 weeks have you been troubled by excessive 
passage of gas through the anus? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
5. How often during the past 2 weeks have you been troubled by strong burping 
or belching? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
 
 
 
							
138	
6. How often during the past 2 weeks have you been troubled by gurgling noises 
from the abdomen? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
 
7. How often during the past 2 weeks have you been troubled by frequent bowel 
movements? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
8. How often during the past 2 weeks have you found eating to be a pleasure? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
9. Because of your illness, to what extent have you restricted the kinds of food 
you eat? 
Very Much Much somewhat A little  Not at all 
 
10. During the past 2 weeks, how well have you been able to cope with everyday 
stresses? 
Extremely 
poorly Poorly Moderately Well 
Extremely 
Well 
 
11. How often during the past 2 weeks have you been sad about being ill? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
12. How often during the past 2 weeks have you been nervous or anxious about 
your illness? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
13. How often during the past 2 weeks have you been happy with life in general? 
Never A little of the time 
Some of the 
time 
Most of the 
time All of the time 
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14. How often during the past 2 weeks have you been frustrated about your 
illness? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
15. How often during the past 2 weeks have you been tired or fatigued? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
16. How often during the past 2 weeks have you felt unwell? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
17. Over the past week, have you woken up in the night? 
Every night 5-6 nights 3-4 nights 1-2 nights Never 
 
18. Since becoming ill, have you been troubled by changes in your appearance? 
A great deal A moderate amount Somewhat A little bit Not at all 
 
19. Because of your illness, how much physical strength have you lost? 
A great deal A moderate amount Somewhat A little bit None 
 
20. Because of your illness, to what extent have you lost your endurance? 
A great deal A moderate amount Somewhat A little bit None 
 
21. Because of your illness, to what extent do you feel unfit? 
Extremely 
Unfit 
Moderately 
Unfit 
Somewhat 
Unfit A little Unfit Fit 
 
 
22. During the past 2 weeks, how often have you been able to complete your 
normal daily activities (school, work, household)? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
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23. During the past 2 weeks, how often have you been able to take part in your 
usual patterns of leisure or recreational activities? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
24. During the past 2 weeks, how much have you been troubled by the medical 
treatment of your illness? 
Very Much Much Somewhat A little Not at all 
 
25. To what extent have your personal relations with people close to you (family 
or friends) worsened because of your illness? 
Very Much Much Somewhat A little Not at all 
 
 
26. To what extent has your sexual life been impaired (harmed) because of your 
illness? 
Very Much Much Somewhat A little Not at all 
 
27. How often during the past 2 week, have you been troubled by fluid or food 
coming up into your mouth (regurgitation)? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
28. How often during the past 2 weeks have you felt uncomfortable because of 
your slow speed of eating? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
29. How often during the past 2 weeks have you had trouble swallowing your 
food? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
30. How often during the past 2 weeks have you been troubled by urgent bowel 
movements? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
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31. How often during the past 2 weeks have you been troubled by diarrhoea? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
32. How often during the past 2 weeks have you been troubled by constipation? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
33. How often during the past 2 weeks have you been troubled by nausea? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
 
34. How often during the past 2 weeks have you been troubled by blood in the 
stool? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
 
35. How often during the past 2 weeks have you been troubled by heartburn? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
36. How often during the past 2 weeks have you been troubled by uncontrolled 
stools? 
All of the 
time Most of the time 
Some of the 
time 
A little of the 
time Never 
 
 
         Thank you for completing this questionnaire.  
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          PPIPF STUDY: RCT of Omeprazole/Placebo in IPF 
          (PI: Prof John Simpson, Rec: 13/YH/0284) 
          Subject Initial:_________        Study ID/Trial ID________     Date:___/___/______ 
 
DeMeester Reflux Associated Questionnaire (DeMRQ) 
 
This questionnaire is designed to assess the impact of reflux symptom in your 
activities of daily life. 
Please circle the response applicable to your symptoms. 
In the last 2 weeks have you suffered from:  
          
1) Heartburn (burning sensation in chest): [Flow of Gastric Contents into     
Oesophagus] 
 
None - 0 - No heartburn 
 
Minimal - 1 - Occasional episodes 
 
Moderate - 2 - Reason for medical visit 
 
Severe - 3 - Interference with daily activities 
 
2) Regurgitation - (Flow of Gastric Contents into Mouth) 
 
None - 0 - No regurgitation 
 
Minimal - 1 - Occasional episodes 
 
Moderate - 2 - Predictable on position or straining 
 
Severe - 3 - Episodes of Pulmonary Aspiration (nocturnal cough, recurrent 
pneumonia) 
 
3) Dysphagia – (Difficulty swallowing or food getting stuck) 
 
None - 0 - No dysphagia 
 
Minimal - 1 - Occasional episodes 
 
Moderate - 2 - Required liquids to clear 
 
Severe - 3 - Episode of meat impaction requiring medical treatment 
 
Total symptom score (heartburn + regurgitation + dysphagia) = ____________ 
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Thank you for completing the questionnaire. 
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Appendix 2: PPIPF study: Protocol 
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1.	Lay	summary	
	
Idiopathic	pulmonary	fibrosis	(IPF)	is	a	disease	of	unknown	cause	in	which	areas	of	
normal	lung	tissue	are	replaced	by	scars.	As	a	result	it	becomes	harder	for	the	lungs	
to	extract	oxygen	from	the	air.	IPF	is	commonly	progressive,	and	around	50%	of	
patients	diagnosed	with	the	disease	die	after	approximately	3	years.	The	most	
common,	troublesome	symptoms	of	IPF	are	breathlessness	on	exertion,	and	cough.	
No	drug	treatments	have	been	unequivocally	shown	to	improve	the	death	rate,	or	to	
significantly	impact	upon	symptoms,	in	IPF.	
	
In	recent	years	it	has	been	recognised	that	cough	can	be	caused	by	small	amounts	of	
liquid	coming	up	from	the	stomach	and	“going	down	the	wrong	way”	into	the	lungs,	
a	process	commonly	known	as	“reflux”.	As	liquid	in	the	stomach	is	usually	acidic,	
patients’	lungs	may	repeatedly	be	exposed	to	small	amounts	of	acid.	Reflux	is	
unusually	common	in	IPF	and	could	potentially	contribute	to	the	debilitating	cough	
found	with	the	disease.	However	there	are	many	potential	causes	for	cough	in	IPF.	
	
Stomach	acid	can	be	efficiently	“switched	off”	by	drugs	called	“proton	pump	
inhibitors”,	one	of	which	is	called	omeprazole.	If	reflux	of	stomach	acid	does	
contribute	to	cough	in	IPF,	omeprazole	might	be	expected	to	reduce	cough.	The	
purpose	of	this	study	is	therefore	to	test	whether	omeprazole	does	reduce	cough	in	
patients	with	IPF.	Sixty	patients	with	IPF	will	be	randomly	allocated	to	have	3	
months	of	omeprazole	or	a	placebo.	Neither	the	patient	nor	the	doctor	will	be	aware	
which	treatment	has	been	given,	ie	this	is	a	randomised	“double-blind”,	placebo-
controlled	trial.	Patients’	cough	frequency	will	be	measured	before	and	after	
treatment	and	the	change	in	cough	frequency	compared	in	those	receiving	
omeprazole	and	those	receiving	placebo.	Change	in	cough	frequency	is	the	main	
thing	we	aim	to	compare,	but	a	range	of	other	measurements	will	be	assessed	such	
as	the	numbers	of	patients	eligible	to	take	part,	agreeing	to	randomization	and	
providing	outcome	data,	patients’	lung	function,	symptom	scores,	the	amount	of	
reflux,	and	the	amount	of	inflammation	in	the	lungs.	
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2.	Background	
	
Idiopathic	pulmonary	fibrosis	(IPF)	is	the	commonest	of	the	idiopathic	interstitial	
pneumonias	(IIPs).1,2	Clinically	the	disease	is	characterised	by	exertional	
breathlessness	and	cough,	both	of	which	may	be	debilitating	for	patients.1,2	
Pathological	features	include	the	deposition	of	excessive	fibrotic	matrix	in	the	
alveolar	regions	of	the	lung,	usually	in	a	predominantly	basal	and	subpleural	
distribution.3	IPF	tends	to	become	progressively	worse,	and	median	survival	from	
time	of	diagnosis	is	typically	estimated	at	3	years.1,2,4	No	pharmacological	treatments	
have	significantly	impacted	upon	mortality	in	IPF,	and	increasingly	attention	is	
focusing	on	more	patient-centred	end-points	in	clinical	trials.	However	the	
treatment	of	cough	associated	with	IPF	remains	notoriously	difficult,	and	new	
approaches	are	required.			
	
2.1.	Pathogenesis	of	IPF	
	
The	pathogenesis	of	IPF	remains	poorly	defined.	The	main	prevailing	theory	is	that	
the	alveolar	epithelium	sustains	damage	from	an	environmental	cause(s),	probably	
on	a	repeated	or	perpetual	basis.	In	genetically	predisposed	individuals,	the	injury	
leads	to	an	aberrant	repair	process	where	myofibroblasts	release	inappropriately	
high	amounts	of	interstitial	collagen.	The	rate	of	deposition	of	collagen	exceeds	the	
rate	of	resorption,	and	fibrosis	ensues.	The	histological	hallmark	of	IPF	is	thought	to	
be	the	“fibroblastic	focus”,	a	characteristic	lesion	in	which	myofibroblasts	generate	–	
and	sit	within	–	a	loose	stroma	of	immature	collagen,	typically	right	beneath	
abnormal	alveolar	epithelium.5,6	This	histological	appearance	broadly	supports	the	
prevailing	view	of	pathogenesis.		
	
The	nature	of	environmental	insults	initiating	or	perpetuating	the	cycle	of	damage	
and	aberrant	repair	remains	elusive.	Several	candidates,	most	notably	viruses,	have	
been	proposed.7	However,	in	recent	years,	a	contribution	from	aspirated	
gastrointestinal	contents	has	received	a	great	deal	of	attention.	Under	physiological	
conditions,	stomach	contents	are	acidic,	and	it	is	recognised	that	“micro-aspiration”	
of	stomach	content	into	the	lung	is	a	common	occurrence.	Bile	acids	may	also	be	
aspirated	into	the	lungs.	Stomach	acid	and	bile	acid	can	induce	injury	in	alveolar	
epithelial	cells,	and	the	suggestion	has	emerged	that	micro-aspiration	of	
gastrointestinal	contents	may	contribute	to	the	pathogenesis	of	IPF	through	
repeated	epithelial	injury.		
		
2.2.	Reflux	in	IPF	
	
Gastro-oesophageal	reflux	is	significantly	more	frequent	in	patients	with	IPF	than	in	
age-	and	sex-matched	controls.8-13	Certainly	the	accumulated	evidence	suggests	that	
over	50%	of	patients	with	IPF	have	“distal”	gastro-oesophageal	reflux.	Studies	have	
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suggested	that	surgical	correction	of	reflux	in	IPF	reduces	disease	progression.14	
However,	many	patients	with	IPF	are	unsuitable	for	significant	surgical	intervention.	
Effective	medical	interventions	are	likely	to	prove	more	useful	in	this	context.		
	
3.	Omeprazole	
	
3.1.	Drug	class	and	licensed	indications	
	
Omeprazole	is	a	substituted	benzimidazole,	and	belongs	to	the	“proton	pump	
inhibitor”	(PPI)	class	of	drugs.	Omeprazole	specifically	inhibits	the	hydrogen-
potassium-ATPase	(H/K-ATPase)	enzyme	at	the	apical	surface	of	gastric	parietal	cells.	
H/K-ATPase	is	responsible	for	delivering	hydrogen	ions	to	the	lumen	of	the	stomach,	
thus	acidifying	the	contents.	Omeprazole’s	dose-dependent	and	specific	inhibition	of	
the	enzyme	therefore	neutralizes	gastric	acid	contents.	Omeprazole	inhibits	basal	
and	induced	gastric	acid	release.	
	
Omeprazole	has	been	used	clinically	for	many	years.	It	is	licensed	for	use	in	gastro-
oesophageal	reflux,	erosive	oesophagitis,	duodenal	ulcer,	gastric	ulcer,	eradication	of	
Helicobacter	pylori	(in	combination	with	antibiotics),	and	Zollinger-Ellison	syndrome.	
It	is	also	used	for	the	prevention	of	gastric	adverse	events	associated	with	use	of	
non-steroidal	anti-inflammatory	drugs.		
	
3.2.	Studies	of	PPI	in	IPF	
	
Randomised	controlled	trials	directly	comparing	omeprazole	and	placebo	in	IPF	are	
lacking.	A	search	using	“omeprazole	AND	idiopathic	pulmonary	fibrosis”	on	
clinicaltrials.gov	reveals	no	matches.	Small	studies	have	reported	a	reduced	rate	of	
disease	progression	in	patients	treated	with	PPI	with	or	without	fundoplication.15	A	
retrospective	study	suggested	that	patients	with	IPF	on	PPI	had	improved	survival	
and	less	marked	fibrosis	than	patients	not	taking	PPI.16	
	
3.3.	Dose	and	duration		
	
Omeprazole	is	generally	prescribed	in	doses	of	20mg	or	40mg	daily.	Short-term	use	
(eg	for	2	months)	and	long-term	use	are	both	commonly	employed	in	clinical	
practice.	Omeprazole	is	effective	at	suppressing	stomach	acid	within	2	hours	in	most	
individuals.17,	18	A	daily	dose	of	20mg	results	in	gastric	pH	levels	>4	for	approximately	
12	hours.19	This	influenced	our	choice	of	omeprazole	20mg	bd	for	the	current	study.	
	
3.4.	Clinical	pharmacology		
	
Omeprazole	is	rapidly	absorbed	from	the	gastrointestinal	tract	and	is	highly	bound	to	
plasma	proteins.	An	intravenous	formulation	is	available,	but	the	good	bioavailability	
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of	omeprazole	has	led	us	to	favour	oral	administration.	Omeprazole	is	principally	
metabolized	in	the	hepatic	cytochrome	P450	(CYP)	enzyme	system,	and	eliminated	
principally	in	the	kidneys	(the	remainder	being	eliminated	by	the	faecal	route).		
	
	
	
As	a	result,	omeprazole	has	a	longer	half-life	in	patients	with	advanced	liver	disease.	
It	may	interact	with	drugs	that	are	metabolized	by	the	P450	system.	Arguably	the	
most	important	interactions	are	with		
	
• warfarin	
• diazepam	
• phenytoin	
• ketoconazole	or	other	azoles	
For	the	purposes	of	this	study,	warfarin	will	be	contraindicated	as	it	has	been	
associated	with	adverse	effects	in	IPF.20	Patients	on	phenytoin	and	long	term	
diazepam	will	be	excluded.	Patients	on	azole	drugs	will	be	excluded	(but	allowed	to	
enter	the	study	once	azoles	are	discontinued).	Patients	with	documented	cirrhosis	
will	be	excluded.	These	points	are	reiterated	in	the	Exclusion	Criteria	section	(section	
4.6,	page	12).	
	
3.5.	Adverse	effects	
	
Omeprazole	is	widely	used	and	has	a	good	safety	record.	In	general,	adverse	events	
have	been	recorded	in	under	5%	of	patients,	with	rates	approximating	closely	to	
those	in	patients	taking	H2-antagonists	or	placebo.21-24		
	
The	most	common	adverse	events	are	diarrhoea,	headache,	abdominal	discomfort	
and	nausea.	
	
Important,	rare	adverse	events	include:	skin	reactions,	anaemia,	agranulocytosis,	
haematuria,	proteinuria,	and	urinary	tract	infection.	
	
For	details	please	refer	to	section	4.8	in	SmPC.	
	
3.6.	Administration	schedule	chosen	for	this	trial	
	
Omeprazole	20mg	bd,	to	be	taken	before	food.	
	
3.7.	Manufacture	and	supply	
	
Omeprazole	and	matched	placebo	will	be	supplied	by	Victoria	Pharmaceuticals,	
Royal	Hospitals,	Belfast	BT12	6BA.	
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4.	Study	Design	
	
4.1.	Hypothesis	
	
Omeprazole	reduces	cough	in	IPF.	
	
4.2.	Trial	Description	
	
Prospective,	randomised,	double-blind,	allocation-concealed,	single-centre	pilot	trial	
of	omeprazole	in	patients	with	IPF.	The	trial	is	designated	a	‘pilot’	trial	in	that	the	
trial	seeks	to	provide	proof	of	concept	with	respect	to	reduction	in	cough,	with	a	
view	to	designing	definitive	multi-centre	trials	in	IPF.	To	this	end,	a	key	focus	of	the	
pilot	trial	will	be	on	rates	of	participant	eligibility,	recruitment	and	retention,	and	on	
the	yield	and	quality	of	data	in	respect	of	the	proposed	secondary	outcomes	for	
those	future	definitive	trials.	
	
4.3.	Patient	Population	and	Recruitment	
	
Patients	fulfilling	pre-defined	criteria	for	IPF	aged	between	40	and	85.	
The	study	seeks	to	recruit	prevalent	(rather	than	only	incident)	IPF	cases.	At	the	time	
of	writing	the	Newcastle	regional	ILD	clinic	sees	approximately	18	patients	per	week	
and	records	suggest	that	approximately	six	different	IPF	patients	are	seen	per	week.		
We	 estimate	 that	 50%	 of	 these	 patients	 may	 be	 eligible	 for	 inclusion	 in	 the	 trial	
(exclusion	 expected	 to	 be	 largely	 due	 to	 existing	 PPI	 use)	 and	 that	 50%	of	 eligible	
patients	will	consent	to	take	part,	resulting	with	randomising	on	average	1.5	patients	
per	 week.	 	 Therefore,	 over	 a	 21	month	 recruitment	 phase,	 we	 estimate	 that	 136	
patients	would	be	available	of	whom	we	aim	to	recruit	and	randomise	60.	However	
we	 recognize	 that	 these	 are	 approximations	 and	 that	 elements	 of	 these	 estimate	
may	change;	estimation	of	actual	rates	of	eligibility,	randomization	and	retention	will	
be	made,	in	line	with	the	pilot	nature	of	this	trial.			
Patients	can	also	be	identified	and	referred	for	participation	in	trial	from	Participant	
Identification	 Centres	 (PICs)	 by	 their	 treating	 clinicians.	 Potential	 eligible	 patients	
would	be	sent	a	Patient	Invitation	Letter	and	Patient	Information	Sheet	by	clinicians	
who	 are	 responsible	 for	 their	 usual	 clinical	 care.	 The	 study	 team	 will	 follow	 up		
patients	who	have	expressed		their	interest	in	the	study.	
	
4.4.	Sample	size	
	
Sixty	patients	will	be	randomised	1:1	to	omeprazole	or	placebo.		In	keeping	with	the	
principles	of	a	pilot	study	no	formal	sample	size	calculations	have	been	performed	as	
analyses	 of	 outcome	 data	 will	 be,	 by	 definition,	 exploratory	 in	 nature.	 	 However,	
recommendations	 for	 good	 practice	 are	 that	 20-30	 patients	 per	 treatment	 arm	
should	 provide	 sufficient	 data	 to	 assess	 the	 feasibility	 of	 the	 trial,	 investigate	 the	
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distribution	 of	 outcome	measures	 and	 estimate	with	 adequate	 precision	 standard	
deviations	of	key	study	parameters.25,26		The	attrition	rate	for	randomised	patients	in	
this	study	 is	not	known	(and	is	part	of	the	feasibility	assessment).	 	Randomising	60	
patients,	 however,	will	 allow	 for	up	 to	33%	attrition	while	 achieving	 the	minimum	
recommended	 sample	 size	 of	 20	 patients	 per	 treatment	 arm	with	 complete	 study	
follow-up.	
	
4.5.	Inclusion	criteria	
	
A	pragmatic	clinical	definition	of	IPF	will	be	used,	in	which	recruited	patients	must	
fulfill	all	of	the	following	criteria	
	
• IPF	 is	 considered	 the	 most	 likely	 diagnosis	 by	 the	 regional	 interstitial	 lung	
disease	multidisciplinary	team	meeting	(ILD-MDT)	
• history	of	cough,	with	or	without	exertional	dyspnoea	
• high	 resolution	 computed	 tomography	 (HRCT)	 scan	 features	 of	
honeycombing	in	a	predominantly	basal	and	subpleural	distribution	
• bibasal	crackles	on	auscultation	
• features	of	a	restrictive	ventilatory	defect	(vital	capacity	(VC)	<90%	predicted	
and/or	diffusion	factor	for	carbon	monoxide	(Tco)	<90%	predicted)		
• aged	40-85	years	
	
Patients	with	radiological	emphysema	will	be	eligible	so	long	as	the	diagnosis	of	IPF	
is	secure,	ie	all	the	features	above	are	satisfied.	
	
If	the	regional	ILD-MDT	cannot	reach	a	clear	consensus	as	to	the	diagnosis,	the	case	
will	be	referred	to	2	experts	 in	ILD	from	outside	the	region,	and	the	patient	will	be	
eligible	if	both	consider	IPF	to	be	the	most	likely	diagnosis.	
	
Patients	taking	a	PPI	during	screening	will	potentially	be	eligible.	 In	these	cases	the	
indication	for	on-going	treatment	will	be	reviewed.		
• Patients	 taking	 short	 courses	 (eg	 2	months)	 of	 PPI	will	 be	 eligible	 once	 the	
treatment	has	been	discontinued	for	a	minimum	of	1	month.		
• There	 are	 few	 licensed	 indications	 for	 long-term	 omeprazole	 other	 than	
Zollinger-Ellison	 syndrome.	 Therefore,	 unless	 there	 is	 a	 known	 diagnosis	 of	
Zollinger-Ellison	 or	 a	 history	 of	 significant	 dyspepsia	 or	 gastrointestinal	
bleeding	during	a	previous	discontinuation	of	PPI,	patients	on	long-term	PPI	
will	be	asked	to	consider	a	trial	of	supervised	discontinuation.		
If	patients	taking	omeprazole	(or	a	related	stomach	treatment)	wish	to	take	part,	we	
shall	contact	the	GP	to	check	that	the	GP	is	aware	and	in	agreement.	The	patient	will	
then	be	asked	 to	 sign	 a	 consent	 form	 to	 agree	 to	 try	 a	period	off	 treatment	 for	 2	
weeks.	If	symptoms	return	during	that	2-	week	period	the	patient	should	go	back	on	
treatment	 and	 not	 take	 part	 in	 the	 study.	 If	 patients	 manage	 well	 without	 the	
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treatment	 for	 2	 weeks,	 they	 will	 be	 asked	 to	 sign	 a	 second	 consent	 form	 before	
starting	the	study.		
	
Patients	taking	antacids,	prokinetics	or	raft	alginates	at	the	time	of	screening	will	be	
eligible	if	they	have	been	off	these	treatments	for	a	period	of	at	least	2	weeks.	
	
	
4.6.	Exclusion	criteria	
	
• known	allergy	to	omeprazole	or	other	PPI	
• concomitant	use	of	warfarin,	diazepam,	phenytoin	or	ketoconazole	
• concomitant	use	of	 a	 regular	PPI,	 antacid,	prokinetic	or	 raft	 alginate	during	
the	trial	period.	
• history	of	upper	 respiratory	 tract	 infection,	 lower	 respiratory	 tract	 infection	
or	exacerbation	of	IPF	in	the	4	weeks	before	starting	study	drugs	
• active	 trial	of	 treatment	 for	 IPF	 (eg	prednisolone,	pirfenidone,	nintedanib,	N-
acetylcysteine)	started	in	the	4	weeks	before	starting	study	drugs	
• documented	history	of	hepatic	cirrhosis	
• pregnancy	or	lactation	
• ILD-MDT	considers	the	most	likely	cause	of	the	patient’s	ILD	to	be	a	condition	
other	 than	 IPF,	 for	 example	 rheumatoid	 lung,	 systemic	 sclerosis	 ILD,	
asbestosis,	chronic	hypersensitivity	pneumonitis,	sarcoidosis,	etc.	
• concurrent	enrolment	in	a	trial	of	a	CTIMP	for	IPF	
	
4.7.	Intervention	
	
Patients	 will	 be	 randomised	 1:1	 to	 omeprazole	 20mg	 twice	 daily	 or	 matching	
placebo,	to	be	taken	orally	before	food	for	90	days.	
	
4.8.	Primary	outcomes		
	
4.8.1	Primary	efficacy	outcome	
	
The	change	in	frequency	of	objectively	measured	cough	from	beginning	of	the	study	
(i.e.baseline)	to	the	end	of	treatment	(ie	within	the	last	2	weeks	of	last	treatment).	
This	will	be	compared	in	the	two	groups.	
	
4.8.2	Feasibility	outcomes	
	
• Rates	of	eligibility,	recruitment,	randomization	and	study	completion	
• Feasibility	and	acceptability	of	trial	procedures	
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4.9.	Secondary	outcomes	
	
The	 following	 outcomes,	 proposed	 as	 secondary	 efficacy	 outcomes	 for	 any	 future	
trial,	will	be	measured,	with	the	focus	of	analysis	being	on	data	yield	and	quality	
• Change	 in	 symptoms	 of	 cough	 at	 the	 end	 of	 treatment	 (as	 measured	 by	
validated	questionnaire)	
• Change	 in	 symptoms	 of	 reflux	 at	 the	 end	 of	 treatment	 (as	 measured	 by	
validated	questionnaire)	
• Change	in	acid	and	non-acid	reflux	after	treatment	
• Change	in	VC	and	Tco	at	the	end	of	treatment	
• Change	in	6	minute	walk	distance	at	the	end	of	treatment	
• Markers	of	lung	inflammation	in	bronchoalveolar	lavage	(BAL)	fluid	at	the	end	
of	 treatment	 (eg	 concentration	 of	 transforming	 growth	 factor	 beta,	
interleukin-8	etc)	
• Change	in	lung	infection	in	BAL	fluid	at	the	end	of	treatment	
• Patient-reported	adverse	events	
	
	
	4.10	Statistical	analysis	
	
The	primary	outcome	measure	is	change	in	cough	frequency	when	comparing	the	
objective	assessments	before	treatment	(baseline)	and	in	the	last	2	weeks	of	
treatment.	Exploratory	statistical	analyses	will	be	conducted	around	this	end-point.		
In	particular,	using	analysis	of	covariance,	we	will	estimate	the	mean	difference	in	
the	change	in	objective	cough	frequency	(adjusting	for	baseline	objective	cough	
frequency)	and	report	this	estimate	with	a	95%	confidence	interval.		Further,	both	
baseline	cough	frequency	and	PPI	naivity	have	been	identified	as	possibly	prognostic	
for	the	primary	outcome,	we	will	therefore	also	consider,	if	feasible,	an	analysis	
which	adjusts	for	both	baseline	cough	frequency	and	PPI	naivity.34	
	
The	analyses	of	all	other	outcomes	will	be	mainly	descriptive,	with	95%	confidence	
intervals	reported	where	appropriate.		Confidence	limits	for	the	estimated	standard	
deviations	of	key	study	parameters	will	also	be	calculated	and	used	in	sensitivity	
analyses	for	sample	size	calculations	for	future	definitive	trial	applications.			
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5.	Trial	procedures	
	
5.1.	Screening	
	
Medical	records	of	patients	attending	the	regional	interstitial	lung	disease	in	
Newcastle	will	be	screened	by	members	of	the	clinical	team	(Dr	Forrest,	Prof	
Simpson,	Dr	Funston,	Mr	Jones)	or	the	research	nurse	assigned	to	the	study.	Eligible	
patients	will	be	provided	with	information	relating	to	the	study	either	in	person	
(when	they	attend	the	clinic),	or	by	letter.	Patients	will	be	informed	that	they	may	
take	as	long	as	they	like	to	consider	the	information	provided,	and	to	answer	any	
questions.	Patients	on	a	PPI	will	be	considered	as	in	section	4.5,	page	12.	A	screening	
log	will	be	maintained.		
	
5.2.	Informed	consent	
	
The	Chief	Investigator	is	responsible	for	ensuring	that	informed	consent	for	trial	
participation	is	given	by	each	subject.	An	appropriately	trained	doctor	may	take	
consent.	If	no	consent	is	given	a	subject	cannot	be	randomised	and	entered	into	the	
trial.	The	subject	will	be	asked	to	sign	the	consent	form	which	will	then	be	
countersigned	by	the	person	taking	consent	and	will	be	retained	in	the	trial	site	file.		
	
5.3.	Withdrawal	of	consent	
	
Participants	have	the	right	to	withdraw	from	the	study	at	any	time	for	any	reason,	
and	without	giving	a	reason.		The	investigator	also	has	the	right	to	withdraw	patients	
from	the	study	 intervention	 if	 it	 is	 judged	to	be	 in	 the	patient’s	best	 interests.	 It	 is	
understood	by	 all	 concerned	 that	 an	excessive	 rate	of	withdrawals	 can	 render	 the	
study	uninterpretable	and	therefore,	unnecessary	withdrawal	of	patients	should	be	
avoided.	 	 Should	 a	 patient	 decide	 to	 withdraw	 from	 the	 study,	 all	 efforts	 will	 be	
made	to	report	the	reason	for	withdrawal	as	thoroughly	as	possible.			
There	are	three	withdrawal	options:		
1. Withdrawing	 completely	 (i.e.	 withdrawal	 from	 allocated	 treatment	 and	
provision	of	follow-up	data)	
2. Withdrawing	 active	 participation	 in	 trial	 but	 allowing	 continued	 review	 by	
research	team	of	healthcare	records	
3. Withdrawing	partially	but	continuing	to	provide	follow-up	data	by	attending	
clinic.	
We	will	encourage	participants	that	decide	to	withdraw	to	choose	option	2	or	3	but	
if	they	wish	to	withdraw	completely	we	will	retain	data	collected	up	to	the	point	of	
withdrawal.		Participants	will	be	asked	if	they	would	be	happy	for	the	reason	for	the	
decision	to	withdraw	to	be	recorded.	Participants	who	withdraw	completely	will	not	
be	replaced	but	the	rate	of	withdrawal	will	be	monitored	and	reported	to	the	DMC.	
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5.4.	Randomization	
	
Participants	 will	 be	 randomized	 to	 omeprazole	 or	 placebo	 in	 a	 1:1	 ratio,	 using	
random	permuted	blocks.	The	randomization	allocation	schedule	will	be	generated	
by	a	statistician	with	no	other	 involvement	 in	 the	study	to	achieve	concealment	of	
allocation.	Randomization	will	be	performed	by	a	member	of	site	staff,	appropriately	
trained	 and	 identified	 on	 the	 delegation	 log,	 using	 a	 secure	 password-protected	
web-based	system	administered	by	Newcastle	Clinical	Trials	Unit.	
	
Contact details for Randomization: https://apps.ncl.ac.uk/random/ 
(Available 24 hours a day) 
Assignment	to	either	omeprazole	or	placebo	will	be	blinded	to	both	the	participant	
and	the	research	team	(double	blinded).	Randomization	will	generate	two	numbers:	
a	unique	3-digit	“Study	ID”	number	for	each	participant	and	a	unique	2-digit	“Bottle”	
number	(which	will	match	a	“Trial	patient	no.(Pack	number)”	on	a	medication	pack	
held	in	Pharmacy	at	the	Royal	Victoria	Infirmary).		Both	numbers	will	be	entered	on	
to	the	prescription	which	is	delivered	to	Pharmacy.			
5.5.	Study	Drug	Termination	Criteria	
	
The	study	drug	(omeprazole	or	placebo)	will	be	continued	until	one	of	the	following	
conditions	are	met	(whichever	comes	first):	
• 90	days	of	treatment	
• study	drug-related	serious	adverse	reaction	
• decision	by	the	patient’s	GP	or	a	consultant	he/she	is	attending	that	a	PPI		
should	be	prescribed	on	clinical	grounds	
• the	patient	withdraws	from	the	study	
• death	or	discontinuation	of	active	medical	treatment	
	
5.6.	Clinical	Management	of	Patients	in	the	Study	
	
Administration	of	either	omeprazole	or	placebo	will	be	outside	of	usual	clinical	care	
for	all	patients	entered	into	the	study.	
	
Lung	function	(VC	and	Tco)	is	a	routine	part	of	patient	care,	and	patients’	entry	in	to	
the	study	will	be	timed	to	correspond	to	routine	measurement	of	lung	function	
wherever	possible.	
	
Six	minute	walk	test	and	bronchoscopy	with	BAL	are	used	in	clinical	practice	for	ILD	
when	indicated,	but	are	not	considered	routine.	Cough	and	reflux	questionnaires,	
objective	cough	monitoring,	pH	impedance	manometry,	and	issue	of	adverse	event	
diaries	are	outside	of	usual	care	for	patients	entered	into	the	study.	
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All	other	aspects	of	usual	patient	care	will	be	delivered	to	patients	prior	to,	during	
and	after	completion	of	the	study.	
	
5.7.	Study	Procedures	for	Unblinding	
	
The	investigator	or	treating	physician	may	unblind	a	participant’s	treatment	
assignment	in	the	case	of	an	emergency,	when	knowledge	of	the	study	treatment	is	
essential	for	the	appropriate	clinical	management	or	welfare	of	the	subject.	Should	a	
treating	clinician	require	emergency	unblinding,	the	investigator	will	be	contacted	
via	an	emergency	contact	telephone	number	(0191	208	7770,	mobile:	
07765920130).	The	investigator	will	contact	the	clinical	trials	pharmacist	at	the	Royal	
Victoria	Infirmary	during	working	hours	or	if	out	of	working	hours	the	on	call	
pharmacist	for	the	Newcastle	upon	Tyne	Hospitals	NHS	Foundation	Trust	for	
emergency	unblinding.	The	date	and	reason	for	the	unblinding	must	be	recorded	in	
the	case	report	form	(CRF).	
	
	
6.	Study	Assessments	
	
A	summary	of	study	assessments	and	patient	visits	is	shown	in	the	Table	below.	
		 Days	-7	to	0	
(ie	any	3	days	in	
the	lead	up	to	
starting	study	
medication	
Days	1-87	 Days	88-90	
§§	
Confirm	
eligibility	 *	 	 	 	 	 	 	
Consent	 *	 	 	 	 	 	 	
Demographics	 *	 	 	 	 	 	 	
VC	and	TLco	 *	 	 	 	 *	 	 	
6	minute	walk	
test	 *	 	 	 	 *	 	 	
Cough	
questionnaire	 *	 	 	 	 *	 	 	
Reflux	
questionnaire	 *	 	 	 	 *	 	 	
Commence	24h	
cough	
monitoring	 *	 	 	 	 *	 	 	
Commence	24h	
oesophageal	
physiology	tests	 	 *	 	 	 	 *	 	
Randomization	 	 	 *	 	 	 	 	
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Issue	
omeprazole	or	
placebo	 	 	 *	 	 	 	 	
Issue	adverse	
event	diary	 *	 	 	 	 	 	 	
Take	study	
medication	 	 	 	 *	 *	 *	 *	
Bronchoscopy	
and	BAL	 	 	 	 	 	 	 *	
§§	-	the	tests	scheduled	for	“days	88-90”	should	ideally	be	performed	on	these	days,	
but	can	be	performed	at	any	point	in	the	2	weeks	before	completing	
omeprazole/placebo.	
	
6.1.	Demographics		
	
Patients’	age,	gender,	smoking	history	and	current	medications	will	be	recorded.	
	
6.2.	Vital	capacity	and	transfer	factor		
	
These	will	be	performed	in	the	Chest	Clinic,	Royal	Victoria	Infirmary,	to	standards	
laid	out	in	international	guidelines.27,28	It	is	expected	that	all	patients	will	have	
performed	lung	function	tests	before,	and	be	accustomed	to	the	procedures.	
	
6.3.	Six-minute	walk	distance	
	
This	will	be	performed	according	to	international	guidelines,29	under	medical	
supervision	at	the	Royal	Victoria	Infirmary.	By	definition,	patients	can	stop	the	test	at	
any	point	if	they	feel	too	breathless	or	unwell	to	continue.	
	
6.4.	Cough	and	reflux	questionnaires	
	
Validated	questionnaires	will	be	administered	at	the	Royal	Victoria	Infirmary,	and	
may	include	The	De	Meester	reflux-related	symptoms	questionnaire,	The	Reflux	
Symptoms	Index	(RSI),	The	Gastrointestinal	Quality	of	Life	Index	(GIQOLI)	and	the	
Leicester	Cough	Questionnaire	(LCQ).	
	
6.5.	Objective	cough	monitoring	
	
24-hour	ambulatory	cough	sound	recording	involves	patients	being	fitted	with	a	CE	
marked	lightweight	sound	recording	apparatus	(Vitalojak,	Vitalograph	Ltd,	
Buckingham,	UK).	These	are	generally	well	tolerated	by	patients	without	
discomfort.30	The	cough	frequency	is	calculated	from	a	standard	sound	recording	
with	the	assistance	of	validated	custom-written	software.31	Anonymised	sound	
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recordings	will	be	transferred	to	a	secure	server	at	the	University	of	Manchester	site.	
Files	will	be	compressed	using	software	to	remove	silences,	background	noise	and	
the	majority	of	speech.	The	resulting	files	will	then	be	listened	to	and	the	location	of	
cough	sounds	electronically	tagged.	A	report	documenting	the	number	of	coughs	per	
hour	will	then	be	generated	and	returned	to	the	chief	investigator.	
Cough	counting	will	be	done	by	Dr	Jacky	Smith	(Co-Investigator,	University	of	
Manchester)	and	her	team,	which	consists	of	3	trained	cough	counters.	To	reduce	
the	impact	of	variability	between	counters,	for	any	individual	subject,	all	cough	
recordings	are	counted	by	the	same	cough	counter.	Blind	re-count	of	10%	of	the	
recording	data	is	done	by	a	second	counter,	and	the	differences	between	cough	
counters	are	calculated.	It	is	then	compared	to	95%	limits	of	agreement	based	on	a	
large	dataset	counted	by	the	most	experienced	cough	counters,	to	make	sure	the	
agreement	is	good	and	consistent	with	previous	work.	
	
6.6.	Oesophageal	physiology	
	
Oesophageal	physiology	testing	has	two	parts	-	oesophageal	manometry	and	
ambulatory	pH/impedance	testing.	Oesophageal	manometry	uses	pressure	sensors	
to	measure	the	oesophageal	muscular	contraction	and	relaxation	of	the	gasto-
oesophageal	sphincter.	pH/impedance	testing	uses	sensors	of	acidity	and	electrical	
resistance	to	measure	“reflux”	of	material	from	the	stomach.		The	test	runs	over	a	
24-hour	period	but	hospital	admission	is	not	required.	The	tests	are	performed	in	the	
Endoscopy	Department	at	the	Royal	Victoria	Infirmary.	A	fine	nasogastric	tube	is	
passed	for	the	manometry	test,	which	takes	around	twenty	minutes	and	involves	the	
patient	performing	a	number	of	swallows.	The	tube	is	then	removed	and	a	second,	
finer	nasogastric	tube	is	passed	and	left	in	place	for	24	hours,	connected	to	a	data-
recording	box.	The	test	does	not	significantly	restrict	normal	activities.		Insertion	of	
the	tube	can	be	slightly	uncomfortable	but	pain	is	unusual.	The	tube	is	removed,	in	
the	Royal	Victoria	Infirmary,	the	following	day.	
	
6.7.	Bronchoscopy	and	BAL		
	
Bronchoscopy	and	BAL	will	be	performed	at	the	Royal	Victoria	Infirmary	or	the	
Freeman	Hospital,	according	to	standard	practice	and	international	guidelines.32,33	
All	patients	will	have	an	intravenous	cannula	placed,	and	ECG	monitoring	and	oxygen	
saturation	monitoring	will	be	performed	throughout.	Patients	will	receive	topical	
local	anaesthetic	to	the	nose,	mouth,	vocal	cords	and	respiratory	tract	as	required.	
Patients	will	receive	supplemental	oxygen.	Patients	will	also	be	offered	intravenous	
sedation,	usually	in	the	form	of	midazolam.	The	bronchoscopist	will	review	previous	
HRCT	scans	and	where	possible	will	perform	BAL	in	a	segment	with	changes	of	IPF	
but	without	advanced	honeycombing,	in	order	to	minimise	the	small	theoretical	risk	
of	pneumothorax.	Three	aliquots	of	saline	(60ml)	each	will	be	instilled	and	aspirated.	
After	lavage	has	been	performed,	endobronchial	biopsies	will	be	taken	for	later	
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analysis	of	cough	nerve	fibre	content.	The	patient	will	be	monitored	for	at	least	2	
hours	after	the	procedure.	Patients	who	have	had	sedation	will	be	advised	that	they	
may	not	drive,	work,	drink	alchohol,	operate	moving	machinery	(including	drills	etc	
at	home),	or	sign	legal	documents	for	the	remainder	of	the	day,	and	must	return	
home	accompanied	by	a	responsible	adult.	
	
6.8.	Assessment	of	BAL	fluid	
	
The	quantity	of	BAL	fluid	retrieved	will	be	recorded.	An	aliquot	of	BAL	fluid	will	be	
sent	to	the	NHS	Microbiology	Laboratory	to	test	for	culture,	with	the	aim	of	
detecting	potentially	pathogenic	bacteria.	The	remainder	of	the	sample	will	be	taken	
to	research	labs	at	Newcastle	University.	Samples	will	be	centrifuged.	The	cell	pellet	
will	be	reconstituted,	and	used	to	make	an	estimation	of	total	cell	count.	Cytospin	
preparations	will	be	made	on	glass	slides	for	future	examination.	Cell-free	
supernatant	will	be	stored	frozen	until	further	use.	Supernatant	will	be	assessed	for	
the	levels	of	mediators	including	(but	not	limited	to)	transforming	growth	factor	
beta,	pepsin,	bile	acids,	matrix	metalloproteinases,	and	interleukins.	
	
7.	Pharmacovigilance	
	
7.1.	Definitions	
	
Adverse	 event	 (AE):	 any	untoward	medical	occurrence	which	does	not	necessarily	
have	 a	 causal	 relationship	 with	 the	 treatment.	 “Treatment”	 includes	 all	
investigational	agents	(including	comparative	agents)	administered	during	the	course	
of	 the	study.	 	Medical	 conditions/diseases	present	before	 starting	 study	 treatment	
are	only	considered	adverse	events	if	they	worsen	after	starting	study	treatment.	
	
Adverse	reaction	(AR):	any	untoward	and	unintended	response	to	an	Investigational	
Medicinal	 Product	 related	 to	 any	 dose	 administered.	 All	 AEs	 judged	 by	 either	 the	
reporting	 investigator	or	 the	 sponsor	as	having	 reasonable	 causal	 relationship	 to	a	
medicinal	product	qualify	as	adverse	 reactions.	 	The	expression	“reasonable	causal	
relationship”	 means	 to	 convey	 in	 general	 that	 there	 is	 evidence	 or	 argument	 to	
suggest	a	causal	relationship.	
	
	
Serious	Adverse	Event	(SAE)	or	Serious	Adverse	Reaction	(SAR):	any	untoward	
medical	occurrence	or	effect	that	at	any	dose:	
• results	in	death	
• is	life	threatening	(i.e.	the	subject	was	at	risk	of	death	at	the	time	of	the	event;	
it	does	not	refer	to	an	event	which	hypothetically	might	have	caused	death	if	
it	were	more	severe)	
• requires	prolongation	of	existing	hospitalisation	
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• results	in	persistent	or	significant	disability	or	incapacity.	
• is	a	congenital	anomaly	or	birth	defect.	
	
Medical	judgement	should	be	exercised	in	deciding	whether	an	AE/AR	is	serious	in	
other	situations.		Important	AE/ARs	that	are	not	immediately	life-threatening	or	do	
not	result	in	death	or	hospitalisation	but	may	jeopardise	the	subject	or	may	require	
intervention	to	prevent	one	of	the	other	outcomes	listed	in	the	definition	above,	
should	also	be	considered	serious.	
	
7.2.	Assessment	of	Causality	
	
Each	AE	should	be	clinically	assessed	for	causality	based	on	the	information	
available,	i.e.	the	relationship	of	the	AE	to	the	study	drug.	The	assignment	of	the	
causality	should	be	made	by	the	Chief	Investigator	or	the	Principal	Investigator	
responsible	for	the	care	of	the	participant	using	the	definitions	in	the	table	below.		
All	adverse	events	judged	as	having	a	reasonable	suspected	causal	relationship	to	
the	study	drug	(i.e	definitely,	probably	or	possibly	related)	are	considered	to	be	
adverse	reactions.		If	any	doubt	about	the	causality	exists,	the	Principal	Investigator	
should	consult	the	Chief	Investigator.		In	the	case	of	discrepant	views	on	causality	
between	the	Principal	Investigator	and	others,	all	parties	will	discuss	the	case	and	
will	refer	as	necessary	to	the	Data	Monitoring	and	Safety	Committee	(DMSC).		In	the	
event	that	no	agreement	is	reached	the	MHRA,	Research	Ethics	Committee	(REC)	
and	other	bodies	will	be	informed	of	both	points	of	view.	
	
	
Relationship	 Description		
Unrelated	 There	is	no	evidence	of	any	causal	relationship.	The	clinical	event	
has	an	incompatible	time	relationship	to	the	study	administration	
drug,	and	could	be	explained	by	underlying	disease,	or	other	drugs	
or	chemicals.	
Unlikely	 There	is	little	evidence	to	suggest	there	is	a	causal	relationship	(eg.	
the	event	did	not	occur	within	a	reasonable	time	after	study	drug	
administration).	There	is	another	reasonable	explanation	for	the	
event	(eg.	the	participant’s	clinical	condition).	
Possible	 There	is	some	evidence	to	suggest	a	causal	relationship	(eg.	
because	the	event	occurs	within	a	reasonable	time	after	the	study	
procedure).	However	the	influence	of	other	factors	may	have	
contributed	to	the	event	(eg.	the	participant’s	clinical	condition).	
Probable		 There	is	evidence	to	suggest	a	causal	relationship,	including	a	
reasonable	time	relationship	with	the	study	drug	administration,	
and	the	influence	of	other	factors	is	unlikely.	
Definitely	 There	is	clear	evidence	to	suggest	a	causal	relationship	and	other	
possible	contributing	factors	can	be	ruled	out.	
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Not	assessable	 There	is	insufficient	or	incomplete	evidence	to	make	a	clinical	
judgement	of	the	casual	relationship.	
	
	
Suspected,	Unexpected	Serious	Adverse	Reaction	(SUSAR):	an	adverse	reaction	that	
is	both	unexpected	and	serious.		An	adverse	reaction	is	‘unexpected’	if	its	nature	or	
severity	is	not	consistent	with	the	applicable	product	information.	
	
	
	
7.3.	Assessment	of	expectedness	
	
The	assessment	of	expectedness	will	be	performed	by	the	CI	against	the	Reference	
Safety	Information	(RSI)	for	the	trial.		The	RSI	is	[enter	the	chapter	of	IB	or	section	of	
SmPC	here].		As	this	is	a	double-blinded	study,	the	blind	should	be	maintained	as	far	
as	 possible.		 Participants	 experiencing	 events	 that	 are	 serious,	 related	 and	
unexpected	(i.e.	meet	the	criteria	of	a	SUSAR)	must	be	unblinded	(as	per	section	5.7)	
as	only	those	events	related	to	omeprazole	would	be	considered	SUSARs	and	require	
expedited	reporting.	
	
	
7.4.	Adverse	Event	Reporting	Period	
	
The	AE	reporting	period	for	this	trial	begins	upon	enrolment	into	the	trial	and	ends	7	
days	following	administration	of	the	last	dose	of	study	drug.	All	AEs	assessed	by	the	
PI	as	possibly	related	to	the	study	drug	and	all	SAEs	that	occur	during	this	time	will	
be	followed	until	they	are	resolved	or	are	clearly	determined	to	be	due	to	a	patient’s	
stable	or	chronic	condition	or	intercurrent	illness(es).	
7.5.	Adverse	Event	Reporting	Requirements	
	
AEs	should	be	reported	and	documented	on	the	relevant	pages	of	the	CRF,	in	
accordance	with	the	procedures	outlined	below.	The	PI	at	each	site	will	also	evaluate	
all	AEs	for	expectedness	in	addition	to	causality.	
	
7.6.	Reporting	AEs	(including	ARs)	
	
Because	this	trial	is	recruiting	a	population	that	has	cough	and	breathlessness,	it	is	
expected	that	many	of	the	participants	will	experience	AEs.	Events	that	are	expected	
in	this	population	(ie	events	in	keeping	with	the	patient’s	underlying	medical	
condition)	should	not	be	reported	as	AEs.	An	adverse	reaction	(AR)	is	an	AE	which	is	
related	to	the	administration	of	the	study	drug.	If	any	AEs	are	related	to	the	study	
drug	(i.e.	are	ARs)	they	must	be	reported	on	the	AE	form	within	the	CRF.	It	is	the	
responsibility	of	the	PI	to	record	all	relevant	information	in	the	CRF.	Any	questions	
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concerning	adverse	event	reporting	should	be	directed	to	the	Chief	Investigator	(or	
Trial	Manager	in	the	absence	of	the	Chief	Investigator)	in	the	first	instance.	
	
As	trial	participants	are	suffering	from	progressive	disease	(IPF)	it	is	expected	that	
many	participants	will	experience	worsening	cough	and	breathlessness.		Hence	
subjective	worsening	of	cough	and	breathlessness	should	not	be	reported	as	AE	
unless	they:			
	
• 	required	hospital	admission	for	assessment	and	treatment	
• required	antibiotic	treatment	via	GP	surgery	or	chest	clinic	
	
Severity	 of	 AEs	 will	 be	 graded	 on	 a	 three-point	 scale	 (mild,	 moderate,	 severe).		
Relation	of	the	AE	to	the	treatment	(causality)	should	be	assessed	by	the	investigator	
at	site.		 
	
7.7.	Reporting	Serious	Adverse	Events	(SAEs),	Serious	Adverse	Reactions	(SARs)	and	
Suspected,	Unexpected	Serious	Adverse	Reactions	(SUSARs)	
	
Please	see	Flowchart	1	below	to	aid	with	reporting	procedures	
	
Serious	 Adverse	 Events	 (SAEs)	 and	 Serious	 Adverse	 Reactions	 (SARs,	 including	
SUSARS	 and	 expected	 SARs)	 will	 be	 reported	 to	 the	 Chief	 Investigator	 and	 Trial	
Management	 Team	 within	 24	 hours	 of	 the	 site	 Principal	 Investigator	 becoming	
aware	of	the	SAE/SAR/SUSAR.	Reporting	of	SAEs	will	be	via	SOHO66	system.	
	
If	an	SAE	occurs,	reporting	will	follow	the	regulatory	requirements	as	appropriate	
and	all	SUSARs	will	be	the	subject	of	expedited	reporting.	SAEs	will	be	evaluated	by	
the	PI	for	causality	(i.e.	their	relationship	to	the	study	drug)	and	expectedness.	Once	
the	PI	becomes	aware	that	an	SAE	has	occurred	in	a	study	patient,	they	must	
complete	the	SAE	form	in	the	CRF	and	report	the	information	to	the	CTU	within	24	
hours.		The	SAE	form	must	be	completed	as	thoroughly	as	possible	with	all	available	
details	of	the	event,	signed	by	the	PI	or	designee.		If	the	PI	does	not	have	all	
information	regarding	an	SAE,	they	will	not	wait	for	this	additional	information	
before	notifying	CTU.		The	form	can	be	updated	when	the	additional	information	is	
received.	Follow	up	information	should	include	whether	the	event	has	resolved,	if	
and	how	it	was	treated,	whether	the	patient	continues	in	the	study	or	has	been	
withdrawn	from	treatment	and	information	regarding	unblinding	of	any	patients.	
The	SAE	form	should	be	transmitted	by	fax	to	the	Newcastle	CTU	on	0191	5800400		
	
The	CTU	is	responsible	for	reporting	SAEs	that	are	considered	to	be	related	and	
unexpected	to	the	Sponsor.	The	Sponsor	will	report	any	SUSARs	to	REC,	and	the	
MHRA	within	15	days	of	becoming	aware	of	the	event	(as	per	Joint	Research	Office	
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Standard	Operating	Procedure	03).	In	the	event	of	a	fatal	or	life	threatening	SUSAR	
reporting	to	the	relevant	regulatory	authorities	should	take	place	within	7	days.	
	
The	Co-ordinator	of	the	main	REC	should	acknowledge	receipt	of	related,	
unexpected	safety	report	within	30	days.	
 
	
7.8.	Reporting	SAEs	to	the	DMSC	
	
SAEs	will	be	reported	to	the	DMSC	within	the	same	timelines	as	for	regulatory	
reporting.	A	copy	of	each	report	will	be	sent	to	the	DMSC.	
	
7.9.	Pregnancies	
7.9.1.	Time	period	for	collecting	pregnancy	information	
All	pregnancies	in	female	participants	and	female	partners	of	male	participants	will	
be	collected	after	the	start	of	dosing	and	until	last	follow-up	visit.	
	
7.9.2.	Action	to	be	taken	if	pregnancy	occurs	
Adverse	event	
	
Not	Serious	
	
	
Not	sure	 	 Serious	
	
	
	
Unrelated	 Related	 	 													Unrelated	
	
															Related	
	
	
	
	 	 	
	
Expected 
	
Unexpected	
	
Complete		
CRFs	
Complete	
CRFs	
Complete	
SAE	 form	
or	 contact	
CI	
Complete	SAE	form	
	
Complete	
SAE	form	
Complete	
SAE	form		
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The	 investigator	will	 collect	 pregnancy	 information	 on	 any	 female	 participant	who	
becomes	 pregnant	 while	 participating	 in	 this	 study.	 The	 investigator	 will	 record	
pregnancy	 information	 on	 the	 appropriate	 form,	 and	 submit	 it	 to	 the	 Chief	
Investigator	within	2	weeks	of	learning	of	a	participant's	pregnancy.	The	participant	
will	also	be	followed-up	to	determine	the	outcome	of	the	pregnancy.	Information	on	
the	 status	 of	 the	 mother	 and	 child	 will	 be	 forwarded	 to	 the	 Chief	 Investigator.	
Generally,	 follow-up	 will	 be	 no	 longer	 than	 8-12	 weeks	 following	 the	 estimated	
delivery	date.		
Any	premature	termination	of	the	pregnancy	will	be	reported.	While	pregnancy	itself	
is	 not	 considered	 to	 be	 an	 AE	 or	 SAE,	 any	 pregnancy	 complication	 or	 elective	
termination	of	a	pregnancy	for	medical	reasons	will	be	recorded	as	an	AE	or	SAE	(see	
AE/SAE	 section	 of	 the	 protocol	 for	 definitions	 and	 a	 description	 of	 follow-up).	 A	
spontaneous	 abortion	 is	 always	 considered	 to	 be	 an	 SAE	 and	 will	 be	 reported	 as	
such.	
	
Furthermore,	any	SAE	occurring	as	a	result	of	a	post-study	pregnancy	and	considered	
reasonably	 related	 to	 the	 investigational	 product	 by	 the	 investigator,	 will	 be	
reported	 to	 the	Chief	 Investigator.	While	 the	 investigator	 is	not	obliged	actively	 to	
seek	 this	 information	 in	 former	 study	 participants,	 he	 or	 she	may	 learn	 of	 an	 SAE	
through	spontaneous	reporting.		
Any	female	participant	who	becomes	pregnant	while	participating	will	be	withdrawn	
from	the	study.	
	
Any	female	participant	who	becomes	pregnant	during	dosing,	will	stop	dosing	
immediately.	
	
8.	Regulations,	ethics	and	governance	
	
8.1.	End	of	Trial	
The	trial	will	end	when	the	completed	number	of	patients	have	been	recruited	and	
completed	follow-up.	
The	trial	will	be	stopped	prematurely	if:	
• Mandated	by	the	Ethics	Committee		
• Mandated	by	the	MHRA		
• Mandated	by	the	sponsor	eg	following	recommendations	from	the	DMSC		
	
The	REC	that	originally	gave	a	favourable	opinion	of	the	trial	and	the	MHRA	that	
issued	the	Clinical	Trial	Authorisation	will	be	notified	in	writing	if	the	trial	has	been	
concluded	or	terminated	early.	
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8.2.	Research	governance	and	regulatory	approvals	
	
The	trial	will	comply	with	the	principles,	requirements	and	standards	set	out	in	the	
Research	Governance	Framework	and	The	Medicines	for	Human	Use	(Clinical	Trials)	
Regulations	2004	and	subsequent	amendments.	A	favourable	ethical	opinion	from	a	
NHS	Research	Ethics	Committee	and	a	Clinical	Trial	Authorisation	from	the	MHRA	
will	be	obtained	before	the	start	of	the	trial.	
The	trial	will	be	registered	with	the	International	Standard	Randomised	Controlled	
Trial	Number	register.	
	
8.3.	Sponsorship	
	
The	Newcastle	upon	Tyne	Hospitals	(NuTH)	NHS	Foundation	Trust	will	act	as	sponsor.	
	
8.4.	Ethics	
	
The	study	will	be	conducted	in	accordance	with	the	ethical	principles	that	have	their	
origin	in	the	Declaration	of	Helsinki.	Following	detailed	discussion	of	the	study,	
written,	informed	consent	will	be	obtained	from	the	participant.		
	
8.5.	Patient	Confidentiality	
	
Patient	confidentiality	will	be	maintained	at	every	stage	and	compliance	with	the	
Data	Protection	Act	(1998).	
	
8.6.	Good	Clinical	Practice	(GCP)	
	
The	trial	will	be	carried	out	in	accordance	with	the	principles	of	the	International	
Conference	on	Harmonisation	Good	Clinical	Practice	(ICH-GCP)	guidelines	
(www.ich.org).	
	
	
8.7.	Trial	Monitoring	
	
Site	monitoring	will	be	directed	by	the	sponsor	according	to	the	study	risk	
assessment.	Site	visits	will	be	performed	on	a	regular	basis	to	ensure	that	all	
regulatory	requirements	are	met	and	to	monitor	the	quality	of	the	data	collected.	
The	CRF	will	be	used	for	source	data	verification.	
	
8.8.	Indemnity	
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The	Newcastle	upon	Tyne	Hospitals	(NuTH)	NHS	Foundation	Trust	will	provide	
indemnity	for	the	management	and	conduct	of	the	trial.		Newcastle	University	is	
providing	indemnity	for	trial	design.	
	
8.9.	Funding	
	
The	study	is	funded	by	the	British	Lung	Foundation,	with	additional	support	from	the	
Newcastle	Biomedical	Research	Centre.	
	
8.10.	Safety	and	well	being	of	study	participants	
	
Participant	safety	and	well-being	are	protected	by	implementation	of	the	sponsor’s	
standard	operating	procedures	(SOP)	as	set	out	in	the	Research	Governance	
Framework	and	The	Medicines	for	Human	Use	(Clinical	Trials)	Regulations	2004.	The	
sponsor,	NuTH	requires	all	research	to	be	managed	through	a	registered	Clinical	
Trials	Unit	(NCTU	for	this	trial).		Systems	are	in	place	to	ensure	that	all	investigators	
are	able	to	demonstrate	that	they	are	qualified	by	education,	training	or	experience	
to	fulfil	their	roles	and	those	systems	and	procedures	are	in	place	which	can	assure	
the	quality	of	every	aspect	of	the	trial.	
	
If	new	safety	information	becomes	available,	then	study	participants	will	be	
informed	of	this	and	asked	if	they	wish	to	continue	in	the	study.	If	the	subjects	wish	
to	continue	in	the	study	they	will	be	formally	asked	to	sign	a	revised	approved	
participant	information	sheet	and	consent	form.	
	
8.11.	Safety	of	investigators	
	
NuTH	and	Newcastle	University	have	Health	and	Safety	Policies	applicable	to	all	
employees.	All	personnel	should	also	ensure	they	adhere	to	any	other	Health	and	
Safety	regulations	relating	to	their	area	of	work.	The	Chief	investigator	will	ensure	
that	all	personnel	have	been	trained	appropriately	to	undertake	their	specific	tasks.	
As	the	study	fits	closely	to	standard	practice,	there	are	few	risks	identified	which	are	
hazardous	to	the	investigators.	The	study	team	will	complete	GCP	training	prior	to	
start	up.	
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9.	Data	Management,	data	collection	and	recording		
	
9.1.	Data	Collection	
	
All	data	for	individual	subjects	will	be	collected	by	the	chief	investigator	or	by	a	
delegated	investigator	and	recorded	in	the	electronic	CRF.	Due	care	will	be	taken	to	
ensure	data	safety	and	compliance	with	the	Data	Protection	Act	1998.	
	
9.2.	Data	Storage	
	
All	essential	documentation	and	trial	records	will	be	stored	by	the	Chief	Investigator	
in	conformance	with	the	applicable	regulatory	requirements	and	access	to	stored	
information	will	be	restricted	to	authorised	personnel.	
	
9.3.	Archiving	
	
Trial	documentation	and	data	will	be	archived	after	completion	of	the	trial	in	keeping	
with	the	applicable	regulatory	requirements.	
	
9.4.	Trial	management	
	
The	Chief	Investigator	will	take	responsibility	for	the	need	to	change	the	protocol	for	
any	reason,	reviewing	relevant	information	from	other	sources	and	considering	
recommendations	from	the	DMSC.	Day	to	day	management	will	be	undertaken	via	a	
trial	management	group	composed	of	the	Chief	Investigator	and	supporting	staff.	
They	will	meet	regularly	(approximately	monthly)	to	discuss	study	issues.		
	
9.5.	Data	Monitoring	and	Safety	Committee	(DMSC)	
	
A	DMSC	will	be	appointed.	The	committee	will	be	independent	of	the	study	team	
and	will	comprise	a	statistician	and	two	clinicians	with	experience	in	undertaking	
clinical	trials.	The	DMSC	will	meet	to	agree	conduct	and	remit.	The	DMSC	will	
convene	soon	after	set	up	of	the	trial	and	may	do	so	by	teleconference	if	they	wish.		
After	the	first	meeting,	the	DMSC	will	decide	on	the	frequency	of	subsequent	
meetings.	In	the	event	of	an	occurrence	of	an	unexpected	severe	adverse	reaction	
an	additional	unplanned	DMEC	meeting	may	be	convened.	
	
	An	interim	analysis	of	efficacy	is	not	planned	although	this	issue	can	be	discussed	by	
the	DMSC	as	required.	The	DMSC	will	function	primarily	as	a	check	for	safety,	
reviewing	adverse	events.	They	will	report	any	issues	pertaining	to	safety	to	the	
Chief	Investigator.	It	will	be	the	responsibility	of	the	Chief	Investigator	to	inform	the	
sponsor	who	will	take	appropriate	action	to	halt	the	trial	if	concerns	exist	about	
patient	safety.	
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9.6.	Dissemination	
	
The	trial	will	be	reported	in	accordance	with	the	Consolidated	Standards	of	
Reporting	Trials	(CONSORT)	guidelines	(www.consort-statement.org).	Dissemination	
will	be	achieved	in	several	ways:	(1)	the	findings	will	be	presented	at	national	and	
international	meetings	with	open	access	abstracts	on-line	e.g.	the	American	Thoracic	
Society	annual	meeting;	and	(2)	in	accordance	with	the	open	access	policies	
proposed	by	the	leading	research	funding	bodies	we	aim	to	publish	the	findings	in	
high	quality	peer-reviewed	open	access	(via	Pubmed)	journals.	This	will	secure	a	
searchable	compendium	of	these	publications	and	make	the	results	readily	
accessible	to	the	public,	health	care	professionals	and	scientists.	
	
Where	appropriate,	research	details	will	also	be	posted	on	institutional	websites	
available	to	the	general	public.	In	addition,	the	most	significant	results	will	be	
communicated	to	the	public	through	press	releases.	
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11.	Amendment	History	
	
Protocol	version	 Amendmen
t	
Details	 Approved	Date	1.0,	dated	22/07/2013	 Original	submission	 	 REC	–	20/09/2013	(conditional)	MHRA	–	13/09/2013	2.0,	dated	15/09/2013	 Protocol	changes	 Changes	made	for	unconditional	REC	favourable	opinion	–	updated	correct	Funding	Ref.	 REC	only	20/09/2013	3.0,	dated	20/11/2013	 Protocol	changes	 Amendments	to	update	protocol	for	internal	consistency	as	suggested	by	NCTU.	Amendments	made	in	sections	of	Patient	Recruitment,	Randomisation,	Statistical	Analysis,	Pharmacovigilence,	Adverse	Event	Report	Reporting.	Also	updated	contact	numbers	of	study	members.	New	document	added:		Patient	Diary	Card	–	to	help	assess	adverse	events	in	participants,	Patient	Information	Sheet,	GP	information	letters,	Consent	Forms:	updated	with	appropriate	changes	in	version	number	and	date	to	coincide	with	amended	protocol.	
REC	–	10/01/2014	MHRA	–	15/01/2014																																																											4.0,	dated	03/07/2014	 Protocol	changes	 Amendments	in	protocol	to	allow	inclusion	of	PIC	sites	to	help	improve	recruitment	for	the	study.	Also	a	summary	page	has	been	added	to	Participant	Information	Sheet	to	make	it	plain	to	participants	that	the	only	essential	part	of	the	study	is	cough	monitor	and	taking	the	drug.	All	other	tests	are	optional.	Amendments	in	CTA	form	due	
REC	–	26/08/2014	MHRA	–	02/09/2014	R&D	–	11/09/2014	
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to	changes	in	colour	of	the	yellow	TEVA	omeprazole	capsules.	To	maintain	blinding	Victoria	Pharmaceuticals	had	to	source	an	alternative	generic	UK	licensed	omeprazole	from	for	the	study.	Consent	Forms	and	PIS	updated	to	correspond	changes	in	Protocol.	5.0	dated	21/09/2015	 Substantial	Amendment	 Dr	Forrest	changed	to	be	listed	as	co-investigator		Change	of	Senior	Trial	Manager	–	Dr	Lesley	Hall	replaced	Dr	Jennifer	Wilkinson		Change	of	Trial	Manager	–	Mr	Mark	Palmer	replaced	Jessica	Qian		New	Clinical	Research	Fellow	–	Dr	Wendy	Funston	replaced	Dr	Prosenjit	Dutta		Changes	to	randomisation	section	to	bring	in	line	with	current	procedure.	Addition	of	reference	to	SmPC	in	section	3.5	of	Protocol	Update	to	increase	clarity	to	section	5.3	Withdrawal	of	Consent	of	Protocol	and	to	include	3	options	of	withdrawal.	Addition	of	Expectedness	as	section	7.3	in	Protocol.	Addition	of	nintedanib	to	list	of	active	trial	of	treatment	in	exclusion	criteria.	
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Appendix 3: PPIPF study: Consent forms 	
CONSENT	FORM	
	
	
A	pilot,	randomised	controlled	trial	of	omeprazole	in	idiopathic	pulmonary	fibrosis	
	
Chief	Investigator,	Prof	John	Simpson;	Co-Investigator,	Dr	Ian	Forrest,		
Co-	Investigators,	Dr	Chris	Ward,	Prof	Michael	Griffin;	Clinical	Research	Fellows,	Dr	
Wendy	Funston,	Mr	Rhys	Jones.	
	
	
																																																																																																									Please		
																																																																																																																												initial																																																												
	
	
1.	I	confirm	I	have	read	and	understood	the	Patient	Information		 	[													]	
Sheet	(Version	3.1,	dated	05/08/2015)	and	have	had	sufficient		
opportunity	to	ask	questions.	
	
2.	I	confirm	that	study	doctors	have	discussed	with	me	the						 		[													]	
requirement	to	come	off	medications	which	affect	stomach		
function	if	I	am	to	participate	in	the	study,	and	that	they		
have	discussed	what	I	should	do	if	my	symptoms	change.	
	
3.	I	agree	to	a	trial	of	discontinuation	of	PATIENT	TO	COMPLETE	 		[													]	
	
	
	
	
	
	
	________________________	 ________________	 ____________________	Name	of	Patient	 	 Date	 	 Signature			________________________	 ________________	 ____________________	Researcher	 	 Date	 	 Signature		1	for	patient;	1	for	researcher;	1	for	case	notes		
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CONSENT	FORM	
A	randomised	controlled	trial	of	omeprazole	in	idiopathic	pulmonary	fibrosis	Chief	Investigator,	Prof	John	Simpson;	Co-Investigator,	Dr	Ian	Forrest	Co-Investigators	 Dr	 Chris	 Ward,	 Prof	 Michael	 Griffin;	 Clinical	 Research	 Fellows,	 Dr	 Wendy	Funston,	Mr	Rhys	Jones.		 	 	 	 	 	 	 Please	Initial	1. I	confirm	that	 I	have	read	and	understand	the	 information	sheet,	version	3.1,	dated	 7th	 March	 2016,	 for	 the	 above	 study.	 I	 have	 had	 the	 opportunity	 to	consider	 the	 information,	 ask	 questions	 and	 have	 had	 these	 questions	answered	satisfactorily.	 	 	 	 [	 ]	2. I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	 time,	without	giving	any	reason,	and	without	my	medical	care	or	 legal	rights	being	affected.		 	 	 	 [	 ]	3. I	 understand	 that	 relevant	 sections	 of	 my	 medical	 notes	 and	 data	 collected	during	 the	 study	may	 be	 looked	 at	 by	 individuals	 from:	 the	 study	 team;	 the	Study	Sponsor	(The	Newcastle	upon	Tyne	Hospitals	NHS	Foundation	Trust)	or	their	 representatives;	 and	 regulatory	 authorities,	 where	 it	 is	 relevant	 to	 my	taking	 part	 in	 this	 research.	 I	 give	 permission	 for	 these	 individuals	 to	 have	access	to	my	records,	even	if	I	withdraw,	and	I	understand	that	my	records	will	only	be	reviewed	for	information	related	to	my	participation	in	the	study.	 [	 ]	4. I	agree	that	the	research	team	may	record	data	from	my	case	records	solely	for	the	purpose	of	this	study.	 			 	 	 [	 ]	 	 	 	 	 	 	 								]	 	 	 	 	 	 	 	 	 	 	5. I	agree	to	be	randomised	to	either	omeprazole	or	placebo	therapy.	 [	 ]	6. I	 agree	 to	 complete	 lung	 function	 tests,	 a	 6-minute	 walk	 test	 and	 study	questionnaires.	 	 	 	 	 [	 ]	7. I	agree	to	have	24-hour	cough	monitoring.		 	 	 [	 ]	8. I	agree	to	have	24-hour	oesophageal	(gullet)	physiology	tests.	 [	 ]	9. I	 agree	 to	 have	 a	 bronchoscopy	 test	 and	 “lavage”	 and	 that	 the	 lung	 fluid	 not	required	for	NHS	purposes	can	be	used	for	this	study.	 	 [	 ]	10. I	 consent	 to	 the	storage	of	my	cough	recordings	 in	RaDAR.	 I	understand	 that	anonymised	 recordings	 may	 be	 made	 available	 to	 internal	 and	 external	researchers	for	further	research.	Any	recordings	released	for	further	research	will	 be	 subject	 to	 an	 application	 process	 and	 approved	 by	 the	 RaDAR	Management	Team.	 	 	 	 		 [	 ]	11. I	 agree	 that	my	 lung	 fluid	 sample	 can	be	used	 in	 future	 studies	 on	 condition	that	my	identity	cannot	be	determined	from	the	sample.		 	 [	 ]	12. I	 agree	 that	 the	 research	 team	 may	 send	 a	 letter	 informing	 my	 general	practitioner	of	my	participation	in	this	study.	 	 	 [	 ]			________________________	 ________________	 ____________________	
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Name	of	Patient	 	 Date	 	 Signature			________________________	 ________________	 ____________________	Researcher	 	 Date	 	 Signature		1	for	patient;	1	for	researcher;	1	for	case	notes			
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Appendix 4: PPIPF study: PIS 	
PARTICIPANT	INFORMATION	SHEET	
	
SHORT	SUMMARY	
	
A	pilot	study	in	idiopathic	pulmonary	fibrosis	
Does	switching	off	stomach	acid	(with	omeprazole	tablets)	reduce	cough,	and	can	
it	improve	other	features	of	the	disease?	
Study	Team:	Dr	Ian	Forrest	(Co-Investigator),	Prof	John	Simpson	(CI),	Dr	Wendy	
Funston	(Clinical	Fellow)	
	
You	 are	 being	 invited	 to	 take	 part	 in	 a	 research	 study.	 Before	 you	 decide	 it	 is	
important	 for	 you	 to	 understand	why	 the	 research	 is	 being	 done	 and	what	 it	will	
involve.	 This	 page	 gives	 a	 very	 short	 overview.	 The	 following	 pages	 provide	more	
detail	(Part	1	and	Part	2	of	Information	Sheet).	Please	ask	us	if	there	is	anything	that	
is	not	clear	or	if	you	would	like	more	information.	Take	as	much	time	as	you	like	to	
decide	whether	or	not	you	wish	to	take	part.	Thank	you.	
 
 
Idiopathic	pulmonary	fibrosis	(IPF)	causes	breathlessness	and	cough	because	of	
scarring	of	the	lungs,	for	which	we	need	new	and	better	treatments.	Fluid	or	acid	
from	the	stomach	may	contribute	to	IPF.	There	are	ways	to	reduce	acid	from	the	
stomach	(e.g.	a	widely	used	tablet	called	omeprazole).	
	
The	study	involves	patients	having	a	small	recording	device	clipped	on	for	24	hours	
on	two	occasions,	one	before	and	one	at	the	end	of	taking	omeprazole	or	‘placebo’	
tablets	for	3	months.	The	main	aim	is	to	see	whether	the	treatment	you	receive	
improves	cough	or	not.	These	are	the	only	parts	of	the	research	that	are	essential	to	
complete.	
	
If	patients	wish,	however,	they	can	have	additional	tests	performed	as	part	of	the	
study,	which	measure	acid/fluid	in	the	stomach,	and	whether	any	of	this	fluid	has	
reached	the	lung.		
	
The	following	pages	provide	detailed	information	to	allow	you	to	decide	whether	to	
have	only	the	medicine	and	cough	test,	whether	to	have	all	the	tests,	or	whether	not	
to	take	part.								
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PARTICIPANT	INFORMATION	SHEET	
	
PART	1	
	
A	pilot	study	in	idiopathic	pulmonary	fibrosis.	
Does	switching	off	stomach	acid	(with	omeprazole	tablets)	reduce	cough,	and	can	
it	improve	other	features	of	the	disease?	
Investigators:	Dr	Ian	Forrest	(Co-Investigator),	Prof	John	Simpson	(CI),	Dr	Wendy	
Funston,	Dr	Chris	Ward,	Prof	Jeff	Pearson,	Dr	Vicky	Ryan,	Prof	Michael	Griffin,	Mr	
Rhys	Jones,	Prof	Elaine	McColl	(all	Newcastle),	Dr	Jacky	Smith	(Manchester)	
	
	
You	 are	 being	 invited	 to	 take	 part	 in	 a	 research	 study.	 	 Before	 you	 decide	 it	 is	
important	 for	 you	 to	 understand	why	 the	 research	 is	 being	 done	 and	what	 it	will	
involve.		Please	take	time	to	read	the	following	information	carefully.	Talk	to	others	
about	the	study	if	you	wish.		
• Part	1	tells	you	the	purpose	of	this	study	and	what	will	happen	to	you	if	you	
take	part.	
• Part	2	gives	you	more	detailed	information	about	the	conduct	of	the	study.	
Ask	us	 if	 there	 is	 anything	 that	 is	 not	 clear	or	 if	 you	would	 like	more	 information.		
Take	as	much	time	as	you	like	to	decide	whether	or	not	you	wish	to	take	part.	
Thank	you	for	reading	this.	
	
What	is	the	purpose	of	the	study?	
	
There	is	a	distinct	lack	of	effective	treatments	for	idiopathic	pulmonary	fibrosis	(IPF).	
The	most	common,	and	most	distressing,	symptoms	of	IPF	tend	to	be	breathlessness	
and	cough.	These	symptoms	are	particularly	hard	 to	 treat.	There	 is	 some	evidence	
that	 small	 amounts	 of	 acid	 coming	 up	 from	 the	 stomach	might	 contribute	 to	 IPF.	
There	 is	 also	 evidence	 that	 stomach	 acid	 causes	 cough	 in	 some	 other	 lung	
conditions.	 It	 therefore	 seems	 reasonable	 that	 tablets	 that	 reduce	 stomach	 acid	
might	improve	cough	in	IPF.	On	the	other	hand,	stomach	acid	is	part	of	the	digestion	
process,	and	some	people	believe	it	may	help	kill	some	bugs	that	are	swallowed.	The	
most	 scientific	 way	 to	 work	 out	 whether	 cough	 (and	 other	 symptoms	 of	 IPF)	 are	
improved	by	switching	off	stomach	acid	 is	to	perform	what	we	call	a	“double-blind	
randomised	controlled	trial	(RCT)”	of	a	tablet	that	switches	off	stomach	acid.	A	tablet	
called	 omeprazole	 switches	 off	 stomach	 acid	 effectively,	 and	 has	 been	 commonly	
used	in	the	UK	for	over	20	years.		
	
In	an	RCT	half	the	patients	get	omeprazole,	half	get	a	“placebo”	(which	has	no	active	
ingredients	and	does	not	affect	stomach	acid).	Whether	patients	get	omeprazole	or	
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placebo	is	decided	at	random	using	a	computer	programme.	The	key	point	however	
is	that	while	the	patient	is	receiving	treatment,	neither	the	patient	nor	the	doctors	
	
	
know	 whether	 the	 patient	 is	 receiving	 omeprazole	 or	 placebo	 (ie	 the	 study	 is	
“double-blind”).	 Our	 team	will	 only	 find	 out	which	 treatment	was	which	 after	 the	
study	results	have	been	analysed.	
	
Therefore,	 the	 aim	 of	 this	 study	 is	 to	 determine	 whether	 omeprazole	 can	 reduce	
cough	(and	other	symptoms)	in	patients	with	IPF.	If	the	results	are	encouraging,	this	
would	pave	the	way	for	 larger	studies	to	comprehensively	assess	the	potential	role	
of	omeprazole	as	a	new	effective	treatment	for	IPF.		
	
Why	have	you	been	chosen?	
	
You	have	been	chosen	because	you	have	a	diagnosis	of	IPF.	
	
If	 you	are	already	 taking	omeprazole	 (or	a	 related	 treatment	 for	 the	stomach)	you	
may	still	be	eligible	to	take	part	if	you	are	willing	to	try	a	period	off	your	treatment	
and	if	the	doctors	consider	that	this	is	a	safe	option.	
	
Do	you	have	to	take	part?	
	
No.	It	is	up	to	you	to	decide	whether	or	not	to	take	part.		If	you	do,	you	will	be	given	
this	information	sheet	to	keep	and	be	asked	to	sign	a	consent	form.	You	are	still	free	
to	withdraw	at	any	time	and	without	giving	a	reason.		A	decision	to	withdraw	at	any	
time,	or	a	decision	not	to	take	part,	will	not	affect	the	standard	of	care	you	receive.	
	
What	will	happen	to	you	if	you	take	part?	
	
Summary	
	
The	 study	 will	 usually	 involve	 3	 short	 visits	 to	 hospital,	 then	 3-months	 of	 taking	
tablets	 at	 home,	 then	3	 visits	 to	hospital	 again	 (2	 short	 ones	 and	one	 longer	one)	
shortly	before	you	stop	the	treatment.	
	
Do	you	have	to	have	all	the	tests	and	visits?	
	
No.	We	would	obviously	prefer	that	all	patients	in	the	study	have	all	the	tests,	 in	
order	 to	maximise	 the	 information	 available.	 However	we	 recognise	 that	 not	 all	
patients	will	be	able	to	attend	all	the	visits,	and	that	some	patients	may	not	wish	
to	 have	 specific	 tests.	 The	 bare	 minimum	 information	 that	 will	 provide	 enough	
information	for	the	study	is	if	every	patient	has	2	“cough	monitor”	tests	(see	page	
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3	and	the	Appendix).	These	have	no	side	effects	and	are	very	simple	to	perform.	In	
other	 words,	 you	 would	 be	 able	 to	 take	 part	 in	 the	 study	 if	 the	 only	 tests	 you	
wanted	to	be	done	were	the	2	cough	monitor	tests.	
	
	
	
Before	the	study	starts	
	
If	you	are	not	taking	omeprazole	(or	a	related	stomach	treatment)	and	wish	to	take	
part,	you	will	be	asked	to	sign	one	consent	form	before	starting	the	study.			
If	you	are	taking	omeprazole	(or	a	related	stomach	treatment)	and	wish	to	take	part,	
we	shall	contact	your	GP	to	check	he/she	is	aware	and	in	agreement.	You	will	then	
be	asked	to	sign	a	consent	form	to	say	you	agree	to	try	a	period	off	the	treatment	for	
2	weeks.	 If	 your	 symptoms	 return	during	 that	2	weeks	 you	 should	go	back	on	 the	
treatment	and	not	take	part	in	the	study.	If	you	manage	well	without	the	treatment	
for	2	weeks,	then	you	will	be	asked	to	sign	a	second	consent	form	before	starting	the	
study.	
	
The	study	period	
	
After	 providing	 consent	 you	 will	 be	 given	 tablets	 to	 take	 twice	 a	 day,	 preferably	
before	food,	for	3	months.	
	
We	also	ask	you	to	have	a	few	medical	tests	performed	before	you	start	the	tablets,	
and	shortly	before	you	come	off	them.	One	further	test	is	done	just	before	you	stop	
the	tablets.	The	tests	generally	involve	3	visits	to	RVI	before	the	tablets	start,	and	3	
just	before	the	tablets	finish.	An	outline	of	these	tests	and	visits	is	described	in	the	
following	paragraphs.	More	detailed	descriptions	of	 three	of	 the	tests	are	 found	 in	
the	Appendix	accompanying	this	Patient	Information	Sheet.		
	
Before	the	tablets	start	
	
VISIT	 1.	 You	would	 come	 to	 the	Chest	Clinic	 at	RVI	and	have	your	usual	breathing	
tests	(in	almost	all	cases	this	will	be	timed	so	that	the	breathing	tests	double	up	as	
your	routine	clinical	test	and	your	study	test).	The	breathing	tests	are	called	a	“vital	
capacity”	(the	amount	of	air	you	can	blow	out	of	your	chest	after	a	deep	breath)	and	
a	 “transfer	 factor”	 (an	 indication	 of	 how	 efficiently	 gas	 can	 pass	 from	 the	 air	 into	
your	blood).	
	
In	addition	you	would	be	asked	to	perform	a	“6	minute	walk	test”,	in	which	you	walk	
for	up	to	6	minutes	under	medical	supervision	(you	can	of	course	stop	if	you	are	too	
breathless).	Many	patients	in	the	study	will	have	had	a	walk	test	done	before.	
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You	will	also	be	asked	to	complete	a	number	of	questionnaires	which	provide	us	with	
information	 about	 how	 breathless	 you	 are,	 and	 how	 much	 you	 are	 bothered	 by	
cough.	
	
Finally,	you	will	be	asked	to	wear	a	small	device	that	records	how	much	you	cough	
over	a	24-hour	period.	This	 is	 simply	a	 small	 recording	device	which	 is	attached	 to	
the	chest,	and	is	not	uncomfortable.	You	will	be	given	full	instructions	about	how	to	
wear	 the	device,	and	you	simply	go	home	wearing	 the	device,	bringing	 it	back	 the	
next	day	(see	below)	or	whenever	suits	you	best.	Further	details	are	in	the	Appendix.	
We	estimate	that	Visit	1	will	take	around	2	hours.		
VISIT	2.	For	the	second	visit,	you	would	bring	back	the	cough	monitor	to	the	Chest	
Clinic	at	RVI.	Ideally,	visit	2	would	therefore	be	the	day	after	Visit	1,	but	it	does	not	
have	to	be.		
	
At	 visit	 2	 you	would	 have	 “oesophageal	 physiology	 tests”,	which	 are	 tests	 of	 how	
your	stomach	and	gullet	work,	and	how	much	acid	is	produced	in	your	stomach.	You	
need	 to	 miss	 your	 breakfast	 that	 morning.	 The	 test	 usually	 does	 not	 cause	
discomfort.	 A	 thin,	 flexible	 tube	 is	 passed	 through	 your	 nose	 to	 the	 back	 of	 the	
throat,	where	you	swallow	the	end	of	 it.	A	member	of	the	team	then	makes	a	few	
measurements	while	you	sit	comfortably.	The	tube	is	then	removed	and	replaced	by	
a	thinner	tube	which	is	left	in	place	for	24	hours,	ie	you	go	home	with	it	in	place	and	
bring	it	back	the	next	day.	More	details	of	the	test	(and	a	picture	of	a	patient	having	
it	done)	are	in	the	Appendix	at	the	end	of	this	document.	
We	estimate	that	Visit	2	will	take	up	to	around	2	hours.	
	
VISIT	3.	For	the	third	visit,	you	would	come	to	the	Chest	Clinic,	RVI,	to	have	the	nasal	
tube	removed.	You	would	then	be	 issued	with	your	pack	of	tablets	 (omeprazole	or	
placebo),	 to	start	 the	next	day.	You	will	also	be	 issued	with	a	“symptoms	diary”	 in	
which	we	ask	you	to	record	any	symptoms	you	have	when	on	the	treatment.	You	will	
also	be	 issued	with	 contact	numbers	 through	which	you	can	get	 in	 touch	with	 the	
study	team	if	you	have	any	questions.		
We	estimate	that	Visit	3	will	take	less	than	1	hour.	
	
As	the	tablets	come	to	an	end	
	
The	visits	below	would	ideally	be	performed	on	the	3rd	 last,	2nd	 last	and	last	day	of	
treatment,	but	could	be	done	any	time	in	the	last	2	weeks	of	treatment.	
	
VISIT	4	(ideally	3rd	last	day	of	treatment).	This	is	a	duplicate	of	Visit	1,	ie	you	will	have	
breathing	tests,	a	6-minute	walk	test,	complete	questionnaires,	and	have	the	cough	
monitor	fitted	again	for	overnight	use.	
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VISIT	5	(ideally	the	2nd	last	day	of	your	treatment).	This	is	a	duplicate	of	Visit	2,	ie	you	
will	bring	the	cough	monitor	back	to	the	Chest	Clinic	at	RVI,	and	have	the	gullet	and	
stomach	tests,	going	home	with	the	nasal	tube	in	place	for	overnight	use.	You	need	
to	miss	breakfast	that	morning.	
	
VISIT	6	(ideally	the	final	day	of	your	treatment).	You	will	come	to	the	Chest	Clinic	at	
RVI	having	missed	your	breakfast	that	morning	and	the	nasal	tube	will	be	removed.	
You	will	then	go	for	a	telescope	test	of	the	lungs,	where	we	wash	a	small	segment	of	
the	lungs	to	sample	cells	and	fluid	there	(a	“bronchoscopy	and	lavage”).	Many	
patients	in	the	study	will	have	had	a	bronchoscopy	before.	Details	of	bronchoscopy	
and	lavage,	along	with	a	picture	of	a	patient	having	bronchoscopy,	are	found	in	the	
Appendix.	Briefly,	you	are	taken	to	the	dedicated	Bronchosopy	Suite	where	the	
preparations	will	be	as	for	any	patient	having	bronchoscopy	ie	you	will	have	some	
anaesthetic	spray	to	numb	your	mouth	and	nose,	you	will	be	given	some	extra	
oxygen	to	breathe	during	the	test,	and	a	plastic	cannula	(tube)	will	be	placed	in	a	
vein	in	your	hand	or	arm.	Your	heart	rate	and	oxygen	saturations	will	be	measured	
throughout.	 You	 will	 be	 offered	 a	 sedative	 medicine	 (to	 make	 you	 relaxed	 and	
sleepy).	 When	 you	 are	 comfortable	 and	 ready,	 a	 thin,	 flexible	 plastic	 “scope”	 (or	
camera)	with	a	light	on	the	end	is	passed	through	your	nose	or	mouth	and	down	into	
the	lung.	Once	the	tube	is	in	the	lung	we	place	it	in	one	“segment”	of	the	lung	(the	
lungs	have	approximately	23	segments	and	we	seek	to	wash	only	one	of	these),	and	
then	we	slowly	squirt	in	saline	(salty	water)	and	suck	it	back	through	the	scope.	This	
effectively	sucks	up	cells	and	liquid	from	the	furthest	areas	of	the	“segment”.	After	
the	washing	procedure,	we	take	up	to	4	biopsies	from	one	of	your	bronchial	tubes	–	
these	 are	 taken	 with	 forceps	 passed	 through	 the	 telescope.	 The	 biopsies	 are	
generally	 the	size	of	 the	point	of	a	ballpoint	pen,	 ie	approximately	1-2	millimetres.	
Because	 the	 lung	 generally	 contains	 “cough	 nerves”	 but	 not	 “pain	 nerves”,	 and	
because	we	apply	 local	anaesthetic	to	the	area,	the	biopsies	are	painless.	After	the	
wash	and	the	biopsies,	we	remove	the	“scope”	and	you	simply	rest	for	a	couple	of	
hours.	You	are	not	allowed	to	eat	or	drink	until	the	local	anaesthetic	spray	wears	off	
(about	 2-3	 hours),	 and	 if	 you	 have	 received	 sedation	 you	 must	 be	 accompanied	
home	by	a	responsible	adult.	Details	are	in	the	Appendix	and	will	of	course	be	gone	
over	again	before	the	test.		
	
We	estimate	that	Visit	6	will	last	about	4-6	hours	(the	test	itself	takes	about	half	an	
hour,	the	rest	of	the	time	is	preparing	you	for	the	test	or	observing	you	afterwards).	
	
You	 should	 stop	 taking	 tablets	 3	months	 (90days)	 after	 starting.	We	 need	 you	 to	
return	 the	 trial	 medication	 pack	 with	 any	 remaining	 tablets	 within	 7days	 of	
completion	date	 to	Chest	Clinic	RVI.	 It	 is	essential	 to	assess	compliance	as	 soon	as	
possible	 after	 completion	 of	 study	 treatment.	 This	 visit	 will	 be	 very	 brief	
approximately	30	minutes.	
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During	the	study	period	
	
You	 should	 not	 be	 taking	 any	 regular	 antacid	medication	 (namely	 Proton	 Pump	
Inhibitors	 like	 Omeprazole,	 Lansoprazole,	 Pantoprazole,	 Rabeprazole)	 during	 the	
study	 period	 while	 you	 are	 on	 the	 trial	 drug.	 If	 your	 GP	 or	 any	 other	 doctor	
prescribes	 you	 any	 regular	 antacid	medication	 please	 inform	 one	 of	 study	 team	
members	(contact	details	is	on	page	9)	before	taking	the	medication.	
	
	
	
	
What	are	the	possible	risks	and	side	effects	of	taking	part?	
	
The	risks	from	taking	part	are	considered	to	be	low.	Cough	monitoring	is	a	research	
tool,	but	is	not	associated	with	any	known	risks.	All	of	the	other	tests	are	routinely	
carried	 out	 in	 clinical	 practice,	 and	 all	 are	 considered	 to	 be	 low-risk	 procedures.	
Omeprazole	has	been	used	in	clinical	practice	by	millions	of	patients	and	is	regarded	
as	having	an	extremely	low	rate	of	serious	side	effects.			
Side	 effects	 from	 omeprazole	 are	 uncommon	 and	 it	 is	 estimated	 that	 >95%	 of	
patients	 have	 none.	 If	 patients	 do	 get	 side	 effects,	 the	 most	 common	 ones	 are	
diarrhoea,	headache,	abdominal	discomfort	and	nausea.	Rare	side	effects,	affecting	
less	 than	 1%	 of	 patients,	 can	 include	 skin	 reactions,	 low	 blood	 counts	 (including	
anaemia),	blood	or	protein	in	the	urine	and	urinary	tract	infection.	In	most	studies	to	
date,	 the	 rate	 of	 side	 effects	 has	 been	 very	 similar	 whether	 patients	 receive	
omeprazole	or	placebo.		
	
Side	effects	with	omeprazole	are	considered	more	likely	if	patients	are	taking	specific	
drugs	 that	 omeprazole	may	 interact	with.	 These	 include	 some	 treatments	 such	 as	
warfarin,	 diazepam,	 phenytoin	 or	 some	 treatment	 for	 fungal	 infections.	Our	 study	
protocol	has	strict	rules	which	exclude	patients	taking	such	medicines,	which	further	
reduces	the	risks	of	the	study.	
	
Tests	
	
Lung	function	tests.	You	are	very	likely	to	have	had	these	before.	Some	patients	find	
that	 the	 effort	 of	 blowing	 induces	 cough,	 which	 usually	 wears	 off	 after	 a	 few	
minutes.	
	
6-minute	 walk	 test.	 The	 test	 is	 designed	 to	 find	 out	 how	 far	 you	 can	 walk	 in	 6	
minutes,	or	 to	 find	out	 if	 you	have	 to	 stop	within	6	minutes.	 The	 test	 is	 therefore	
quite	likely	to	make	you	breathless.	The	test	is	carried	out	under	supervision,	and	if	
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you	are	very	breathless	the	test	 is	stopped.	Oxygen	 is	available	should	you	wish	to	
use	it	because	of	breathlessness.	
	
We	 are	 unaware	 of	 any	 side	 effects	 associated	 with	 the	 questionnaires	 or	 cough	
monitor.		
	
The	 oesophageal	 physiology	 (stomach/gullet)	 tests	 are	 usually	 very	well	 tolerated.	
Some	patients	have	mild	discomfort	or	a	sense	of	wanting	to	sneeze	when	the	tube	
is	passed	through	the	nose.	Occasionally	patients	will	retch	when	the	tube	is	at	the	
back	 of	 the	 throat,	 but	 this	 usually	 passes	 within	 seconds.	 Some	 patients	 get	 a	
degree	of	irritation	in	the	throat	from	the	tube.	
	
The	 bronchoscopy	 procedure	 has	 some	 common,	 usually	 minor,	 side	 effects.	 The	
local	 anaesthetic	 sprayed	 in	 the	 mouth	 often	 tastes	 sour,	 and	 leaves	 the	 mouth	
feeling	temporarily	numb.	The	telescope	usually	induces	some	cough	when	it	enters	
the	 lung	 initially	–	 the	coughing	usually	 settles	within	a	minute	or	 so.	The	biopsies	
taken	sometimes	 induce	some	coughing	but	should	be	painless,	partly	because	the	
lung	 contains	 “cough	 nerves”	 rather	 than	 pain	 nerves,	 and	 secondly	 because	 we	
apply	local	anaesthetic	to	the	area	to	be	biopsied.	
	
The	 telescope	 is	 passed	 through	 the	mouth	 or	 nose.	 Going	 through	 the	mouth	 is	
usually	 painless	 but	 can	 induce	 some	 some	 gagging.	 The	 nose	 tends	 to	 be	 more	
uncomfortable	until	the	tube	has	passed	(usually	less	than	a	minute).		
However	 bronchoscopy	 is	 considered	 a	 safe,	 routine	 clinical	 procedure,	 which	 is	
generally	 very	 well	 tolerated.	 A	 collapsed	 lung	 (pneumothorax)	 is	 a	 very	 rare	
complication	and	occurs	in	<0.5%	of	patients.	We	select	the	segment	of	the	lung	to	
be	washed	 carefully	 to	minimise	 this	 risk	 still	 further.	 There	 is	 a	 small	 risk	 of	 low	
oxygen	levels	or	an	irregular	heart	beat	(which	is	why	we	monitor	oxygen	levels	and	
an	 ECG	 during	 the	 test,	 to	 pick	 up	 any	 suggestion	 of	 this),	 and	 a	 small	 risk	 of	
congestion	 of	 the	 lungs.	 Studies	 into	 bronchoscopy	 have	 estimated	 the	 risk	 of	 a	
serious	complication	to	be	less	than	1	in	1000,	and	the	risk	of	death	to	be	less	than	1	
in	10,000.	
	
After	the	procedure	a	proportion	of	patients	describe	a	mild	sore	throat	for	around	
24	hours,	as	the	local	anaesthetic	wears	off.	Because	of	the	biopsies,	you	may	cough	
a	small	amount	of	blood	after	the	test	–	this	is	usually	seen	as	spots	or	streaks	in	the	
phlegm	and	very	 rarely	 lasts	 for	more	 than	24	hours.	 If	you	have	sedation	you	are	
likely	to	feel	a	little	sleepy	for	the	rest	of	the	day.	As	well	as	relaxing	you	and	making	
you	 sleepy,	 the	 sedation	 has	 a	 mild	 temporary	 effect	 on	 memory,	 and	 often	 the	
patient	will	not	 remember	having	had	the	procedure.	 	For	all	 these	reasons,	 if	you	
have	 sedation	 you	must	not	drive,	work,	 drink	 alcohol,	 operate	moving	machinery	
(including	power	 tools	etc	 at	home),	or	 sign	 legal	documents	until	 the	next	day.	 If	
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you	 have	 sedation	 you	 must	 be	 accompanied	 home	 by	 a	 responsible	 adult.	 The	
following	day	you	can	resume	your	normal	activities.		
	
In	 the	unlikely	event	 that	we	detect	an	abnormality	at	bronchoscopy	we	would	 let	
you	know,	and	inform	your	GP	of	our	findings.	We	would	discuss	with	you	and	your	
GP	the	best	way	to	investigate	and	manage	any	bronchoscopic	abnormality.	
	
What	are	the	other	possible	disadvantages	and	risks	of	taking	part?	
	
We	are	unaware	of	other	disadvantages	and	risks	of	 taking	part.	We	are	conscious	
however	that	the	study	does	take	up	quite	a	lot	of	your	time	on	the	study	days.	
	
What	are	the	potential	benefits	of	taking	part?	
	
There	is	no	direct	benefit.	
	
	
Is	there	any	reimbursement	for	taking	part?	
	
There	 is	 no	payment	 for	 taking	part	 in	 the	 study.	We	 shall	 be	happy	 to	 reimburse	
costs	for	travel	to	the	RVI	and	parking	at	the	RVI,	but	we	shall	need	receipts	before	
doing	so	please.	
	
	
What	if	there	is	a	problem?	
	
Any	 complaint	 about	 the	 way	 you	 have	 been	 dealt	 with	 during	 the	 study	 or	 any	
possible	harm	you	might	suffer	will	be	addressed.	The	detailed	information	on	this	is	
given	in	part	2.	
	
Will	your	taking	part	in	this	study	be	kept	confidential?	
	
Yes.	 All	 the	 information	 about	 your	 participation	 in	 this	 study	 will	 be	 kept	
confidential.	The	details	are	included	in	Part	2.	
	
Contact	details	
	
Should	you	wish	further	information	please	feel	free	to	contact	us	at	any	time	at	the	
address	or	numbers	below	
	
Dr	Ian	Forrest			 	 	 	 	
Consultant	in	Respiratory	Medicine		 	
Respiratory	Medicine	Unit	
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Royal	Victoria	Infirmary	
Queen	Victoria	Road	
Newcastle	upon	Tyne	NE1	4LP	
0191	282	0149	
	
Prof	John	Simpson		
Consultant	in	Respiratory	Medicine	
Institute	of	Cellular	Medicine	
Medical	School	
Newcastle	University	
Framlington	Place	
Newcastle	upon	Tyne	NE2	4HH	
0191	208	7770	
	
Dr	Wendy	Funston	
Clinical	Research	Associate	
Institute	of	Cellular	Medicine	
Medical	School	
Newcastle	University	
Framlington	Place	
Newcastle	upon	Tyne	NE2	4HH	
0191	208	7770,	07765920130	
	
If	you	would	like	to	talk	to	an	expert	who	is	not	involved	in	the	project,	we	have	an	
independent	advisor	for	this	specific	purpose.	This	person	is	a	fully	qualified	medical	
practitioner	who	is	there	to	answer	any	questions	or	concerns	you	may	have	about	
the	study.	He	is	not	in	any	way	involved	in	the	study,	but	understands	all	of	the	
medical	aspects	of	this	particular	project.	The	contact	details	are	
	
Dr	Graham	Burns	
Consultant	in	Respiratory	Medicine		 	
Respiratory	Medicine	Unit	
Royal	Victoria	Infirmary	
Queen	Victoria	Road	
Newcastle	upon	Tyne	NE1	4LP	
0191	282	0149	
	
This	completes	Part	1	of	the	Information	Sheet.	
If	the	information	in	Part	1	has	interested	you	and	you	are	considering	participation,	
please	 continue	 to	 read	 the	 additional	 information	 in	 Part	 2	 before	 making	 your	
decision.	
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PATIENT	INFORMATION	SHEET	–	PART	2	
	
A	pilot	study	in	idiopathic	pulmonary	fibrosis.	
Does	switching	off	stomach	acid	(with	omeprazole	tablets)	reduce	cough,	and	can	
it	improve	other	features	of	the	disease?	
Investigators:	Dr	Ian	Forrest	(Co-Investigator),	Prof	John	Simpson	(CI),	Dr	Wendy	
Funston,	Dr	Chris	Ward,	Prof	Jeff	Pearson,	Dr	Vicky	Ryan,	Prof	Michael	Griffin,	Mr	
Rhys	Jones,	Prof	Elaine	McColl	(all	Newcastle),	Dr	Jacky	Smith	(Manchester)	
	
	
What	will	happen	 if	you	change	your	mind	and	do	not	wish	 to	carry	on	with	 the	
study?	
	
You	can	withdraw	completely	from	the	study	at	any	time	without	giving	any	reason.		
	
However	all	the	data	collected	is	useful,	therefore	we	would	like	to	use	the	data	you	
have	already	given	us	 for	our	 research	even	 if	you	 leave	the	study.	We	would	also	
like	to	offer	you	the	choice	to	come	in	for	the	final	study	visits	and	collect	your	cough	
monitor	data	although	we	would	need	your	permission	to	do	this	if	you	do	decide	to	
withdraw.		
	
Your	withdrawal	would	not	affect	the	standard	of	care	that	you	can	expect	to	receive	
in	the	future.		
	
What	if	there	is	a	problem?	
	
If	you	have	a	concern	about	your	treatment	by	members	of	staff	during	the	study,	
you	should	ask	to	speak	with	the	researchers	who	will	do	their	best	to	answer	your	
concerns	(contact	numbers	are	found	at	the	end	of	Part	1).	 If	you	remain	unhappy	
and	 wish	 to	 complain	 formally,	 you	 can	 do	 this	 through	 the	 NHS	 Complaints	
Procedure.	Details	can	be	obtained	from	the	hospital.	
	
In	 the	 unlikely	 event	 that	 something	 goes	 wrong	 and	 you	 are	 harmed	 during	 the	
research	study	there	are	no	special	compensation	arrangements.	If	you	are	harmed	
and	 this	 is	 due	 to	 someone’s	 negligence	 then	 you	 may	 have	 grounds	 for	 a	 legal	
action	for	compensation	against	the	Newcastle	upon	Tyne	Hospitals	NHS	Foundation	
Trust	 but	 you	 may	 have	 to	 pay	 for	 your	 legal	 costs.	 The	 normal	 NHS	 complaints	
mechanisms	will	still	be	available	to	you.		
	
Can	you	access	the	results	of	the	research?	
	
Yes.	Should	you	wish	to	know	the	overall	results	of	the	study	please	get	in	contact	
with	the	team	using	the	contacts	at	the	end	of	Part	1.		If	that	is	the	case	we	would	
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send	you	a	summary	of	the	results,	including	a	lay	summary,	after	analysis	of	the	
study	data	is	complete.	
	
Will	your	taking	part	in	this	study	be	kept	confidential?	
All	information	which	is	collected	about	you	during	the	course	of	the	research	will	be	
kept	strictly	confidential.		
	
The	bronchoscopy	and	lavage	test	will	provide	us	with	liquid	and	cells	from	your	
lung.	The	lung	fluid	samples	you	provide	will	be	stored	in	our	freezers,	labelled	with	
a	number	and	the	date	(ie	you	can	not	be	recognised	from	the	stored	fluid	samples).	
The	cells	will	be	used	immediately	and	either	discarded	or	kept	on	glass	slides	for	
later	analysis.	The	slides	will	be	labelled	with	a	number	and	the	date	(ie	you	can	not	
be	recognised	from	the	stored	fluid	samples).		Lung	samples	will	be	used	principally	
to	estimate	the	amount	of	inflammation	in	your	lung,	and	whether	there	is	any	
evidence	that	chemicals	from	the	stomach	have	entered	your	lung	at	any	point.		
	
Because	the	understanding	of	lung	biology	is	moving	forward	all	the	time,	it	is	
possible	that	we	shall	identify	unanticipated	future	uses	for	the	stored	lung	fluid	
samples.	If	we	identify	a	proposed	use	for	these	samples	that	does	not	relate	to	the	
current	study,	we	shall	seek	further	approval	from	the	Research	Ethics	Committee.	In	
all	instances,	confidentiality	will	be	maintained	as	above.	
	
Tests	done	in	the	RVI,	such	as	the	bronchoscopy,	comply	with	NHS	standards,	ie	
there	will	be	clinical	sheets	with	your	details	on	them,	as	there	would	be	for	a	
routine	NHS	bronchoscopy.	These	sheets	are	subject	to	the	usual	NHS	confidentiality	
rules.		
	
Involvement	of	the	GP	
	
Your	GP	may	be	notified	of	your	participation	in	this	study,	with	your	consent.	
	
Will	any	genetic	tests	be	done?	
	
No	genetic	tests	will	be	performed	and	no	genetic	material	will	be	stored.	
	
What	will	happen	to	the	results	of	the	research	study?	
	
We	 intend	 for	 the	 results	 to	 be	 presented	 at	 scientific	meetings	 and	 published	 in	
medical/scientific	journals.	You	would	not	be	identifiable	from	our	data	in	any	such	
meetings	or	publications.		
	
Who	is	organising	and	funding	the	research?	
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The	 research	 is	 funded	 by	 the	 British	 Lung	 Foundation,	 an	 independent	 charity	
funding	 medical	 research,	 with	 support	 from	 the	 Newcastle	 Biomedical	 Research	
Centre.	
	
Who	has	reviewed	the	study?	
The	study	has	been	reviewed	by	the	funding	bodies	above.	It	has	been	reviewed	and	
approved	by	a	Research	Ethics	Committee.	
	
You	will	be	given	a	copy	of	this	Information	Sheet	and	a	signed	consent	form	to	keep.	
Thank	you	for	taking	time	to	read	this	sheet	and	for	considering	taking	part.	
	
Version	3.1,	05	August	2015	
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APPENDIX	
	
1.	COUGH	MONITORING	
	
You	will	be	fitted	with	a	cough	monitor	which	will	record	the	number	of	times	you	
cough	over	a	period	of	24	hours	during	the	day	and	night.	The	researcher	will	attach	
a	sticky	pad	to	your	chest	which	contains	a	small	microphone	(see	right	hand	picture,	
showing	the	apparatus).		A	clip	with	another	small	microphone	will	be	attached	to	
your	clothing.		The	monitor	itself	will	be	kept	in	a	`bumbag'	around	your	waist	(see	
the	left	hand	picture).		You	must	not	get	the	monitor	wet.		
	
	
	
	
The	monitor	does	not	just	record	coughing	sounds;	it	will	also	record	your	activities	
whilst	you	are	wearing	it.		For	example,	it	will	record	your	conversations	and	in	some	
instances	may	record	the	voices	of	people	around	you.		We	do	however	use	
computer	software	(algorithms)	to	remove	parts	of	(cut	down)	the	recording	where	
there	is	no	coughing,	such	as	some	speech,	when	you	are	reading	or	sleeping	and	
distant	noises,	such	as	noise	from	your	television.	The	cut	down	recordings	are	then	
listened	to	and	analysed	by	a	trained	researcher	who	counts	the	number	of	times	
you	have	coughed	during	the	day	and	night.		Please	be	aware	that	if	we	should	hear	
something	on	the	recordings	which	might	place	either	yourself	or	another	person	in	
danger	we	have	procedures	we	are	required	to	follow	in	order	to	report	such	
instances;	otherwise	your	recordings	will	be	treated	as	confidential.	
	
At	the	present	time,	cough	recordings	are	cut	down	using	software	algorithms	and	
then	listened	to	by	a	trained	researcher	in	order	to	calculate	how	often	a	person	
coughs.		In	some	instances	we	may	need	to	listen	to	the	full	24	hour	recording.		We	
are	working	towards	an	automated	system	whereby	our	researchers	will	no	longer	
need	to	listen	to	the	recordings	as	the	software	algorithm	will	count	the	coughs	
automatically.		In	order	to	do	this	we	need	to	use	both	24	hour	and	cut	down	
recordings	to	test	and	develop	new	algorithms	and	compare	how	well	they	work.				
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If	you	take	part	in	this	study	you	will	be	asked	if	you	are	happy	for	your	cough	
recordings	to	be	stored	in	our	research	database	called	RaDAR.	RaDAR	contains	both	
24	hour	and	cut	down	cough	recordings	which	are	used	to	test	and	develop	software	
algorithms.		When	a	24	hour	recording	is	stored	in	RaDAR	any	identifiable	
information	(for	example,	your	name)	is	blanked	out	before	it	is	stored.		All	
recordings	are,	therefore,	anonymised.		None	of	the	researchers	who	may	use	your	
recordings	would	be	able	to	identify	you.		
Recordings	stored	in	RaDAR	are	categorised	by	gender,	age	and	respiratory	condition	
only.		If	your	recordings	are	stored	in	RaDAR	they	will	be	used	by	researchers	at	The	
University	of	Manchester	and	University	Hospital	of	South	Manchester,	and	also	by	
Vitalograph	Ltd	who	developed	the	cough	recording	device.	Other	Universities	or	
commercial	companies	can	also	apply	to	RaDAR	to	use	the	anonymous	recordings	for	
their	own	research.	The	RaDAR	management	team	assess	each	application	received	
for	use	of	cough	recordings	rigorously	and	only	allow	the	data	to	be	used	if	the	study	
is	considered	appropriate.	
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2.	OESOPHAGEAL	PHYSIOLOGY	TESTS	(tests	of	the	gullet	and	stomach)	
	
Oesophageal	physiology	testing	provides	information	about	the	function	of	the	
gullet	and	stomach.		The	test	has	two	parts,	known	as	oesophageal	manometry	and	
ambulatory	pH/impedance	testing.	
	
Oesophageal	manometry	uses	pressure	sensors	to	measure	the	waves	of	muscular	
contraction	travelling	down	the	gullet,	and	also	the	relaxation	of	the	valves	that	help	
to	keep	food	travelling	in	the	right	direction.	
	
pH/impedance	testing	uses	sensors	of	acidity	and	electrical	resistance	to	measure	
“reflux”	of	material	from	the	stomach	back	up	into	the	gullet.		As	reflux	can	occur	
unpredictably	throughout	the	day,	the	test	runs	over	a	24-hour	period	but	hospital	
admission	is	not	required.	
	
Patients	come	to	the	hospital	fasted.	In	the	endoscopy	department,	a	fine	tube	is	
inserted	via	the	nose	into	the	stomach.	The	manometry	test	is	then	performed,	
which	takes	around	twenty	minutes	and	involves	the	patient	performing	a	number	of	
swallows	(see	the	left	hand	picture	below).		This	tube	is	then	removed	and	the	tube	
for	the	pH/impedance	testing	is	inserted	in	the	same	way.	This	is	much	finer	and	is	
left	in	place	for	24	hours,	connected	to	a	data-recording	box.	The	test	doesn’t	
significantly	restrict	normal	activities	but	some	patients	are	self-conscious	about	
going	to	work	etc	with	the	tube	in	place	(see	the	right	hand	picture).		Insertion	of	the	
tube	can	be	slightly	uncomfortable	but	isn’t	painful,	and	the	test	doesn’t	carry	any	
risk.	
	
The	next	day	the	removal	of	the	tube	takes	a	couple	of	minutes	and	the	information	
from	the	test	can	then	be	interpreted.	
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3.	BRONCHOSCOPY	AND	BRONCHOALVEOLAR	LAVAGE	
	
Bronchoscopy	 is	a	 telescope	 test	of	 the	 lung,	and	 lavage	 is	a	procedure	 in	which	a	
small	 segment	 of	 one	 lung	 is	 “washed”	 in	 order	 to	 retrieve	 a	 sample	 of	 cells	 and	
liquid	from	the	deepest	region	of	the	lung.	The	telescope	transmits	light	and	allows	
pictures	of	the	bronchial	tubes	to	be	passed	to	a	television	screen.		
	
For	this	procedure	a	small	plastic	cannula	would	be	placed	in	a	vein	in	your	arm	or	
hand.	A	probe	would	be	placed	on	your	finger	and	ECG	leads	placed	on	your	chest	–	
this	is	entirely	routine	and	simply	allows	us	to	continuously	monitor	your	heart	rate	
and	 the	 oxygen	 levels	 in	 your	 blood.	 You	 would	 be	 given	 oxygen	 through	 nasal	
“spectacles”	or	“plugs”.	You	would	then	be	advised	to	have	 local	anaesthetic	spray	
applied	 to	your	mouth	 (to	numb	 the	 throat	when	 the	 telescope	 is	passed	 into	 the	
lung).	We	would	also	invite	you	to	have	a	medicine	called	a	sedative,	so	that	you	are	
relaxed	 and	 sleepy	 during	 the	 test.	 The	 sedative	 would	 be	 given	 intravenously,	
through	the	cannula	in	your	arm.	
	
When	you	are	relaxed	and	comfortable,	we	would	pass	the	telescope	through	your	
mouth	(through	a	mouthguard	which	you	hold	gently	between	your	teeth	-	this	is	to	
prevent	the	telescope	being	bitten),	or	through	your	nose	(for	the	nose	we	offer	you	
anaesthetic	jelly	for	your	nostril).	The	telescope	is	thin	(less	than	a	centimetre	wide),	
soft	and	flexible	with	a	light	at	the	end.	We	pass	this	over	the	tongue,	past	the	vocal	
cords	(voice	box)	and	into	the	lung.	We	then	instill	some	saline	(salty	water)	through	
the	telescope	then	suck	it	back	(in	this	way	we	sample	cells	from	a	very	small	area	of	
your	 right	 lung).	 The	 bronchoscopy	 and	 lavage	 take	 approximately	 half	 an	 hour,	
which	 includes	 the	 time	 taken	 preparing	 you	 for	 the	 test.	 	 A	 picture	 of	 a	 patient	
having	 a	 bronchoscopy	 is	 shown	 below.	 You	 will	 see	 that	 the	 patient	 is	 lying	
comfortably	in	a	well-lit	room.	The	patient	went	home	shortly	afterwards.	
	
After	the	procedure	you	will	be	allowed	to	rest.	You	will	not	be	allowed	to	eat	or	
drink	for	at	least	2	hours	(because	of	the	local	anaesthetic).	Your	pulse,	blood	
pressure	and	oxygen	levels	will	be	checked	on	the	ward	and	you	will	be	allowed	
home.	If	you	have	had	sedation	we	insist	that	you	either	be	picked	up	by	a	friend	or	
relative,	or	we	shall	arrange	for	a	taxi	to	take	you	home.	Furthermore,	if	you	have	
sedation	you	will	be	advised	not	to	work,	drive,	drink	alcohol	operate	moving	
machinery	or	sign	legal	documents	on	the	remainder	of	that	day.	All	of	these	
measures	are	routine	after	bronchoscopy.	
	
	
	
	
		 Tom 
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Appendix 5: PPIPF study: Patient Diary Card 
 
 
PATIENT DIARY CARD 
 
 
  
Date of Issue: _________      Study ID/Trial patient Number: _________ 
 
Pilot Trial Of Omeprazole in IPF (PPIPF Study) 
 
Sponsor: The Newcastle Upon Tyne NHS Hospitals Foundation Trust 
Funder: British Lung Foundation 
Protocol Number: IAFIPF001 
Eudra CT Number: 2013 – 003301 – 26 
 
Chief Investigator: Prof John Simpson 
 
Instruction for Patients 
 
• This diary will help to assess the effect of medication and also its 
safety 
 
• Please record any change to your health while you are on medication 
(more details inside) 
 
• Please call the Investigator Team if you develop any symptom or 
illness that leads to hospital admission 
      Contact Number: 0191 2087770; Mobile Number: 07765706346 
 
• Please call the Investigator Team if you are Pregnant 
     Contact Number: 01912087770; Mobile Number: 07765706346 
 
• REMINDER: Please bring this diary with you on your last day of 
visit (Visit 6) 
 
• REMINDER: Please stop taking trial medication 90 days after 
starting date. Please return trial medication pack with remaining drugs 
to Chest Clinic OPD (RVI) within 7 days of completion of study 
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medication. We apologize for inconvenience of extra clinic visit but it 
is essential to assess compliance and wellbeing of study participants, 
as soon as possible after completion of study treatment. 
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 Please	record	below	if	you	experience	any	symptom	or	illness	that	are	unusual	or	worse	for	you	during	the	study.	You	do	not	need	to	record	your	usual	cough	or	breathlessness	related	to	your	lung	disease		unless	they	are	worse	and/or	you	needed	medical	attention	or	new	medication	(i.e.	antibiotics)	Please	record	each	symptom	on	a	separate	line.	Please	complete	the	date	and	time	at	which		symptom	started	and	stopped.	Please	record	appropriate	severity	(as	shown)	and	any	action/medication	taken	to	help	with	symptom.	
 
 
Your	Description	(please	record	each	symptom	on	separate	line)	 Severity	*	Mild	=	1	Moderate	=	2	Severe	=	3 
Date/Time	
started	(dd/mm/yy	hh:mm) 
Date/Time	
stopped	(dd/mm/yy	hh:mm) 
Action	
Needed	(any	medication,	consultation	with	GP)	
     
     
     
     
     
     
     
PATIENT DIARY CARD 
       
Pilot Trial of Omeprazole in IPF (PPIPF Study) 
CI: Prof John Simpson           
Protocol Number: IAFIPF001 
Eudra CT Number: 2013-003301-26 
 
StudyID/Trial patient Number :______________________________ 
 
Start Date: ___________________                        Stop 
Date:______________________ 
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* Mild - awareness of symptoms or signs but easily tolerated (Tolerable) 
   Moderate – symptoms interfere with usual activities (Disturbing) 
   Severe – unable to perform usual/daily activities (Intolerable) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
							
201	
 Please	record	below	if	you	experience	any	symptom	or	illness	that	are	unusual	or	worse	for	you	during	the	study.	You	do	not	need	to	record	your	usual	cough	or	breathlessness	related	to	your	lung	disease		unless	they	are	worse	and/or	you	needed	medical	attention	or	new	medication	(i.e.	antibiotics)	Please	record	each	symptom	on	a	separate	line.	Please	complete	the	date	and	time	at	which		symptom	started	and	stopped.	Please	record	appropriate	severity	(as	shown)	and	any	action/medication	taken	to	help	with	symptom.	
 
 
Your	Description	(please	record	each	symptom	on	separate	line)	 Severity	*	Mild	=	1	Moderate	=	2	Severe	=	3 
Date/Time	
started	(dd/mm/yy	hh:mm) 
Date/Time	
stopped	(dd/mm/yy	hh:mm) 
Action	
Needed	(any	medication,	consultation	with	GP)	
     
     
     
     
     
     
     
PATIENT DIARY CARD 
       
Pilot Trial of Omeprazole in IPF (PPIPF Study) 
CI: Prof John Simpson           
Protocol Number: IAFIPF001 
Eudra CT Number: 2013-003301-26 
 
StudyID/Trial patient Number :______________________________ 
 
Start Date: ___________________                        Stop 
Date:______________________ 
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* Mild - awareness of symptoms or signs but easily tolerated (Tolerable) 
   Moderate – symptoms interfere with usual activities (Disturbing) 
   Severe – unable to perform usual/daily activities (Intolerable) 
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Appendix 6: BTS poster presentation: Cyclophosphamide study 
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